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Variability is the law of life, and as no two faces are the same,
so no two bodies are alike, and no two individuals react alike and
behave alike under the abnormal conditions we know as disease.
Sir William Osler (1849-1919)
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Abstract
Genomic variation is the basis of interindividual diﬀerences in observable
traits and disease susceptibility. Genetic studies are the driving force of
personalized medicine, as many of the diﬀerences in treatment eﬃcacy can
be attributed to our genomic background. The rapid development of next-
generation sequencing technologies accelerates the discovery of the complete
landscape of human variation. The main limitation is not anymore the
available genotyping technology or cost, but rather the lack of understanding
of the functionality of individual variations. Single polymorphisms rarely
explain a considerable amount of the phenotype variability, hence the ma-
jor diﬃculty of interpretation lies in the complexity of molecular interactions.
This PhD thesis describes the state-of-art of the functional human vari-
ation research (Chapter 1) and introduces childhood acute lymphoblastic
leukaemia (ALL) as a model disease for studying pharmacogenomic eﬀects
(Chapter 2 and 3). Chapter 4 describes the current interpretations of vari-
ations’ eﬀect and deleteriousness, accompanied by investigations of amino
acid mutability compared to their deleteriousness presented in Paper I.
Chapter 5 describes a pipeline used for calling variants from next-generation
sequencing data and describes the common challenges encountered during
analysis. Chapter 6 provides the motivation for a hypothesis-driven SNP
selection and describes the publicly available resources used for this task.
Following a review of the available large-scale genotyping techniques, Paper
II introduces a novel cost-eﬀective method for genotyping of a large custom
SNP panel by means of multiplexed targeted sequencing and includes recom-
mendations for eﬃcient capture bait design. In Chapter 7 various methods
of integrative analyses of genomic variations are presented, including testing
of overrepresentation of rare variants, eﬀects of multiple SNPs acting in the
same biological pathway, contribution of coding variation to individual’s
disease risk, as well as identifying groups of patients diﬀering in disease
mechanisms deﬁned by aberrations in protein-protein complexes. Chapters
8, 9 and 10 contain three papers applying the methods presented in Chapters
5 - 7 to investigate the heterogeneity of treatment response (Paper III), risk
of infections (Paper IV) and disease aetiology (Paper V) in childhood ALL
patients. Chapter 11 summarizes the thesis and includes some ﬁnal remarks
on the perspectives of genomic variation research and personalized medicine.
In summary, this thesis demonstrates the feasibility of integrative anal-
yses of genomic variations and introduces large-scale hypothesis-driven SNP
exploration studies as an emerging alternative to data-driven genome-wide
association studies. Finally, the ﬁndings of the presented studies set new
directions for future pharmacognenetic investigations and provide a frame-
work for future implementation of personalized medicine.
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Dansk resumé
Genomisk variation er årsagen til individuelle forskelle i fænotype, samt syg-
domsmodtagelighed. Genetiske undersøgelser er den drivende kraft indenfor
skræddersyet medicin, da mange forskelle i behandlingseﬀekt kan tilskrives
vores egen genomiske baggrund. Den hurtige udvikling af næste generation
sekventerings (NGS) teknologier accelererer opdagelsen af det fuldstændige
landskab af den menneskelig variation. Den største begrænsning er ikke
længere tilgængeligheden af genotypebestemmelses teknologi eller dens om-
kostning, men snarere den manglende forståelse af funktionaliteten af de
individuelle variationer. Single nukleotid polymorﬁer (SNPs) kan sjældent
forklare den betydelige mængde af fænotypens variabilitet, hvorfor det stør-
ste problem i fortolkningen ligger i de komplekse molekylære interaktioner.
Denne ph.d.-afhandling beskriver den nuværende forskningsudvikling
indenfor den funktionelle menneskelige variation (Kapitel 1), samt brugen
af akut lymfoblastær leukæmi (ALL) hos børn som en modelsygdom til
kortlægning af eﬀekten af farmakogenomik (Kapitel 2 og 3). Kapitel 4 be-
skriver de nuværende fortolkninger af de molekylære eﬀekter for genetiske
variationer, ledsaget af undersøgelser af aminosyrernes foranderlighed, set i
forhold til deres skadelige potentiale, hvilket præsenteres i Paper I. Kapitel
5 beskriver en arbejdsprocedure, som anvendes til at detektere varianter fra
NGS data, samt de fælles udfordringer for analysen. Kapitel 6 beskriver både
motivationen for en hypotese-drevet SNP udvælgelse, samt de oﬀentlige til-
gængelige ressourcer, der anvendes til denne procedure. Efter en gennemgang
af de foreliggende store genotypebestemmelses teknikker, introducerer Paper
II en ny omkostningseﬀektiv metode til genotypebestemmelse af en stor
brugerdeﬁneret SNP panel ved hjælp af multipleks målrettet sekventering,
som indeholder anbefalinger for eﬀektiv opsamling af bait design. I Kapitel 7
præsenteres forskellige metoder til integrationsfremmende analyser af geno-
miske variationer, herunder afprøvning af en overrepræsentation af sjældne
varianter, virkningerne af forskellige SNPs som interagere i samme biologiske
stofskiftevej, bidrag af kodningsvariation til en individuel sygdomsrisiko,
samt identiﬁcering af patientgrupper med forskellige sygdomsmekanismer
deﬁneret ved aberrationer i protein-protein-komplekser. Kapitel 8, 9 og 10
indeholder tre artikler, der anvender de metoder, der præsenteres i Kapitel
5 – 7 til at undersøge heterogenitet af behandlingsrespons (Paper III), risiko
for infektioner (Paper IV) og sygdomsætiologi (Paper V) i patienter med
ALL. Kapitel 11 opsummerer afhandlingen og indeholder nogle afsluttende
bemærkninger om udsigterne for genomisk variations forskning og persona-
liseret medicin.
Sammenfattende viser denne afhandling muligheden for integrationsfrem-
mende analyser af genomiske variationer og indfører derved store hypotese-
drevet SNP udforsknings undersøgelser som et spirende alternativ til data-
styrede genom-dækkende associationsstudier. Endelig har resultaterne af de
xii CONTENTS
fremlagte undersøgelser sat nye retningslinjer for fremtidige farmakogeno-
miske undersøgelser, samt skabt en ramme for fremtidige gennemførelser af
skræddersyet medicin.
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Introduction
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Chapter 1
Genomic variation
With approximately 7 billion people living on earth, there are no two indi-
viduals that are the same. The diﬀerences between us are written in our
DNA sequences. The completion of the Human Genome Project [127, 70] in
2001 began to shed lights on the details of our genetic code. Nowadays, with
hundreds of individuals being sequenced every week, we begin to understand
far more of the diﬀerences between us, however we are still far away from
understanding the impact of every base in our 3-billion-base long genome.
With every new generation, DNA is subject to mutation and recombina-
tion events, the sequences are mixed, shuﬄed, some bases are lost, added or
turned around. These events result in many types of genomic variation, with
the most important being:
• Single nucleotide polymorphism (SNP) is a single base diﬀerence
in the DNA sequence occurring in at least 1% of the population1. It
is estimated that SNPs constitute approximately 90% of all the human
variation, and occur on average every 100-300 bases along the human
genome comprising an estimated number of 15 million polymorphisms
[5]. SNPs arise as point mutations and due to natural selection become
ﬁxed in the population.
• Copy number variation (CNV) is a form of structural variation
where a section of DNA diﬀers in number of copies between individu-
als. CNVs aﬀect segments of sizes ranging from 1 kilobase to several
megabases and can present as deletion, duplication, segmental dupli-
cation or inversion of the segment [4]. Copy number variations aﬀect
approximately 12% of the human genome [105].
1The exact deﬁnition varies depending on the source, however 1% seems to be the
widely accepted deﬁnition
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• Variable number of tandem repeats (VNTR) are patterns of
repeating sequences of 2-60 bases. Depending on the length of the
repeat the VNTRs are classiﬁed into micro- and minisatellites with up
to 6-bases and above 6-bases repeated blocks respectively. VNTRs are
heritable and are often used in forensic analyses or to analyse pattern
of chimerism after haematopoietic stem cell transplantation.
• Epigenetics describes variation beyond the changes in the DNA se-
quence inﬂuencing gene expression. This mostly includes DNA methy-
lation and histone modiﬁcations. DNA methylation is heritable and
remains stable through cell divisions and may also last for multiple gen-
erations, while heritability of histone modiﬁcations is unknown [106].
Since the completion of the Human Genome Project in 2001 [127, 70]
there have been several international eﬀorts to catalogue human variation.
Among them the International HapMap Project [45] and the 1000 Genomes
Project [119] made signiﬁcant contributions to our understanding of the
common patterns of human genetic variation and the extent of variation
between populations. Providing publicly available catalogues of common
human variations greatly facilitated research of the genetic bases of suscep-
tibility to diﬀerent diseases and provided a foundation for the genome-wide
association studies (GWAS). Data on genetic variation is available from the
Single Nucleotide Polymorphism Database (dbSNP) [118] which serves as a
central, public repository for genetic variation, where each variation has a
unique reference identiﬁer (rsID).
1.1 Genotype to phenotype
The consequence of the genetic variation is the variability in phenotypes,
i.e. observable traits of organisms such as morphology, development or be-
haviour. The concepts of genotypes, phenotypes and their relationship have
been described already in 1911 by Wilhelm Johannsen based on his obser-
vation of self-fertile common bean [61]. The simplest case of genotype to
phenotype consequences are Mendelian traits which are controlled by a sin-
gle locus and are characterized by a simple Mendelian inheritance pattern
summarized by Mendel’s laws [82]:
• Law of Segregation. Assuming diploidy, every individual has two
alleles for a particular trait, and during formation of gametes the allele
pairs segregate and each parent passes one randomly selected allele to
the oﬀspring. The trait in the oﬀspring is dependent on the combination
of dominant or recessive alleles.
• Law of Independent Assortment. Alleles of diﬀerent genes assort
independently of one another during gamete formation.
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Those two laws were formulated by Gregor Mendel in 19th century based
on his observations of colour, shape and position of the oﬀspring of several
generation of pea plants subjected to cross-hybridizing experiments. In
humans genotypes determine traits like hair or eye colour, freckling, blood
group, lactose intolerance or even earwax type. The latter is actually a
Mendelian trait and is determined by a single SNP rs17822931 in ABCC11
gene and can also be used to determine ancestry as the dry earwax is
predominant among East Asians (80-95%) but seen very rarely (0-3%) in
European or African populations [135]. Apart from physical traits and
ancestry, genomic variation inﬂuences our susceptibility to various diseases.
Mendelian disorders like Huntington’s disease, cystic ﬁbrosis or sickle-cell
anaemia are caused by genetic aberrations in a single gene and are highly
heritable. Because of high penetrance of the risk alleles, most of those genetic
disorders are rare and are prevented by natural selection. Up to date more
than 14,000 genes involved in more than 3,500 Mendelian disorders have
been described and are collected in the Online Mendelian Inheritance in Man
(OMIM) database [50].
However, majority of diseases and traits are inﬂuenced by a combination
of genotypes from various associated genomic loci, which makes discovering
the genetic determinants of a disease a rather challenging task. Further-
more, even though the genetic component has a major contribution to an
organism’s phenotype, the ﬁnal result is usually inﬂuenced by the interplay
between the genotype and the environment. This particularly well refers to
complex disease susceptibility, where barely having a set of risk alleles at
associating loci predisposing to a given disease is not a diagnosis by itself
and an appropriate lifestyle can in many cases prevent the occurrence of the
disease. A scientiﬁcally baﬄing example is height, believed to be a complex
interplay of genetics, diet and environment.
1.2 GWAS
In recent years genome-wide association studies (GWAS) have become a
popular way of exploring genomic variations related to speciﬁc traits or dis-
ease risk. The design of these studies includes collecting DNA samples from
a large group of aﬀected (cases) and unaﬀected individuals (controls). The
samples are genotyped for usually around 500,000 - 1 million SNPs and then
for each locus the diﬀerences in minor allele frequency (MAF) of the SNP
are investigated between cases and controls. A p-value of the signiﬁcance of
this diﬀerence is calculated with a chi-squared test, and further corrected for
multiple comparisons usually with Bonferroni correction [26].
Up to date more than 1,400 GWAS studies have been published, re-
porting more than 7,000 SNPs associated to various traits (Figure 1.1) [56].
The largest to date GWA study was conducted by the Wellcome Trust
Case Control Consortium investigating 14,000 cases of common diseases and
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Published  Genome-­‐Wide  Associations  through  07/2012  
Published  'tĂƚƉчϱyϭϬ-­‐8  for  18  trait  categories  
NHGRI  GWA  Catalog  
www.genome.gov/GWAStudies  
www.ebi.ac.uk/fgpt/gwas/    
Figure 1.1. Findings of all Genome-Wide Association stud-
ies published up to July 2012 gathered across the chromosomes.
Colour of the dots reﬂects the type of trait or disease investigated.
Source: www.genome.gov/gwastudies.
3,000 shared controls [19]. This study demonstrated the power of GWAS to
discover new disease genes and established the gold standard for the ﬁeld.
Despite the success of GWAS in detecting new disease associations, we are
still far from translating the ﬁndings into clinical settings. The majority
of SNPs investigated by commercially available genotyping arrays reside in
non-coding regions of the genome, which poses a diﬃculty in the biological
interpretation of the association signals. SNPs are inherited in linkage
disequilibrium (LD) blocks, which means that there is little recombination
activity within a block, resulting in similar MAF distribution among the
SNPs within such block. In most cases the disease-associated SNP detected
by GWAS is not the true causative SNP, but rather it is in high linkage
disequilibrium with the causal variant. This creates a need for GWAS
follow-up studies where the associated locus is investigated in detail to ﬁnd
the true causative variant [29]. An obvious deleterious candidate would be
a SNP aﬀecting the protein sequence and in turn protein function, however
there exist also many regulatory variations aﬀecting the expression of the
gene or protein. These variants remain diﬃcult to interpret as the existing
annotations and our understanding of the function of the non-coding genome
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is rather limited.
Another limitation of GWAS is that the assayed SNPs are selected to have
considerably large MAF, which in turn leads to discovery of many common
associated variations but all with rather small eﬀect sizes. Despite many
eﬀorts and resources invested in investigating the common variations in
human genomes, the promises to ﬁnd the genetic components of heritable
traits have lead to many disappointments. Even with regard to traits like
height, with estimated heritability of 80-90%, the more than 200 associated
genetic variants discovered up to date together account for approximately
10% of the trait heritability [3]. The missing heritability could be potentially
explained by other factors including rare variants, copy number variations,
epigenetics and environmental exposures inﬂuencing the ﬁnal phenotype.
This motivates investigating the heritability of traits and susceptibility to
diseases applying systems biology approaches, where one should investigate
the system as a whole, or at least at higher levels of functional abstraction,
rather than concentrating on the contributions of the individual common
variations.
Finally, the GWA studies investigate the genetic variations across the entire
genome and present a data-driven study design. This creates a need for
strict statistical corrections for multiple testing, as simply by chance many
false positive results would be expected when testing thousands of loci.
Despite the undoubted need for this procedure, many true weaker associated
loci are discarded in this step. Another implication of the need to perform
multiple testing correction is the need for large cohort sizes in order to obtain
suﬃcient power to detect the associations with signiﬁcantly low p-values.
As a guideline, sample sizes of at least 1,000 cases and 1,000 controls are
required to detect odds ratios ~1.5 in size with at least 80% power [138].
1.3 Identifying disease variants with NGS
An emerging alternative to GWAS is the next-generation sequencing
(NGS) technology, which allows investigating of all the bases in the
genome, including rare variants, indels and structural rearrangements.
New sequencing technologies are developed constantly increasing the out-
put and its quality, and at the same time decreasing the per-base cost.
This leads to routine human genome sequencing becoming both feasi-
ble and aﬀordable. With the massively parallel sequencing technologies
we are able to sequence the whole human genome within a few days
at a relatively low cost of approximately $10,000 per genome (source:
http://www.genome.gov/sequencingcosts/), or even $5,000 from vendors such
as Complete Genomics (http://www.completegenomics.com/). Among the
most important applications of NGS are variant discovery, new genome
assemblies, transcriptomics, methylation proﬁling and discovery of new mi-
croorganisms from environmental samples by metagenomics (Figure 1.2) [83].
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sets of molecules, and this capability will further add to the value of these 
data. The details of a given application will determine which technology 
is best suited for a particular situation. For example, read-length is more 
important for de novo sequencing and metagenomics with unknown 
organisms. For digital gene expression, read-length is much less impor-
tant and the number of reads becomes paramount. Thus, the absolute 
number of Mb/h is a useful metric but tells only part of the story with 
the number of reads sometimes a more important indicator. Whether 
interested in the number of reads or the number of bases, researchers and 
healthcare providers should be preparing now for what they will do with 
orders of magnitude more sequence data.
High-throughput sequencing is not without issues. Even if sequencing 
were entirely free (which is not likely to happen), there are other costs 
that will limit the benefits derived from very cheap data generation. The 
huge quantity of sequences will shift the bottleneck from the generation 
of data to its analysis. There are important challenges112 for the analysis 
of such data that will require changes to the programs used to align and 
assemble sequence. The various sequencing technologies generate differ-
ent read-lengths, different error rates and different error profiles relative 
to traditional data and to each other. In addition to simply analyzing 
the sequence data, new methods will be needed to analyze and integrate 
the massive data sets and then apply those results to various types of 
biological information. The new technologies will no doubt raise issues 
with many aspects of the current research and diagnostic infrastructure, 
and those issues should be considered now. The complexity of analy-
sis will rise markedly, but the opportunities for an immensely deeper 
understanding of disease, its causes and personalization of treatment 
will be even greater.
Overcoming these obstacles will be critical for taking full advantage of 
artifacts. This prevents a full analysis of the 
genome and leads to a reduction in the types 
of genomic or genetic changes that can be 
detected110. The throughput of current array 
platforms cannot accommodate experiments 
with 104–106 samples for a reasonable cost 
and within a reasonable time frame. Although 
the use of genome tiling arrays provides solu-
tions to some of these challenges, a complete 
picture of the transcriptome remains a techni-
cal and algorithmic challenge. The increased 
content of tiling arrays makes cost of array 
manufacture and processing an issue that has 
limited their use for large numbers of samples. 
Microarrays will continue to be widely used for 
the foreseeable future because of their exten-
sive legacy data and installed instrument base. 
However, depending on how deeply one wishes 
to sequence, digital gene expression has now 
matched or exceeded microarrays in terms of 
reagent and disposable costs per sample111. 
The different sequencing platforms can gen-
erate anywhere from 500,000 to 500,000,000 
reads per run and those are distributed across 
up to 50 channels, making it possible to analyze 
that many samples simultaneously. The costs 
of both microarrays and sequencing are, in 
many cases, <$400 per sample, so the choice 
of platform becomes dependent on the type 
of experiment and the available instrumenta-
tion ,with recurring costs becoming less of a 
factor.
Similarly, for genetic analysis, various types of genotyping arrays have 
provided a wealth of data on many phenotypes with the ability to read-
ily analyze thousands of samples, but remain fundamentally limited by 
the requirements for known variations and the current inability to cost 
effectively include all rare variants and singleton SNPs not covered by 
linkage disequilibrium. Both genotyping and expression arrays are also 
limited by sequence differences across genomes, requiring new sets of 
arrays as different species are examined. If our understanding of genome 
variation is limited to human samples, the full benefits that are attain-
able by studying other species, including disease and drug safety models, 
will be lost.
Capillary electrophoresis–based sequencing technologies are also 
unable to pierce the price and performance barriers to enable high- 
content, genome-wide experiments requiring thousands of genomic 
samples. To make genome-scale studies tractable, researchers have applied 
complexity-reduction techniques, or have relied on biological inference 
to select genes or gene regions of interest, thus looking under the lamp-
post rather than opening the genome for a full inspection. Without the 
availability of true whole-genome sequencing technologies, many regions 
of the genome will remain refractory to analysis, and many rare variants 
will remain undiscovered, limiting our understanding of genomic varia-
tion and disease.
There are now multiple high-throughput sequencing technologies 
that can address the present limitations of both hybridization-based 
technologies and classic sequencing. These technologies vary in their 
sequencing throughput in terms of samples and sequences, their com-
plexity of sample preparation requirements and their output in terms 
of read-lengths1–5. Additionally, some of these techniques allow single-
molecule sequencing, instead of the traditional sequencing of amplified 
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Figure 3  What can high-throughput sequencing do for you? The breadth of information that can be 
generated with high-throughput sequencing and the variety of sample sources is illustrated.
PER SP ECT IVE
©
20
08
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
up
  h
ttp
://
ww
w.
na
tu
re
.c
om
/n
at
ur
eb
io
te
ch
no
lo
gy
Figure 1.2. Applications of next-generation sequencing tech-
nologies. Source: Kahvejian et al. [64].
With the constantly decreasing cost of sequencing, NGS is likely to
substitute SNP arrays for genotyping purposes in the near future [129]. The
limitating factor in ge ome r search is not any ore the available t chnology
or its cost, but rather our abilities of interpretation of the genomic informa-
tion. Even though we are able to sequence the whole human genome, our
understanding is mostly limited to the protein coding regions constituting
approximately 1% of the whole sequence corresponding to approximately
30 megabases (Mb) in length. For this reason exome sequencing became
popular strategy to identify disease-causing vari tio , as variations af-
fecting protein sequence often result n loss of function of the pro ein and
are t erefore easy to interpret biologically. Exome sequencing is based on
target enrichment technique where subset of whole genome DNA is captured
by means of complementary RNA baits or a microarray and sequenced
instead of the initial sample. This strategy proved to be extremely useful
in identifying causal rare variants for Mendelian disorders, where in most
cases the caus tive variants are non-synonymous coding with large eﬀect
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sizes [88, 89]. Exome sequencing has a signiﬁcant advantage over microarray
genotyping platforms as genotyping is not limited by probe design and it
allows for detection of novel variants. Target enrichment can also be used
on smaller custom genomic targets deﬁned by needs of speciﬁc project and
then multiplexing techniques can be used to further reduce the cost of the
experiment. As compared to whole genome sequencing (WGS), targeted
sequencing requires less sequencing output to produce required coverage and
therefore more samples can be assayed at the same cost. An obvious limita-
tion of exome sequencing is that it does not take into account any non-coding
regions, which comprise 99% of the genome and might also contribute to
disease risk. Additionally, WGS allows for examining the whole spectrum of
genetic variants, including structural variations and copy number variations,
while targeted sequencing is mostly useful for detecting SNPs and indels.
1.4 Personal genomes
Several companies took advantage of the advances in SNP genotyping
technologies and published research ﬁndings of GWA studies and oﬀer
direct-to-consumer genetic testing of thousands of SNPs. Companies like
23andMe (www.23andme.com), deCODEme (www.decodeme.com) or Navigenics
(www.navigenics.com) can analyse genetic variation for relatively low cost
and report back the individual’s risk for a number of common diseases, the
ancestry, as well as some of the individual’s traits. 23andMe has been ag-
gressively marketing their product and the standard oﬀering is a 1M Illumina
Chip based SNP assay. The reported relative disease risk is evaluated by
comparison with a disease risk of someone of the same age and gender in the
general population. The health report can be a way of identifying diseases to
which one is susceptible without the necessity of going to a doctor, however
the results should be taken with a pinch of salt as the massive-scale SNP
assays are not error free, and even though the overall percentage error might
be very small, such errors could produce wrong risk assessment and produce
a false sense of security or needless concerns. Even more concerning is the
limited current understanding and predictability of most diseases. The ﬁnd-
ings from GWA studies of common diseases often have very low odds ratio
and alone contribute very little to development of the disease. For instance,
my own 23andMe report states that I have a 1.94x higher risk than average
of developing Crohn’s disease, which translates to 0.9% overall estimated
risk. This report is not likely to raise my concern about my susceptibility
to Crohn’s disease. On the other hand, my risk of obesity according to my
DNA is typical for people of my age, gender and ancestry, translating to my
individual risk of 67.2%, which makes me more aware of the importance of
diet and exercise despite the genotypes. Clearly, the opportunity to know
what we are susceptible to can inﬂuence our life-style choices and in this way
beneﬁt our health, however there is also a possibility that a report of a high
10 CHAPTER 1. GENOMIC VARIATION
risk of developing a certain disease can cause unnecessary anxiety in an indi-
vidual. Often much more informative for the patient would be to investigate
the family history and the environmental and life-style factors, which are
likely to have much more inﬂuence on the disease risk than common genomic
variation. On top of that, even though the genotyping concordance between
the diﬀerent platforms used by the three aforementioned companies are very
high, the predicted genetic disease risks can be quite diﬀerent [59], which
leads us to believe that our understanding of the genetic basis of the diseases
is actually very little and such information cannot yet be used in reliable
assessment of the genetic contribution to disease risk of an individual.
Investigating individual genome variation can be used in a variety of ways
beyond looking at disease susceptibility. There have been several successful
published stories of deﬁning the migration history and physical traits of
ancient individuals, including the Saaqaq genome of an individual from the
extinct Palaeo-Eskimo Saqqaq culture sequenced from a lock of hair preserved
in permafrost [103] or the genome of an Aboriginal Australian sequenced
from a lock of hair found in a museum [102]. Genome sequencing also tried
to explain more contemporary questions, when the genome of a heavy metal
rocker Ozzy Osbourne was sequenced in a hope to reveal the secrets of
apparent lack of inﬂuence of his excessive drinking, drug abuse and partying
on his health. Despite discovering a rare variant in a gene ADH4 responsible
for alcohol metabolism and variants pointing to higher likelihood of alcohol
and cocaine addiction, the mystery remains unresolved as our understanding
of the variations function is not suﬃcient to interpret them reliably. The
Personal Genome Project [25] is currently trying to overcome some of those
limitations, and improve our understanding of the ways how the genomic
proﬁle together with environmental exposures ultimately lead to traits.
The study aims to recruit up to 100,000 individuals and to collect exten-
sive information on their genomic sequence, tissues, environment, traits and
others and undoubtedly will provide researchers with plenty of valuable data.
The development of modern medicine has almost exclusively been empiric
without prior knowledge of the interactions between drugs and biological
pathways. Not surprisingly, this frequently has lead to treatment failure or
unacceptable toxicities.The work presented in this thesis aims at discovering
the impact of genomic variations on treatment response and disease hetero-
geneity by combining the eﬀects of variations in functional modules they are
likely to operate in, deﬁned by protein-protein interactions and biological
pathways.
Chapter 2
Childhood acute lymphoblastic
leukaemia
Acute lymphoblastic leukaemia (ALL) is a cancer of lymphoid cells, a sub-
type of white blood cells involved in the body’s immune system. Acute
refers to the relatively short time course of the disease, ALL would be fatal
within few weeks if left untreated. The disease is characterized by excess of
lymphoblasts, which are immature lymphoid cells not capable of performing
their normal function, e.g. ﬁghting infections. ALL arises from a malignant
degeneration in a single lymphoid stem cell, which followed by dysregulated
proliferation leads to clonal expansion and accumulation of lymphoblasts,
which impairs normal haematopoiesis (Figure 2.1). Underrepresentation of
normal erythrocytes, leukocytes and platelets in blood and bone marrow
leads to clinical symptoms including anaemia, fatigue, pallor, bone pain,
bruising and susceptibility to infections.
2.1 Epidemiology and aetiology
ALL is the most common malignancy aﬀecting children, representing 25% of
all paediatric cancers. The annual incidence of ALL is approximately 4 cases
per 100,000 children in the Nordic countries, with peak incidence in children
aged 2-5 years [57]. The causes of leukemia remain largely unknown, however
genetic lesions leading to lymphoid stem cell transformation are believed to
be triggered by a combination of environmental exposures, infections and
inherited susceptibility [39].
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Figure 2.1. Blood cell development. Diﬀerent blood and immune
cell lineages, including T- and B-lymphocytes, diﬀerentiate from a
common blood stem cell. A malignant degeneration in a single
lymphoid stem cell may lead to development of ALL. Source: www.
cancer.gov
2.2 ALL classiﬁcation
There exist many subtypes of ALL characterized by diﬀerent prognostic pro-
ﬁles. The subtypes reﬂect the lineage of lymphoid development aﬀected,
with approximately 85% of childhood ALL resembling B-cell lineage and
15% resembling T-cell lineage (Figure 2.1). Further classiﬁcations include
speciﬁc cytogenetic aberrations, including abnormal number of chromosomes
or chromosomal translocations. The most common aberrations in B-lineage
ALL include hyperdiploidy, t(12;21) chromosomal translocation resulting in
ETV6/RUNX1 fusion gene and t(9;22) resulting in BCR/ABL fusion gene,
while activating mutations in NOTCH1 are the most common aberrations in
T-lineage ALL [123] .
Childhood ALL patients from Nordic countries are treated according to com-
mon treatment protocols established by the Nordic Society for Paediatric
Haematology and Oncology (NOPHO). At diagnosis patients are classiﬁed
as standard risk (SR), intermediate risk (IR) or high risk (HR) patients. In
the Danish cohorts studied in Papers III, IV and V this risk stratiﬁcation is
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based on 1) age at diagnosis, 2) white blood cell count (WBC) at diagnosis,
3) immunophenotype and 4) cytogenetics. Furthermore, minimal residual
disease (MRD) levels at the end of induction therapy has been registered in
the NOPHO ALL2000 protocol, but not applied for risk grouping, except
for the very rare patient cases with >0.1% MRD levels after three months
of therapy, who were oﬀered haematopoietic stem cell transplantion in ﬁrst
remission [116].
2.3 Chemotherapy
The length of chemotherapy treatment in ALL is between 24 and 36 months
depending on risk stratiﬁcation and involves in the current NOPHO protocol
up to 15 chemotherapeutic drugs, some of which are even given at varying
doses or routes of administration. Treatment is divided into three phases
[115]:
• Induction phase is a short and intensive treatment phase with the
aim to kill most of the leukemic cells and obtain clinical remission,
where no leukemic cells are detectable in bone-marrow aspirated by
conventional morphological examinations. In this phase a combination
of three to four drugs is used including a glucocorticosteroid, Vincristine
(an antimicrotubule agent), an anthracycline and/or asparaginase.
• Consolidation phase is targeted at killing most of the remaining
leukemic cells by alternating cycle of drug combinations, including
antimetabolites, alkylating agents and an epipodophyllotoxin.
• Maintenance phase is a long and less intensive treatment phase. The
aim of this therapy is to kill any residual leukemic cells, not eradicated
by the induction and consolidation therapy to prevent relapse. Main-
tenance therapy is based on combination of following antimetabolites:
mercaptopurine and methotrexate.
• In addition, central nervous system directed therapy is given.
The speciﬁc drugs used in childhood ALL treatment, together with their
mechanisms of action, biology and relevant pharmacogenetics are described
in Chapter 3.2.
Current cure rates for childhood ALL after ﬁrst-line therapy approach
80-85% in the developed countries [116, 99]. However, even within risk-
adapted treatment groups, there is substantial interindividual variability in
treatment response. Nearly all chemotherapeutic drugs have narrow thera-
peutic range, which means that the diﬀerences between toxic and therapeutic
14CHAPTER 2. CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
doses are small. Even though treatments are traditionally adjusted to pa-
tient’s age, weight and other clinical parameters at presentation, still the
interidividual diﬀerences in pharmacokinetics (”what the body does to the
drug”) and pharmacodynamics (”what the drug does to the body”) largely
inﬂuence the treatment eﬃcacy. Many childhood ALL patients suﬀer from
treatment-related toxic side eﬀects, which are likely to be a result of too
high bioavailability of a certain drug caused for instance by ineﬃcient eﬄux
system. On the other hand approximately 10-15% of patients experience a
relapse of the disease, which in many cases could be attributed to insuﬃ-
cient drug disposition. Several studies have indicated that patients with the
optimal host pharmacogenetics proﬁles have cure rates above 90% [33, 117].
Identifying failing mechanisms in the remaining patients and then individu-
ally adjusting the chemotherapy to mirror the drug disposition of the most
favourable pharmacogenetics proﬁles could potentially bring the overall ALL
cure rates to above 90%.
Chapter 3
Pharmacogenomics
Pharmacogenomics1 is a particular ﬁeld of studies dedicated to investigating
genetic diﬀerences in metabolic pathways. Such variations are believed to
aﬀect the individual responses to drugs and determine the diﬀerences be-
tween eﬀective and toxic drug doses. The pharmacogenetic polymorphisms
can aﬀect either the pharmacokinetics of the drug and reside then in genes
involved in absorption, distribution, metabolism and excretion (ADME)
properties of the drug, or the pharmacodynamics of the drug and involve
variations in the drug targets and downstream signalling pathways [112].
The ﬁeld of pharmacogenomics oﬀers a great promise to the future of per-
sonalized medicine, where the drug dosing will be adjusted to patient’s
individual genetic makeup. Discovering the molecular mechanisms underly-
ing drug exposure and eﬀect will allow clinicians to minimize the toxic side
eﬀects and avoid the problem of lack of response due to too low dosage. A
clear advantage of pharmacogenomics is that the genotype of an individual
remains constant and is not aﬀected by the treatment itself. Moreover, a
variety of reliable genotyping methods exist which can be suited to the needs
of a particular experiment [79]. The constant increase in genomic infor-
mation data available facilitates the clinical interpretation of ﬁndings, and
resources reviewing and curating this knowledge like the Pharmacogenomics
Knowledgebase (PharmGKB) [54] or DrugBank [131] create a comprehensive
foundation for the personalized medicine.
1Precise deﬁnitions of pharmacogenetics and pharmacogenomics diﬀer depending on
the source, however there is a general consensus on the two terms being interchangeable.
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3.1 Pharmacogenetics in ALL
Childhood acute lymphoblastic leukaemia is for several reasons a model dis-
ease for studying pharmacogenetics eﬀects [24, 33]:
• It has an early onset and therefore only limited environmental exposures
playing a role in the etiology of the disease.
• It is the most common childhood cancer.
• The clinical subsets deﬁned by the clonal karyotype are well-described.
• It is a ’liquid’ tumour and is therefore relatively easy to study through
blood samples or bone-marrow aspirates.
• It is in general highly chemosensitive.
• Patients experience signiﬁcant interindividual diﬀerences in treatment
response and toxicities.
• It is almost uniformly treated within the collaborative groups allowing
for use of patient samples from other cohorts for validation of ﬁndings.
The bioavailability of drugs depends largely on eﬃciency of transport of
those drugs inside the cell, how they are metabolized, and ﬁnally how rapidly
they are secreted from the cell (Figure 3.1). Uptake of drugs inside the cell
is mediated by the solute carrier (SLC) family of membrane trasnport pro-
teins, which can modulate drug levels within the body by regulating their
absorption, distribution, metabolism, and elimination (ADME) [114]. The
most important enzymes metabolizing childhood ALL drugs include enzymes
from cytochrome P40 superfamily activating or inactivating the drugs (phase
I enzymes) and glutathione S-transferases enzymes conjugating drugs with
endogenous substances which makes them suitable for excretion (phase II
enzymes)[15]. Phase I enzymes comprise mixed function oxidases, which act
mostly in the liver and by oxidation, reduction, hydrolysis or cyclization con-
vert a prodrug to a pharmacologically active compound, or can transform
a nontoxic molecule into a poisonous one. Phase II enzymes interact with
the polar functional groups of phase I metabolites by conjugating reactions
and are usually detoxicating. Eﬄux of the drugs is mediated mostly by the
ATP-binding cassette (ABC) transporters, with the most studied member
being P-glycoprotein, also known as multidrug resistance protein 1 (MDR1)
or ABCB1. This ATP-dependent drug eﬄux pump has a broad substrate
speciﬁcity, it inﬂuences the drug accumulation and often mediates the de-
velopment of resistance to anticancer drugs [47]. The pathways of drug
metabolism and transport are very polymorphic, which results in high inter-
individual bioavailability of the drug and subsequently diﬀerences in treat-
ment response. Many of the enzymes share the same substrates and many
cancer agents are metabolized by the same enzymes which creates a complex
interplay of the drug dosage, pharmacogenetics and treatment response.
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activation or inactivation, and phase 2 enzymes, which
conjugate drugs with endogenous substances making
them more water-soluble and suitable for excretion. As
detoxifying pathways and drug eﬄux systems are very
polymorphic and in addition often share the same
anticancer agent as a substrate, polymorphisms in such
genes are likely to influence treatment response. However,
other drugs that modify these pathways would also
influence the efficacy or toxicity of the treatment.15,102,105
Cytochrome P450 Enzymes
The cytochrome P450 (CYP) phase 1 enzymes and
particularly the CYP3A subfamily are involved in the
activation (eg, cyclophosphamide and epipodophyllo-
toxins) or inactivation (eg, glucocorticosteroids and vinca
alkaloids) of many anticancer agents.106–109 Furthermore,
the glucocorticosteroids induce CYP3A enzymes, which
may influence the clearance of the glucocorticosteroids
themselves, but also of other anticancer agents, such
as vincristine.15,102,110 Most of the CYP genes are highly
polymorphic, but the clinical consequence remains
uncertain.11,19 Some polymorphisms such as the
CYP3A5*3 6986A>G and CYP3A5*6 30597G>A in
exon 7 generate alternative splicing, resulting in truncated
proteins, which may lead to decreased functional levels of
CYP3A5, compared with the wild-type allele.11 Some
studies show significant association with CYP3A4*1B
and CYP3A5*3 with treatment-related leukemia, drug-
induced toxicities, and higher etoposide clearance.12,14,15
However, this has not been supported by others (Table 1).
TABLE 3. Polymorphisms not Investigated Clinically, With Potential Relevance to Childhood Acute Lymphoblastic Leukemia
Therapy
Site of Action
Implicated
Drugs Polymorphism
Selected
Polymorphisms
Chromosomal
Location MAF
Functional
Consequence References
Metabolism CPM CYP2B6 -82T>C rs34223104 19q13.2 0.024 Enhanced transcription 86
CYT CDA -897C>A rs10916823 1p36.2-p35 0.02* Change expression 87
CYT CDA -451C>T rs532545 1p36.2-p35 0.264 Change expression 87
CYT CDA -92A>G rs602950 1p36.2-p35 0.333w Change expression 87
CYT CDA 208G>A NA 1p36.2-p35 ND Reduced activity 88
Transport CYT hENT1 -1345C>G rs731780 6p21.2-p21.1 0 Increase in expression 89
CYT hENT1 -1050G>A rs70914 6p21.2-p21.1 0 Increase in expression 89
CYT hENT1 -706G>C rs747199 6p21.2-p21.1 0.2 Increase in expression 89
Regulation
of drug
target
response
ASP ASNS -92G>A NA 7q21.3 ND Increase in expression 90
*See reference in table.
wAccording to PharmGKB.10
ASP indicates asparaginase; CPM, cyclophosphamide; CYT, cytarabine; MAF, minor allele frequency (European populations or Utah residents with ancestry from
northern and western Europe), according to NCBI Entrez SNP database; NA, not applicable.
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FIGURE 1. A simplified model of the general route of a drug with metabolism in the liver, transport in and out of the cell,
intracellular metabolism, and final cytotoxic effect of drug. The arrows indicate direction of route. CYPs indicate cytochrome P450
enzymes; GSTs, glutathione S-transferases.
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Figure 3.1. A simpliﬁed model of the general route of a drug
with metabolism in the liver, transport in and out of the cell, in-
tracellular metabolism, and ﬁnal cytotoxic eﬀect of drug. The ar-
rows indicate direction of route. CYPs indicate cytochrome P450
enzymes; GSTs, glutathione S-transferases. Source of ﬁgure and
legend: Davidsen et al. 2008 [33].
3.2 Drugs in childhood ALL
The following chapter brieﬂy describes the chemotherapeutic drugs com-
monly administered during childhood ALL treatment, their mechanisms of
action and the most important relevant pharmacogenetics domains.
3.2.1 Glucocorticoids
The glucocorticoid (GC) drugs commonly used in treatment of childhood
ALL include prednisone, prednisolone (active metabolite of prednisone) and
dexamethasone. They are metabolized in the liver by CYP3A and GST
enzymes. Glucocorticoids act by binding to glucocorticoid receptor (GR)
and by either binding to GREs (consensus sequence: GGT ACA NNNTGT
TCT) of target genes or interacting with AP-1 or NF-B transcription
factors they induce apoptosis in leukemic cells [125]. The response can be
inﬂuenced by proteins involved in the GR-inactivating complex, including
heat shock proteins 70 (Hsp70) and 90 (Hsp90), vitamin D receptor (VDR),
and cytokines, such as tumour necrosis factor (TNF) or interleukins (ILs)
[33].
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3.2.2 Vincristine
Vincristine is an antimicrotubule agent exerting its anticancer eﬀect by bind-
ing to tubulin, and thereby disrupting microtubule structures of the cell cy-
toskeleton and mitotic spindle leading to mitotic arrest and cell death [63].
Vinca alkaloids, including vincristine, are mostly metabolized by CYP3A en-
zymes, and are transported by several members of the ATP-binding casette
transporters family. Among others ABCB1, ABCC1, ABCC2, ABCC3,
ABCC10 and RALBP1 have been reported in association with vincristine
resistance [94].
3.2.3 Anthracyclines
Two of the anthracycline drugs commonly administered in childhood ALL
treatment are doxorubicin and daunorubicin. Anthracyclins interact with
DNA by intercalation (squeezing between the base pairs) and inhibit replica-
tion processes by preventing progression of topoisomerase II (TOP2A) [85].
Anthracyclines are transported inside the cell by SLC22A16 and exported
by amongst others: ABCB1, ABCC1, ABCC2, ABCG2 and RALBP1. The
three main metabolic routes are: one-electron reduction (carried out by sev-
eral oxidoreductases, including NADH dehydrogenases and nitric oxide syn-
thases), two-electron reduction (carried out by various enzymes depending
on the cell type, including CBR1, CBR3, AKR1A and AKR1C3) and degly-
cosidation (involving enzymes such as: POR, XDH and NQO1)[124].
3.2.4 Asparaginase
Asparaginase is an enzyme converting asparagine to aspartic acid and am-
monia. In general, leukaemic cells do not synthesize asparaginase like nor-
mal cells, and are therefore dependent on its exogenous sources for sur-
vival. By catalysing the depletion of circulating asparagine, asparaginase
leads to leukemic cell death [17]. Induction of asparagine synthetase (ASNS)
in leukemic cells could potentially lead to asparaginase resistance [100].
3.2.5 Methotrexate
Methotrexate (MTX) is an anti-metabolite acting by inhibiting the dihydro-
folate reductase (DHFR) and thereby inhibiting DNA synthesis and cellu-
lar replication by restricting access to folate coenzymes. It acts speciﬁcally
during the S-phase of the cell cycle, where it prevents the growth and prolif-
eration of dividing cancer cells. Pharmacogenetics of methotrexate is quite
complex as the drug interferes with numerous components of the folate path-
way, including: TYMS,MTHFR andMTHFD1, and aﬀects both thymidylate
synthesis and purine de novo synthesis. Methotrexate absorption is mediated
mostly by SLC19A1 and SLC46A1 [48], and it is pumped out of the cell by
several ABC transporters. Inside the cell it is polyglutamated by FPGS, and
this process can be reversed byGGH [100, 84]. Compared to monoglutamated
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MTX, the long-chained MTX polyglutamates are retained intracellularly and
have increased aﬃnity for the target enzymes. Polymorphisms in any of the
mentioned genes might aﬀect the systemic exposure of the drug.
3.2.6 Mercaptopurine
Mercaptopurine (6-MP) is an immunosuppressive drug, which upon conver-
sion to active nucleotide metabolites by hypoxanthine phopshoribosyltrans-
ferase (HPRT1) is incorporated into DNA and RNA. 6-MP inhibits purine nu-
cleotide synthesis and metabolism, and exerts its cytotoxic eﬀect on leukemic
cells by causing DNA strand breaks during aberrant post-replication mis-
match repair [100]. Inactivating pathways catalysed by xanthine oxidase
(XDH) or the polymorphic thiopurine methyltransferase (TPMT) are com-
peting with the synthesis of active metabolites [137]. Some of the methylated
6-MP metabolites, most notably the methyl-thioinosine monophosphate, are
strong inhibitors of purine de novo synthesis and may thus enhance the in-
corporation of thioguanine into DNA [52]. The dependency between TPMT
activity and the eﬀective 6-MP dose has been demonstrated in childhood
ALL patients [108] (Figure 3.2), and it is up to date the only example of clin-
ical translation of pharmacogenetics studies into ALL treatment protocols
[107, 116].
3.2.7 Cytarabine
Cytarabine is an anti-metabolite drug, which after being metabolized to cy-
tosine arabinoside triphosphate gets incorporated into human DNA instead
of the highly similar deoxycytidine. During the S phase of the cell cycle the
drug damages the DNA and blocks the progression of cells from the G1 phase
to the S-phase [21]. The implicated mechanisms of resistance to cytarabine
include: ineﬃcient cellular uptake due to low levels or activity of SLC29A1,
reduced levels of activating enzyme deoxycytidine kinase (DCK), or increased
levels of inactivating enzymes 5’nucleotidase (NT5C) or cytidine deaminase
(CDA) [69].
3.2.8 Cyclophosphamide
Cyclophosphamide is an alkylating agent metabolized in the liver to phos-
phoramide mustard, which after attaching to the alkyl group of the guanine
base of DNA forms cross-links between and within DNA strands preventing
DNA from being separated for synthesis or transcription. Additionaly, it can
induce mispairing of the nucleotides and introduce mutations in the DNA,
which together with inhibition of replication lead to disruption of DNA func-
tion and cell death [131]. Metabolic transformation of cyclophosphamide is
mediated mostly by the CYP enzymes: CYP2B6, CYP2C9 and CYP3A4,
and the detoxiﬁcation mostly by ALDH1A1.
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statistically (P ￿ .22) in boys (17.1 ± 5.5 U/mL of packed
erythrocytes) versus girls (18.2 ± 5.2 U/mL of packed erythro-
cytes), nor was there a statistically significant difference in the
proportion of boys versus girls who were TPMT heterozygous or
homozygous deficient (14 [14%] of 98 boys versus five [6.1%]
of 82 girls) (P ￿ .091).
DISCUSSION
6-Mercaptopurine is one of the most widely used medications
for the treatment of childhood acute lymphoblastic leukemia. It
has been previously shown that patients who inherit TPMT de-
ficiency develop severe (3,5–7) and potentially fatal (8) hema-
topoietic toxicity when treated with conventional doses of
6-mercaptopurine (i.e., 50–75 mg/m2 per day). However,
TPMT-deficient patients can be safely treated with 6-mercapto-
purine if they are given substantially lower doses (i.e., 6%–10%
of conventional doses) (3,5,6). The mechanism of 6-mercapto-
purine intolerance in TPMT-deficient patients is the absence of
the principal metabolic inactivation pathway for thiopurines in
hematopoietic tissue, TPMT-catalyzed S-methylation of 6-mer-
captopurine and its thioguanine nucleotide metabolites (19).
TPMT activity is inherited as an autosomal co-dominant trait:
About one in 300 Caucasian, African, African-American, and
Asian populations are TPMT deficient (9–11,20,21), and ap-
proximately 10% of these populations inherit intermediate
TPMT activity due to heterozygosity at the TPMT locus. It was
not previously known whether TPMT heterozygous individuals
could tolerate 6-mercaptopurine doses comparable to homozy-
gous wild-type patients or whether they were at a higher risk of
dose-limiting 6-mercaptopurine toxicity. This study has estab-
lished that this genetically defined subset of the population ac-
cumulates statistically significantly higher cellular levels of the
active thioguanine nucleotide metabolites and experiences
greater toxicity when treated with conventional doses of 6-mer-
captopurine. This finding indicates that the genetic polymor-
phism of TPMT has a substantially greater influence on toler-
ance to acute lymphoblastic leukemia chemotherapy than would
be the case if only the relatively rare TPMT-deficient patients
were intolerant to full-dose 6-mercaptopurine.
This study has shown that, at conventional 6-mercaptopurine
doses of 75 mg/m2 per day, TPMT heterozygotes accumulate
approximately twofold more thioguanine nucleotides in their
erythrocytes when compared with homozygous wild-type pa-
tients. This difference in thioguanine nucleotide accumulation
translated into a fivefold greater cumulative incidence of 6-mer-
captopurine dose-limiting toxicity in TPMT heterozygotes com-
pared with TPMT wild-type patients (Fig. 6; 35% versus 7%
cumulative incidence). Consistent with this finding, TPMT wild-
type patients tolerated 75 mg/m2 per day of 6-mercaptopurine
during 84% of scheduled therapy compared with 65% in het-
erozygous patients and only 7% in TPMT-deficient patients
(Fig. 5). These data indicate that no TPMT-deficient patient will
tolerate full-dose 6-mercaptopurine and that TPMT heterozy-
gotes will require 6-mercaptopurine dose reductions signifi-
cantly more often than TPMT-homozygous wild-type patients.
Table 2. Rates* of primary toxic effects according to thiopurine S-methyltransferase phenotype
Homozygous wild-type
(n ￿ 161)
Heterozygous
(n ￿ 17)
Homozygous mutant
(n ￿ 2) P†
No. of weeks‡ 14 849 1521 35
Hepatotoxicity 0.50 0.07 0.00 .035
Thrombocytopenia 1.28 2.63 20.00 .137
Weeks of missed MP due to neutropenia 8.24 14.88 25.7 .007
Weeks of missed MP 17.68 23.60 51.43 .003
Hospitalization (fever and neutropenia or infection) 4.67 3.56 11.40 .128
*Units￿ number of toxic events or missed therapy per 100 weeks at risk, up until the time that the 6-mercaptopurine (MP) dose was altered to prevent toxicity.
†Compares heterozygotes to homozygous wild-type by use of generalized estimation equations for longitudinal binary data.
‡Number of weeks in which MP was expected to be delivered up until the MP dose was altered to prevent toxicity. This excludes weeks when no MP was
scheduled to be given.
Fig. 6. Cumulative incidence (95% confidence intervals) of re-
quiring a decrease in 6-mercaptopurine dose (from 75 mg/m2 per
day) to prevent toxicity among patients who were homozygous
wild-type, heterozygous, and homozygous deficient for thiopu-
rine S-methyltransferase (P<.001). Values ￿ final cumulative
incidences at the end of therapy and are also indicated at 1 year
for those with heterozygous or wild-type status.
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Figure 3.2. Cumulative incidence (95% conﬁdence intervals)
of requiring a decrease in 6-mercaptopurine dose (from 75 mg/m2
per day) to prevent toxicity among patients who were homozy-
gous wild-type, heterozygous, and homozygous deﬁcient for thiop-
urine S-methyltransferase (P<.001). Values ￿= ﬁnal cumulative
incidences at the end of therapy and are also indicated at 1 year
for those with heterozygous or wild-type status. Source of ﬁgure
and legend: Relling et al. 1999 [108].
3.2.9 Epipodophyllo oxins
Two of the epipodophyllotoxins used in childhood ALL treatment are etopo-
side and teniposide, used mainly in the consolidation/intensiﬁcation phases
[40]. They act by inhibiting topoisomerase II enzyme (TOP2A and TOP2B),
thereby preventing DNA re-ligation and causing breaks in DNA strands. The
eﬀects are cell cycle dependent and occur mainly during the S and G2 phases
[51]. Etoposide is metabolized by CYP3A and CYP3A5, or it can be con-
verted to O-demethylated metabolites by prostaglandin synthases (PTGS1
and PTGS2) or myeloperoxidase (MPO). The metabolites can be inactivated
by GSTT1, GSTP1 and UGT1A1, and eﬄux is mediated by ABCC1, ABCC3
and ABCB1 [132].
Part II
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Chapter 4
Predicting SNP eﬀects
The use of exome and genome sequencing in disease genetics allows us to de-
tect previously unknown variants in genomic samples. The biggest challenge
of those studies is the interpretation of the variants and prioritizing them to
dissect the causative variants from neutral variants from a list of thousands
of polymorphisms. A successful approach has been developed for identify-
ing the causative variants for Mendelian disorders using exome sequencing,
where common variants are discarded and rare non-synonymous variants are
considered to be the most likely candidates [88, 89]. This strategy however
would not be successful in studying common diseases, therefore being able
to predict the functional eﬀect of any variation is crucial to interpret the
impact on the susceptibility to disease.
4.1 SNP eﬀect on transcript
As SNPs occur on average every 100-300 bases along our genome, we can
expect that the vast majority of them would not have a functional eﬀect on
any protein. The eﬀect of the SNP depends on its location relative to the
coding sequence or regulatory elements. Examining the eﬀect of a variation
allele on a transcript allows for predicting the likely functional eﬀect of the
variation [81]. Diﬀerent types of variation eﬀects exerted on the transcripts
are illustrated in Figure 4.1.
4.2 Protein-coding changes
The polymorphisms aﬀecting protein-coding sequence are the most studied
up to date, with the interpretation being guided by applying both evo-
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than generalized tools due to their ability to incorporate
more speciWc models and reduce noise through prior
knowledge (Radivojac et al. 2008; Torkamani and Schork
2008). Integration of other datasets, such as genome-wide
expression and copy number analysis will also be crucial in
providing the best candidates for focused analysis (TCGA
2008).
Many of the issues resulting from small sample size or a
candidate gene approach that were present in early studies
will be mitigated through the decreasing cost of sequenc-
ing. However, the rapidly approaching dream of inexpen-
sive complete genome sequencing will also bring about a
new set of analysis challenges. Current cancer genome
sequencing projects are able to constrain their analysis by
focusing on protein-coding regions and non-synonymous-
coding mutations since that is the majority of generated
data. Next generation sequencing eVorts will likely include
the copious amounts of non-coding genomic sequence pres-
ent in the human genome which have not yet been exam-
ined by most existing sequencing eVorts. The results from
GWAS and small-scale experiments have already demon-
strated that non-coding mutations can have a signiWcant
impact on cellular function, but novel analysis methods are
needed to leverage this new data.
The exponentially increasing ability to sequence has
enabled experiments that were previously prohibitively
expensive. This new technology leads to an exciting time in
the Weld of cancer mutation research, but puts the burden on
the computational tools to provide the greatest value from
the generated data. Next generation tools will have to be
both accurate and fast to process the large amounts of
incoming data, and it will require multilateral eVorts to
fully mine each dataset.
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that could be used for mapping or analysis of the various kinds of se-
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Source: Lee et al. 2009 [72].
lutionary and biochemical evidence. This class of variations is also best
understood as any variation resulting in an amino acid chang , premature
stop codon or changing the coding frame is likely to aﬀect the function of the
protein. The strongest and ost widely applied predic of deleteriousness
is th evolutionary conservation ased on the assumption that the natural
selection drives the evolution of species by eliminating deleterious mutations
and conserving the essential positions. The impact of a mutation might also
depend on the location of he varia ion in speciﬁc structural domain of the
protein or a binding site, as well as on the similarity of the biochemical and
physical properties of the substituted amino acids. Based on comparison
of disease-causing non-synonymous coding SNPs from HGMD Pro 2009
[28] and all the no - ynonymous coding Ps from Ensembl release 54
[58] we demonstrated that the mutability of amino acids does not correlate
with the deleteriousness of the change (Figure 1a in Paper I). Transitions
b tween more similar amino acids re more permissible and substituting
for amino acids diﬀering in p ysicochemical properties is more likely to
be disruptive for the protein (Figure 1b,c,d in Paper I). There exist many
co putational tools using these information for predicting whether a given
non-synonymous coding variation is deleterious, including the most popular:
SIFT [87] and PolyPhen-2 [1]. Excellent reviews of those and variety of
other computational SNP eﬀect prediction tools are provided by Lee et al.
2009 [72] and Cooper et al. 2011 [29]. While assessing the deleteriousness
of a mutation can be very valuable, the ultimate goal is to understand what
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changes a given variation exerts on the molecular level. For this purpose the
EPipe Consortium (http://www.cbs.dtu.dk/services/EPipe/) has developed
a pipeline for assessing diﬀerential predictions of functional changes between
the wild-type and mutated proteins (Paper I). EPipe integrates a large
number of individual prediction tools, including predictions of sub-cellular
localization, post-translational modiﬁcations and sequence motifs, allowing
for more ﬁne-grained assessment of the impact of variation on the function
of the protein.
Finally, it is important to consider that synonymous variations, even though
they do not change the ﬁnal protein sequence and are usually considered
to be non-functional, have been demonstrated to also aﬀect protein struc-
ture and function by changing the translation kinetics and aﬀecting protein
folding [66, 65]. Those instances may be not as frequent and obvious as the
causality of non-synonymous coding variants, but they should not be ignored.
4.3 Non-coding variations
Since the protein-coding portion of the genome constitutes only 1% of its
total length, the majority of genetic variations reside in the non-coding
regions. Evolutionary analyses show that many non-coding regions are also
conserved between species implying functional importance of those regions.
Moreover, many GWAS results reside in non-coding regions and are not
in linkage disequilibrium with any coding variations, which supports the
hypothesis of functionality beyond coding regions. Apart from the coding
region of the genome, there exist many regulatory variations which may
reside in microRNA binding site, promoter region, transcription factor bind-
ing site or other regulatory feature, resulting in changed gene expression or
alternative splice variant. It is estimated that any individual has many more
functional regulatory variants than coding variants, however they are likely
to have smaller eﬀect sizes [128]. Similarly as for coding variants, the basis
for assessing deleteriousness of non-coding variant is comparative genomics,
however due to the rapid evolution of the non-coding DNA it includes only
comparison of closely related species, and can only be applied to homologous
regions, missing the human-speciﬁc sequence.
Several experimental eﬀorts are addressing those issues, including the Ency-
clopedia of DNA Elements (ENCODE) Consortium attempting to generate
whole-genome functional annotations, including non-coding regions like non-
coding RNAs and cis-regulatory elements in diﬀerent cell types [110] and
a range of expression quantitative trait loci (eQTL) studies are detecting
variations aﬀecting gene expression. Regulatory variations might be more
complicated to validate experimentally due to their spatial and temporal
patterns of action.
Even though signiﬁcant progress is being made in the ﬁeld of functional
human variation, we are still far from understanding the impact of any varia-
tion on the molecular level. An important consideration is that even proving
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molecular functionality of a variation (e.g. loss of protein function or change
of expression) does not always prove the deleteriousness of the variant or its
causality with respect to the studied phenotype. The task of interpretation
of genomic changes is complicated by the fact that at many positions in the
genome there exist several overlapping transcripts, and a single variation
can have diﬀerent eﬀects on any of them. To fully understand the functional
result of the variation it is necessary to integrate into analysis the knowledge
about tissue-speciﬁc gene expression and alternative transcripts, as well
as details of the mechanisms of regulation. Finally, the function of each
variation should be assessed in a broader context, investigating how it can
aﬀect protein-protein interaction networks or biological pathways.
4.4 Paper I- Protein annotation in the era of personal
genomics
The following paper describes the current state of art of annotation of protein
function and introduces an integrative pipeline for investigating diﬀerential
predictions of protein function, as well as presents some perspectives for the
personal genomics.
As a part of genomic variation background presented in the paper, we have
collected data on the known coding variations at the time from Ensembl
release 54 (NCBI genome build 36) and investigated their distribution across
the genome (Figure 2, Paper I), as well as compared the mutability and
deleteriousness of amino acid changes based on comparison of all known
non-synonymous coding SNPs and the disease-causing SNPs extracted from
HGMD Pro 2009 (Figure 1, Paper I).
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Introduction — personal genomics is here
The era of personal genomics has begun. DNA sequen-
cing technologies are constantly becoming faster and
cheaper, and human genomes are already being
sequenced by the thousands (1000 genomes consortium,
http://1000genomes.org/; Personal Genome Project,
http://www.personalgenomes.org/). However, without
proper downstream analysis, genome sequencing is most
useful for the understanding of chromosomal organization
and stratification of individuals, and does not lead to the
identification of functional variation. To harvest the
benefits of personal genomes, it is not enough to
sequence them — we also have to annotate and compare
large-scale functional variation (Figures 1 and 2).
Protein annotation is an old discipline. Ever since the first
protein sequences became available there has been a need
for identifying their functional features, since not all amino
acid residues in a sequence are equally important to the
function of the protein. At a coarse-grained level, annota-
tion is a matter of putting proteins into the right boxes,
which can be formalized by ontologies describing protein
structures, molecular functions, biological processes and
signalling pathways.Oneexample isGeneOntology [1]. At
themost fine-grained level, annotation aims at pinpointing
specific functional residues that constitute, for example,
the active sites of enzymes, post-translational modification
sites or essential structural motifs.
The overall goal of protein annotation is to provide a
structured view on function to allow for a more efficient
use of the available data. An important point of such efforts
is that annotated data lends itself more easily to analysis,
comparison and integration with other kinds of data. Auto-
mated annotation of structural and functional properties of
proteins from their amino acid sequences is often possible,
because similar functional or structural elements can be
identified through homology (common ancestry) with
already annotated proteins. In light of the flood of data
being produced, automation of annotation is becoming
increasingly important for complementingmanual annota-
tion [2]. This also means that the individual tools used for
annotation — as well as more complex workflows integrat-
ing many such tools — must be able to deal with the
rapidly growing amounts of data, and some newer predic-
tion methods used for sequence annotation have indeed
been cleverly designed to automatically update and retrain
themselves as new data becomes available [3!!].
Here, we review the current status of methods for the
annotation of protein function as seen in light of the
recent developments within the field of personal geno-
mics. With the current data challenge in mind, we
describe the different levels of annotation and which
types of features to annotate, and summarize the most
relevant annotation tools, namely predictors of local (pos-
itional) and global protein features. We then introduce
some examples of more advanced workflows in which the
outputs from multiple feature predictors are combined.
Finally, we discuss some of the challenges involved in
moving from single sequences and simple tools to pan-
genome comparisons through complex workflows. As a
special case we will focus on the promises of comparative
protein annotation in the context of human health.
Sequence versus structure
Protein structure is commonly considered the main deter-
minant of protein function, although the importance of
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intrinsically unstructured regions is becoming increas-
ingly recognized [4]. While sequence conservation
usually implies structural similarity, the same is not
always true for sequence–function relationships. This is
illustrated by paralogues, which often have different
functions despite having similar sequence and structure.
Moreover, a single mutation can fundamentally change
the function of a protein; for example, a mutation in a
binding pocket can entirely alter the substrate specificity
of an enzyme. Whereas inherited mutations with such
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Figure 1
Human variation and disease-causing SNPs. Disease-causing coding SNPs often perturb structure and/or function in proteins. This figure looks at
amino acid changes induced by disease-causing non-synonymous coding SNPs (35 445 SNPs from HGMD Pro 2009) compared to a background of all
non-synonymous coding SNPs (100 410 SNPs from Ensembl release 54; NCBI genome build 36). Mutability of amino acids (barplot in (a)) shows Arg
(R) to be the most changed while Cys (C) and Trp (W) to be the least changed. In this statistics, 70% of Gly (G) changes and 80% of Cys and Trp
changes are disease-associated. Heatmaps show a comparison as log 2 ratio of normalised counts (b) of all non-synonymous changes (c) and
disease-associated changes (d). Blue data points (b) represent more permissible amino acid transitions, while the red data points represent more
disease-causing ones. Various symmetries can be seen with the blue data points reflecting the fact that amino acids similar in physicochemical
properties can be interchanged without being disruptive (e.g. I and L, D and E, T and S) opposed to substituting for amino acids differing in properties
(e.g. W and S). In case of disease-causing transitions (red data points), the symmetries are fewer, suggesting such functional changes are often
disruptive and occurring unidirectionally. The transitions to and from tyrosine (Y) were not identified in the disease-causing SNPs dataset, possibly due
to limited size of the data set, thus marking strong blue spots.
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dramatic consequences are strongly selected against on an
evolutionary time scale, they are highly relevant in the
context of understanding variation between individuals.
This means that overall sequence and structure similarity
are generally useful for inferring function among well-
conserved proteins, but carry little or no information
about the functional consequences of random point
mutations, whether they are inherited or somatic.
To overcome this challenge, the functionally important
residues in the proteins must be identified, implying a
change in focus from global to positional features. One
way to do this is to manually annotate proteins or
protein families with information on, for example,
catalytic and ligand-binding residues as is done by
SMART [5], the Catalytic Site Atlas [6] and Firestar
[7]. Unfortunately, our knowledge on functionally
important residues is very incomplete, which prevents
comprehensive manual annotation. We must thus rely
on predictions. Fortunately, many functionally import-
ant residues are part of so-called linear motifs, which
are short, evolutionarily variable sequence patterns
involved in post-translational modifications, protein
targeting, cleavage and interactions. Due to their short
length and rather poor conservation, most linear motifs
are difficult to predict. Nonetheless, depending on the
availability of experimental data prediction methods
have been developed for many of the most important
ones.
Prediction of linear motifs and protein
features
Tools for predicting protein features come in different
flavours, the main difference being whether they predict
positional or global features.
The proper subcellular localisation of a protein inside
eukaryotic cells is crucial for the function, as it determines
the availability of other potentially interacting proteins
and metabolites. Thus, many prediction tools deal with
subcellular localisation, and some of the most successful
methods are SignalP [8], Phobius [9], Philius [10], Tar-
getP [11], WoLF PSORT [12], BaCelLo [13] and LOC-
Tree [14]. Although subcellular localisation per se is a
global property of the protein, the localisation signals that
control it are most often positional. To understand differ-
ences in subcellular localisation between individuals one
must therefore look at these positional motifs — global
properties like amino acid composition will not be
particularly informative.
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Figure 2
Chromosomal distribution of SNPs in coding regions. The plot shows the number of SNPs per chromosome (MT = mitochondrial). Over 71K
synonymous and 100K non-synonymous SNPs in coding regions of the human genome are recorded in Ensembl release 54 (NCBI genome build 36).
Chromosome sizes decrease from Chr-1 (247M) to Chr-22 (49M), but the number of non-synonymous SNPs generally correlates poorly with this.
Especially Chr-17 (79M) and 19 (64M) have disproportionately high numbers of non-synonymous SNPs.
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Other types of protein features are much more readily
identified as being controlled by the presence of motifs
and thus allow for simpler interpretation in the context of
protein variants. Such positional features include all the
well-known post-translational modifications: Attachment
of lipid moieties to direct proteins to the proper cellular
location through anchoring to the cell membrane [15,16];
various kinds of glycosylation and glycation to help fold,
protect and stabilise proteins [17–19]; phosphorylation,
the most common post-translational modification and a
crucial part of all intracellular signalling events [3!!,20];
ubiquitination [21] and sumoylation [22] to regulate a
wide range of protein functions. In this context, motifs for
binding, recognition and peptide cleavage can also be
considered easily interpretable.
Prediction of transmembrane protein segments and thus
implicitly subcellular localisation has also been highly
successful, where one of the best tools for predicting
transmembrane helices in protein sequences is Philius
[10]. Although it does not rely on the presence of specific
motifs as such, it is guided by special amino acid pre-
ferences inside the transmembrane helices as well as at
the helix boundaries. Prediction of other properties, for
example globular protein secondary structure [23,24],
surface exposure of individual amino acid side chains
[25], destabilisation upon point mutations [26] and intrin-
sic protein disorder [27,28] also rely on such more dis-
tributed sequence features.
A number of tools are available for the prediction of
deleterious single amino acid substitutions and typically
combine homology considerations (alignment) with infor-
mation derived from protein structure and physicochem-
ical properties of the exchanged amino acids [29–32].
Complex workflows and pipelines
When analysing the effects of single point mutations,
multiple sequence-based predictions need to be run on
the same sequence and the results viewed in the context
of each other. A few prediction pipelines, which automate
this task, are currently available.
The Eukaryotic Linear Motif resource for functional sites
in proteins, ELM [33!,34], contains a large number of
regular expressions for identifying linear motifs. A num-
ber of context-based rules and filters are employed to
improve predictive power and cover subcellular localis-
ation, phylogeny (homology), protein structure and Pfam
domain definitions [35]. The output from ELM is pre-
sented in an easily accessible form to allow for a quick
overview of the individual predictions.
Dasty2 is a web-based service capable of running numer-
ous prediction servers and annotation databases [36]
complying with the distributed annotation system
(DAS) standard [37]. The results from the remote servers
are collected and presented to the user in an interactive
and user-friendly format. Although Dasty2 and ELM
produce superficially similar outputs, they actually
represent two fundamentally different ways of creating
annotation. While ELM stores all prediction tools locally
and thus is an example of a centralised resource, Dasty2
relies on remote services and thus is distributed comput-
ing-wise.
Using tools such as ELM or Dasty2, it is relatively easy to
arrive at consensus predictions and to gauge the different
types of prediction against each other. However, neither
method allows for any simple way of identifying pre-
dicted features, which are functionally differential, the
central element of personal genomics. When studying
genetic variation between individuals, be it single-
nucleotide polymorphisms (SNPs) either coding or
non-coding, larger structural variation within genes (inser-
tions and deletions), somatic mutations or simply alter-
natively spliced variants of the same gene, it is absolutely
essential to be able to zoom in on the differences rather
than looking at all functional aspects. Such differences are
likely to be responsible for the main changes in the
behaviour of the protein.
A pipeline focusing on functionally differential features is
currently in development by the EPipe Consortium
(http://www.cbs.dtu.dk/services/EPipe/). It is similar to
both ELM and Dasty2 in the sense that EPipe integrates
a large number of individual prediction tools, both local
and distributed (including selected linear motifs from
ELM). However, unlike both ELM and Dasty2, sets of
related sequences can be submitted to EPipe for com-
parison, and differential predictions are highlighted in the
multiple alignment of the sequences, and if available also
on protein structures. An example of the kind of analysis
facilitated by EPipe is shown in Figure 3.
To understand the impact of protein variation and
ultimately the cause of disease-associated changes to
proteins, tools for comparative sequence analysis are
absolutely essential, as they facilitate the separation of
inconsequential changes to the protein scaffolds (neu-
tral changes) from changes affecting crucial protein
function.
Discussion and outlook
In the above, we have argued that personal genomics
requires a change in how we approach protein annotation.
In particular, the focus must change from the functions of
entire proteins to smaller functional building blocks to
facilitate meaningful comparisons. However, one must
not lose sight of the fact that proteins are social molecules,
which interact with each other in many different settings.
Thus, to fully appreciate the impact of small molecular
changes such as mutations one needs to see them in the
proper context. If, for example, a protein under the
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control of a kinase loses a phosphorylation site, the overall
impact should be analysed by looking at the interaction
partners both upstream and downstream in the signalling
pathway and not only by looking at the changed protein
itself. Somatic mutations in cancer are often activating or
deactivating a pathway, where variations across different
members of a pathway eventually lead to the same
phenotypic effect. A single point mutation can drive
the activation of a pathway such as the E17K mutation
in the AKT-1 pleckstrin homology domain (Figure 3) that
forms one of several genetic mechanisms that can activate
the PI3K/AKT cell-proliferation pathway [38].
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Figure 3
Using EPipe to study AKT1 variants. E17K and R25C are opposing somatic mutations in AKT-1 affecting the pleckstrin homology domain; E17K leads
to constitutive activation by pathological localisation to the plasma membrane and decreases sensitivity to an allosteric kinase inhibitor. R25C results
in a kinase that does not efficiently bind phosphoinositides, fails to localize to the membrane, and is not activated. EPipe indicates that E17K induces
changes in secondary structure (PsiPred), surface exposure (NetSurfP), and a Pfam domain ‘DUF1658’ found many times in the genome of Coxiella
(known to exhibit antiapoptotic activity via AKT1) interestingly disappears [52]. R25C shows a change in surface exposure, secondary structure and
disordered regions (IUpred). All of these predictions imply structural changes that, in the absence of other information, could prioritise novel mutations
for further investigation. Only part of the alignments are shown in this figure.
www.sciencedirect.com Current Opinion in Structural Biology 2010, 20:335–341
In the case of kinase/phosphoprotein-driven signalling,
such network considerations have already been formalized
in the NetworKIN method [39!]. The impact of small
molecular changes could also be studied in connectionwith
protein complexes known to be involved in human dis-
eases as demonstrated recently [40,41!!]. Other pathway
databases such as the Kyoto Encyclopedia of Genes and
Genomes, KEGG [42], take an even broader view on
things. Here, metabolic and regulatory pathways, drug
interaction networks and disease associations can be stu-
died from the molecular level all the way up to tissues and
organisms. For an overview of pathway databases, see the
Pathguide online resource described by Bader et al. [43].
Integrating pathways with an assessment of the effect of
individual molecular changes would represent an import-
ant step forward in our general understanding of the
impact of variation. As an example, take the case of allelic
variants of cytochrome p450 enzymes, a large family of
enzymes involved in general drug metabolism [44]. Un-
derstanding the functional impact of variations in such
important enzymes using some of the approaches men-
tioned above could be useful in the context of achieving
truly personalized medicine. Many SNP associations can
be traced to coding changes in proteins such as blood
group [45], skin colour [46], sickle-cell anaemia [47] and
metabolic cold adaptation [48,49] to name to few. Phe-
notypic annotation of protein (and non-coding) variants
still needs further work, but is already enabling efforts
reconstructing features from anonymous DNA
[50!!,51!!]. Several commercial efforts such as deCO-
DEme, 23andMe, Knome, BioResolve and Navigenics
are already taking a limited amount of individual vari-
ation-associated phenotypic predictions directly to con-
sumers at an affordable price.
If personal genomics is to have an impact on our un-
derstanding of human biology and health, it is essential to
put the small molecular variations among humans into the
context of the pathways and networks they operate in and
eventually relate to the individual instead of race or
geographic region.
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Chapter 5
Variant calling with NGS
NGS technologies rely on randomly fragmenting the DNA into small seg-
ments and produce millions of short sequencing reads (25-500 bp) coming
from those segments. After several rounds of this fragmentation and sequenc-
ing, multiple overlapping reads are obtained which can be either mapped
back to the reference genome or assembled into a continuous sequence.
Variant calling is then simply identifying the positions where the sequenced
base is diﬀerent from the base in the reference genome. This task is compli-
cated by many factors including sequencing errors, alignment errors and low
coverage. This chapter describes the pipeline used for NGS data handling
for SNP calling as well as the common obstacles encountered during analysis.
5.1 Raw read quality control
Every base in each sequencing read is assigned a quality score derived from
the noise estimates of the image generated by a sequencing platform. The
standard for reporting per-base quality scores is the Phred quality score [41]
deﬁned as:
QPhred =  10log10P (error)
This means that a Phred score of 20 corresponds to 1 in 100 probability
that a given base is called incorrectly. The base quality scores are used
for quality control of the raw reads and further during alignment steps and
downstream analysis. Typically reads with average low qualities are dis-
carded from further analysis and low quality ends of reads are trimmed oﬀ to
35
36 CHAPTER 5. VARIANT CALLING WITH NGS
prevent alignment problems. Another important step is removal of sequenc-
ing adaptor sequences which might have accidentally been sequenced and
could bias the alignment. It is also a good practice to investigate the overall
quality of raw data by checking for any deviations of per-base sequence
quality and GC content, as well as overrepresented sequences and k-mers.
Those few simple steps can improve the overall read quality dramatically
and prevent from including reads coming from contamination by sequence
adaptors or of bacterial or viral origin in the downstream analysis.
5.2 Alignment
After ﬁltering of raw reads, the high-quality reads are mapped back to the
reference genome. This task is complicated by many possible mismatches in
the reads caused either by true variants or indels or by sequencing errors.
With the short read length it is particularly diﬃcult to correctly align the
sequencing reads in highly repetitive regions and regions with high levels of
diversity, such as the major histocompatibility complex (MHC) region. This
can be partly overcome by using longer reads and paired-end sequencing
allowing for more accurate estimation of the origin of the read.
The existing widely used alignment algorithms are mostly based ei-
ther on hashing of the reads or the reference genome (e.g. Novoalign
[http://novocraft.com/], Stampy [76]), or on the Burrows-Wheeler trans-
form (BWT) algorithm for eﬀective data compression (e.g. BWA [73],
Bowtie [71]). Detailed description of the algorithms is beyond the scope of
this thesis, but in general the hash-based methods produce more accurate
results, while the BWT-based aligners are considerably faster and more
memory-eﬃcient. In analysis presented in Paper II, III and IV the chosen
aligner was BWA, which seemed to be the gold-standard tool at the time of
analysis.
The need to perform the mapping in a fast and eﬃcient manner may some-
times compromise the accuracy of mapping. Since the correct alignment is
crucial for accurate SNP calling, it is important to perform a few alignment
reﬁning steps. Presence of indels often aﬀects the alignment around them
and might lead to discovery of many false-positive variations, therefore per-
forming additional local realignment around indels using Smith-Waterman
algorithm can signiﬁcantly improve the alignment accuracy [37]. Most of
the available sequence alignment programs report a mapping quality score
for each aligned sequence, which quantiﬁes the probability that the given
alignment is correct. Therefore usually one of the ﬁrst steps in evaluating of
the quality of the alignment would be discarding the reads with low mapping
scores.
Another common source of SNP calling errors may arise from excess of PCR
duplicates, which may lead to multiple counting of an allele arising in fact
from the same source biological sequence. Thus in order to only account for
unbiased variant allele evidence, it is important to remove any sequences
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with the same sequence, start site and orientation which could suggest that
they represent multiple reads of the same unique DNA fragment ampliﬁed
by PCR.
Finally, variant calling takes into account the quality scores of the appro-
priate bases, therefore it is important that the scores are well-calibrated.
It was shown that the quality scores produced by base-calling algorithms
do not always accurately reﬂect the true error rates [16]. The Genome
Analysis Toolkit [80] implements base-quality recalibration by comparing
the sequenced sample to the reference genome at sites with no known SNPs
at the same time accounting for the machine cycle and dinucleotide content.
5.3 SNP calling
SNP calling (or: variant calling) determines at which positions there are
polymorphisms, while genotype calling is deﬁning the exact genotype for
each individual at those positions. The standard approach to SNP calling is
to compare the proportion of high quality sequences containing the reference
and the non-reference allele at a given position. In principle, the same
method is used for detection of short indels and multiple nucleotide poly-
morphisms (MNPs) by SNP calling programs, with the only diﬀerence that
gapped mapping technique is used to identify locations where there is either
a compression or an expansion of the genomic sequence. Conventionally, if
the fraction of reads with the alternative allele is between 20 - 80% then
a heterozygous genotype is called, and a homozygous genotype is called
otherwise [90]. While this works well for high coverage data (>20x), for
moderate sequencing depths applying probabilistic methods which provide
a posterior probability for each genotype accounts for the uncertainty in
genotyping. SNP and genotyping calling procedures can be further improved
by incorporating prior information about the known polymorphic sites, as
well as the LD patterns between sites. The resulting list of polymorphisms
can be further reﬁned by examining sequencing depth at the variant site,
distribution of base quality scores, as well as biases in strand representation
and position along the read. Additionally, clusters of SNPs in a small region
often indicate errors in alignment arising for example due to highly similar
paralogous sequences, therefore those should be carefully examined and
possibly ﬁltered out.
Identiﬁcation of novel rare variants or point mutation requires much more
stringent ﬁltering than genotype calling at known sites. In the latter case
prior knowledge about observed alleles and their expected frequencies can
increase our conﬁdence in the observed genotype. For variant detection
purposes one has to ensure suﬃcient sequencing depth, as well as closely
investigate all possible sources of sequencing, alignment and SNP calling
errors. Identifying mutations in tumour samples can be particularly challeng-
ing as cancer DNA commonly acquires copy number alterations resulting in
diﬀerent number of copies of whole chromosomes or its parts, and therefore
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the assumption of diploid genome held by most widely used variant callers
might not be best suited for variant calling in these samples. Moreover, due
to contamination with normal tissue and the heterogeneity of the tumour,
identifying mutations in cancer DNA requires very high sequencing depth to
obtain reliable results.
SAMtools [74] SNP caller was used in analyses presented in Paper II, III and
IV and at the time of analysis this tool seemed to be the most commonly
used software for this task. Recently, also Uniﬁed Genotyper from Genome
Analysis Toolkit [80] receives a lot of attention, using similar method for
SNP detection with additional features including applying prior informa-
tion on known SNP sites. There are many other variant callers available
based on diﬀerent assumptions than the two aforementioned tools, including
FreeBayes [44] which includes haplotype information up to the length of
sequencing reads, the Complete Genomics caller [20] using local assembly
or Cortex [60] performing almost complete de novo assembly using coloured
de Bruijn graphs for variant detection. Due to greater complexity of these
tools, the computational power required to run them is much bigger than for
the traditional variant callers. The performance of the new tools will have to
be comprehensively reviewed and assessed on an independent dataset before
they are routinely implemented in NGS pipelines.
The steps commonly used in handling NGS data for variant detection
are summarized in Figure 5.1. Additional steps are included speciﬁc for
multiplexed targeted sequencing technology used in Papers II, III and IV
in this thesis: sorting of the raw reads by the unique barcode identifying
the sample of origin and ﬁltering out SNPs residing outside of the targeted
regions.
5.4 CNV calling
Traditionally CNVs are detected by applying a circular binary segmentation
(CBS) algorithm [93] on the signal intensities from individual SNP markers
on SNP arrays. The algorithm divides a genomic region into segments and
tests whether the normalized signal intensities of the neighbouring segments
are diﬀerent, suggesting that they represent diﬀerent copy number states.
After identifying the segments of the same copy number, the segment ends
are joined forming a circle to perform another likelihood ratio test whether
the signal intensities have diﬀerent means. An alternative to this method
GADA (Genome Alteration Detection Algorithm) [98] was applied to de-
tect CNVs from the Aﬀymetrix Gene-Chip Mapping 500K array set for 62
childhood ALL samples and 200 healthy controls in Paper V in this thesis.
Brieﬂy, GADA algorithm starts with developing a compact linear algebra
representation for the genome copy number from normalized probe inten-
sities, then applies sparse Bayesian learning to infer copy number changes
locations, and ﬁnally a backward elimination procedure to rank the inferred
breakpoints is applied.
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Figure 5.1. The pipeline used to call SNPs and genotypes from
raw sequencing reads obtained from multiplexed targeted sequenc-
ing experiment.
NGS data can also be used to investigate copy number variations in genomic
samples with a much better resolution than SNP arrays. The best suited for
this purpose is whole genome sequencing where the mean coverage of the
genome can serve as a baseline value and any signiﬁcant deviations from this
coverage can indicate copy gain or loss. When using NGS data to infer copy
number it is important to take into account the GC content of the region,
as for instance on the Illumina platform regions with extremely low (<20%)
or high (>60%) GC content are known to be underrepresented among the
sequencing reads [12]. Copy number variations can also be estimated from
targeted sequencing data when data for a large population of samples gen-
erated in comparable way is available. In Paper II in this thesis we have
estimated the copy numbers of the high frequency deletions of GSTT1 and
GSTM1 genes. To estimate the copy number, a depth ratio was calculated
from the number of reads in the targeted genomic region normalized by size
of the region and total number of reads for the sample (Figure 2, Paper II).
The GSTs copy numbers estimated by this method were in 100% concordant
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with the copy number states assayed by multiplexing PCR for the 42 samples
examined by both methods. This method for estimating deletion states of
GST genes has also been applied in two other papers not included in this
thesis: Borst et al. 2012 [14] and Edsgärd et al. 2012 (manuscript accepted
with minor revisions by Frontiers in Cancer Endocrinology).
5.5 Other challenges
As the cost of sequencing declines, the number of NGS applications grows,
however NGS data analysis still presents substantial bioinformatics chal-
lenges apart from the ones already mentioned in this chapter. To start
with, the amount of data produced by sequencers is overwhelming and even
compressed it requires massive disk storage space. In the data analysis
pipeline multiple intermediate data ﬁles are generated which also need to
be temporarily stored, and since those ﬁles are generally large - the soft-
wares processing them require a lot of CPU power, time and memory. The
available computational infrastructure might be not suﬃcient for smaller
labs to conduct NGS analysis on bigger scale. However this obstacle can
be easily overcome by cloud computing services, which lease computational
power to those in need. Another complication is the diversity of the se-
quencing platforms available and lack of common standards for reporting
base calling qualities despite the most commonly used FASTQ format for
storing biological sequences. Even diﬀerent sequencing platforms from the
same manufacturer can have diﬀerent base quality representations, which
can cause a lot of confusion for an inexperienced user. Furthermore, diﬀerent
sequencing platforms require diﬀerent methods for analysis, for instance
when analysing Illumina data one has to take into account that base quality
decreases along the read, while when analysing Roche data one has to be
aware of frequent errors around homopolymer regions. Data produced by
SOLiD sequencers are encoded in colour space with each colour representing
two consecutive bases and therefore the SOLiD data requires its own data
format and speciﬁc alignment programs making use of this information.
With many new sequencing platforms coming to the market we can expect
even more data formats to come and new pitfalls of sequencers to take care
of. The choice of platform is followed by vast choice of software to perform
the analysis, however without gold standards established in the ﬁeld and
lack of comprehensive review articles it is diﬃcult to know which software
is appropriate for the task. Moreover, the programs are often dependent on
speciﬁc data format produced by another upstream software, which compli-
cates freely combining the individual components of a pipeline.
Chapter 6
Hypothesis-driven SNP
selection and assay
This chapter describes the motivation for the genome-wide selection of ge-
nomic variation with potential clinical importance for childhood ALL and
development of custom genotyping method by means of multiplexed targeted
sequencing applied in Papers II, III and IV in this thesis.
6.1 SNP selection
In order to fully investigate the pharmacogenomics in childhood acute lym-
phoblastic leukaemia there is a need to go beyond the limited candidate gene
approaches and explore all potentially clinically important variations. For
this purpose an extensive literature curation was conducted collecting the
current state of art knowledge of drug pharmacokinetics and pharmacody-
namics in ALL, disease mechanisms and response to chemotherapy. This
included previously published functional studies of polymorphisms aﬀecting
metabolism, transport, targets, as well as drug-related toxicity of the 13 most
commonly administered chemotherapeutic drugs [33]. Mechanisms of action
and the most important pharmacogenetic domains of the drugs are descibed
in Chapter 3.2. The list of genes and their respective polymorphisms was
further expanded to include additional aspects of response to chemotherapy,
including immune system functions, apoptosis, mitosis, DNA repair mech-
anisms, drug absorption, metabolism, excretion and cellular transport, as
well as drug targets and metabolic pathways aﬀected by the drugs. Informa-
tion about known drug targets and drug interactions was collected from the
Pharmacogenomics Knowledge Base [54], DrugBank [131] and Comparative
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Toxicogenomics Database [35] (all version: 2008). Further, high conﬁdence
human interactome data [68] was used to expand the list of relevant molecules
with the ﬁrst order protein-protein interaction partners. All known polymor-
phic sites were extracted within the genomic boundaries of the resulting 969
genes using Ensembl API version 57 [58] (based on dbSNP v.130 [118]), and
then ﬁltered based on their consequence to the transcript predicted with En-
sembl Variant Eﬀect Predictor [81]. Only variations with likely functional
eﬀect on the resulting protein sequence or its expression were selected, in-
cluding variations with following eﬀects on their transcripts:
• Non-synonymous coding
• Frame-shift coding
• Stop gained
• Stop lost
• Splice site
• Regulatory region
• Within mature miRNA
• Within non-coding gene
Additionally, information about polymorphic miRNA target sites within
3’ UTR regions of the selected genes was retrieved from Patrocles database
[55].
The full list of resources used in the SNP selection process is summarized
in Table 6.1. The SNP selection process is illustrated schematically in Figure
1 of Paper II in this thesis.
6.2 Available genotyping methods review
After careful selection of the panel of potentially clinically relevant SNPs fol-
lowed the choice of appropriate method to assay the selected polymorphisms.
Commercially available genotyping arrays commonly used for GWAS were
not suited for this application as the SNP arrays are designed to test ran-
dom genome-wide variations with high minor allele frequencies. Majority
of the assayed variations reside in the non-coding regions of the genome,
and therefore the overlap between the list of SNPs selected for genotyping
in this study and the SNPs assayed with commercially available platforms
was little. In addition, studies conducted using GWAS principles are not
hypothesis-driven, and due to the requirements for strict statistical correc-
tions - thousands of samples are needed to achieve genome-wide signiﬁcance
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Resource URL Description
Pharmacogenomics
Knowledge Base
(PharmGKB)
[54]
www.pharmgkb.org Curated knowledge about the impact of genetic
variation on drug response including dosing guide-
lines and drug labels, potentially clinically ac-
tionable gene-drug associations and genotype-
phenotype relationships. The database comprises
variant annotations curated for more than 700
genes in relation to pharmacogenetic of more than
400 drugs and 92 pathways describing drug phar-
macokinetics or pharmacodynamics.
DrugBank [131] www.drugbank.ca Database of drug targets, contains annotations for
6,711 drug entries linked to 4,227 non-redundant
proteins acting as drug targets, enzymes, trans-
porters or carriers.
Comparative
Toxicogenomics
Database (CTD)
[35]
ctdbase.org Database collecting more than 18 million tox-
icogenomic relationships, including associations
between genes, chemicals and diseases.
InWeb [68] in-house database Meta-database of protein-protein interactions
comprising several other resources: BIND [8], Bi-
oGRID [121], CORUM [111], DIP [113], IntAct
[53], HPRD [97], MINT [22], MPact [49], MPPI
[96] and OPHID [18].
Kyoto Encyclo-
pedia of Genes
and Genomes
(KEGG) PATH-
WAY database
[92]
www.genome.jp/
kegg/pathway.
html
Database comprising a large collection of biolog-
ical pathways annotated through literature-based
searches.
Reactome [31] www.reactome.org Database comprising 1,326 manually curated and
peer-revied biological pathways.
Ensembl www.ensembl.org A centralized resource for studying genome se-
quences, genome variations, regulation and com-
parative genomics. Variation database collects
data from dbSNP [118] together with annotations
on the eﬀect of the SNP on the transcript and
on associated phenotypes from HGMD [28], COS-
MIC [42], NHGRI GWAS catalog [56], OMIM
[50], UniProt [9] and others.
Patrocles [55] www.patrocles.
org
Database with annotations of polymorphisms
within microRNAs and their targets.
Table 6.1. This table described the publicly available resources
used for the SNP selection for Papers II, III and IV.
of the results. Designing of a custom SNP array was not feasible either due
to high minimum order quantity requirements much larger than the number
of patients included in this study and therefore setting the costs of this
method too high for implementation in clinical settings.
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Target enrichment [46] methods for next-generation sequencing (Figure 6.1)
are widely used for exome sequencing, GWAS follow-up and resequencing
studies. In a similar manner, capture baits can be custom-designed comple-
mentary to regions harbouring the SNPs of interest from this study. This
method has the advantage of genotyping not only at the exact position of
the target SNPs, but also provides the opportunity to detect any possible
variation in their vicinity. The capture baits are 120 nucleotides long and
are therefore more speciﬁc than the microarray probes, and due to the length
of the baits it is also possible to detect short indels. Another important
advantage of this method is ﬂexibility of the design allowing for modifying
the bait sequences with every order based on observed performance.
6.3 Multiplexing - pilot study
The costs of targeted sequencing, even though much lower than whole genome
sequencing costs, are still too high to apply in clinical settings to screen hun-
dreds of patients. The major cost of the experiments is the cost of the target
capture kit and the cost of sequencing itself. The approximate size of the
total region harbouring all the variations with potential clinical signiﬁcance
for childhood ALL study is 3.5 mega base pairs. With current NGS technolo-
gies the output of the sequencer is suﬃcient to sequence this region to a very
high depth. For the purpose of genotype calling at known SNP loci we esti-
mated a sequencing depth of 10x to be suﬃcient to produce reliable results.
By labelling individual samples with short barcode sequences it is possible to
sequence several samples in one sequencing lane and identify the origin of the
sequencing reads through the unique barcode. By multiplexing the samples
the whole capacity of the sequencer output can be used to produce satisfy-
ing results for multiple samples in one experiment. Multiplexing samples for
sequencing has been shown to be successful [91] and to signiﬁcantly decrease
the cost per sample. In an attempt to decrease the cost even further, we have
tested whether multiplexing of the sample before the target capture step is
possible and whether it produces reliable results and the desired sequencing
depth per sample.
The aim of the pilot study presented in Paper II was to assess applicability
of multiplexed targeted sequencing for genotyping and to investiagate the
inﬂuence of the study design on the achieved performance. We demonstrate
the positioning of the bait with respect to targeted variation can aﬀect the
results and that using two overlapping capture baits instead of one yields
higher sequencing depth at the position of variation, as well as more uniform
coverage in the region surrounding it (Figure 6.2).
Further we examined the physico-chemical properties of the individual
baits and compared the achieved sequencing depth at the regions targeted by
those baits (Figure 6.3). We observed that especially extreme GC content and
low complexity of the targeted region inﬂuenced the results. Additionally,
cross-hybridization of the baits and their potential for self-folding also had an
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Figure 6.1. The workﬂow of Agilent’s Sure Select Target Enrich-
ment System. The genomic sample is fragmented into shorter frag-
ments and hybridized together with biotinylated library of RNA
capture baits. Hybridized RNA-DNA duplexes are pulled down
with streptavidin coated magnetic beads. After washing the beads,
the RNA baits are digested and the subset of initial DNA is ready
for sequencing. Source: www.genomics.agilent.com.
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Figure 6.2. Average depth coverage at the target positions and
their 90 nucleotide ﬂanking sequence. The length of the ﬂanking
sequence corresponds to the length of two 120 nucleotide long con-
secutive baits overlapping with 50% of their length. A. The target
positions were deﬁned as the base pair positioned exactly in the
middle of the 50% overlap of the two consecutive baits. This loca-
tion of the target positions with respect to the baits was chosen for
the performance analysis due to more uniform distribution of the
coverage depth in the immediate surrounding of the target posi-
tion. B. The target positions were deﬁned as the base pair exactly
in the middle of each single bait. The depth coverage drops in the
proximity of the target position and in general slightly lower depth
coverage is achieved. Figure is a part of Supplementary Material
for Paper II.
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impact on the capture experiment eﬃciency. Examination of targeted regions
which did not get any sequencing coverage revealed that 97% of the baits tar-
geting these regions were prone to encounter cross-hybridization problems,
and 56% of them had a high probability of self-folding. This demonstrates
that designing the baits more carefully can increase the achieved mean cov-
erage depth.
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Figure 6.3. Performance of the baits depends on their physical
and cross-hybridizational properties. For all the baits used in the
experiment here is shown A. the dependence on the GC content of
the bait, B. the potential for cross-hybridization or C. self-folding
of the bait and D. presence of low-complexity regions. The values
in B, C and D are the scores obtained from the OligoWiz probe
design software, where 0 denotes a potentially problematic bait and
100 a good bait with respect to the investigated parameter. Figure
is a part of Supplementary Material for Paper II.
Finally, we examined the combined inﬂuence of the amount of samples
pooled in one sequencing lane together with the properties of the used baits
(Figure 6.4). Pooling of 4, 6 and 12 samples was compared to an experiment
using a single sample by assessing the amount of targeted genomic variations
sequenced at diﬀerent thresholds of minim required requencing depth. Even
though we observed that the performance slightly decreased with an increas-
ing number of pooled samples, the distribution of reads was well balanced
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even with 12 pooled samples and a mean depth of at least 10x was achieved
for approximately 88% of the target positions. The amount of pooling can
be optimized depending on the desired target size and need for high cover-
age and the resulting sequencing depth can be improved by more methodical
custom bait design to achieve more eﬃcient capture .
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Figure 6.4. Percentage of the target regions achieving a mini-
mum sequencing depth threshold of 4x, 10x and 20x. The target
regions are deﬁned as contigs of consecutive baits for the set of
all SureSelect Human X Chromosome Demo Kit baits (AB), the
reduced set of non cross-hybridizing baits (NCH) and the reduced
set of non cross-hybridizing and non self-folding baits (NCH-NSF).
The error lines represent the standard deviation. Figure is a part
of Supplementary Material for Paper II.
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6.4 Paper II - Multiplexing before capture
In the following paper a novel cost-eﬀective strategy of pooling of samples
before capture is described. We have compared target capture of a single
sample with capture of pools of 4, 6 and 12 samples. The results show that
while the distribution of reads between samples is not entirely balanced,
the multiplexing of samples works and the SNP calls obtained from this
method achieve high concordance with standard SNP array calls. We also
demonstrate that detection of copy number variations based on sequencing
depth is possible with this data and produces accurate results. The issue of
optimal bait design is also addressed in the article. We demonstrate that
baits with not optimal physico-chemical properties perform worse in the
experiment. We observed that regions with extreme GC content or low com-
plexity are diﬃcult to target, and we show that baits with high likelihood of
cross-hybridization and self-folding might cause further performance issues.
Finally, we demonstrate that mitochondrial DNA is generally overrepre-
sented in genomic samples and, even with targeted sequencing approach,
reads from mitochondrial regions can dominate the sequencer output if some
capture baits can hybridize to those regions. Therefore we recommend to
remove any such baits from the capture library design to maximize the ”on
target” sequencing coverage.
Supplementary Information accompanies the paper on the Leukemia website
(http://www.nature.com/leu) and parts of the material are included as ﬁgures
in the preceding chapter.
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Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant
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Genetic variants, including single-nucleotide polymorphisms
(SNPs), are key determiners of interindividual differences in
treatment efficacy and toxicity in childhood acute lymphoblastic
leukemia (ALL). Although up to 13 chemotherapeutic agents are
used in the treatment of this cancer, it remains a model disease
for exploring the impact of genetic variation due to well-
characterized cytogenetics, drug response pathways and
precise monitoring of minimal residual disease. Here, we have
selected clinically relevant genes and SNPs through literature
screening, and on the basis of associations with key pathways,
protein–protein interactions or downstream partners that have
a role in drug disposition and treatment efficacy in childhood
ALL. This allows exploration of pathways, where one of several
genetic variants may lead to similar clinical phenotypes
through related molecular mechanisms. We have designed a
cost-effective, high-throughput capture assay of B25000
clinically relevant SNPs, and demonstrated that multiple
samples can be tagged and pooled before genome capture in
targeted enrichment with a sufficient sequencing depth for
genotyping. This multiplexed, targeted sequencing method
allows exploration of the impact of pharmacogenetics on
efficacy and toxicity in childhood ALL treatment, which will
be of importance for personalized chemotherapy.
Leukemia advance online publication, 18 March 2011;
doi:10.1038/leu.2011.32
Keywords: multiplexed genotyping; next-generation sequencing;
target-enrichment; clinically relevant SNPs; childhood acute
lymphoblastic leukemia
Introduction
The cure rate for childhood acute lymphoblastic leukemia (ALL)
after first-line therapy approaches 80–85%.1 To further improve
prognosis, extensive personalization of therapy based on
extensive targeted genetic analyses will be required.2 The
overall goal is to avoid unnecessary adverse and life-threatening
toxicities, unacceptable late effects due to overtreatment and
risk of relapse due to undertreatment.3,4 Several studies have
indicated that for patients with the most favorable genetic
variants, event-free survival may be more than 90%.5,6 High-
throughput technologies in combination with imputing allow
genome-wide mapping of genetic variants that subsequently can
be associated with treatment failures or specific toxicities.7 In
addition to the genes and single-nucleotide polymorphisms
(SNPs) already known to be involved in drug disposition or
specific toxicities (for example, thrombosis, osteopenia or
immune function), such genome-wide variation studies (GWAS,
genome-wide association study) are likely to reveal important
variations in genes not previously linked to the biological issue
in question. However, extensive research including clinical
trials will subsequently be needed before this new information
can be implemented in childhood ALL treatment protocols.
Furthermore, the impact of the genetic variations can often only
be fully understood within the frame of a specific treatment
protocol.2 Finally, current commercially available solutions for
GWAS for hypothesis-driven genetic investigations are not
easily applied clinically, as the techniques and commercial
platforms are either designed to explore random variations
across the genome that rarely cover all variations of interest for a
specific study, or the costs of custom-made approaches are too
high for implementation in clinical settings. We here describe a
novel multiplexing method enabling us to screen childhood ALL
patients for B25 000 clinically relevant SNPs simultaneously,
targeted by custom-designed baits. Furthermore, eight child-
hood ALL samples are pooled together before capture enrich-
ment, making this a very cost-effective platform, allowing future
targeted genetic mapping of large cohorts of patients. The
choice of pooling 8 patient samples was based on results from a
pilot study, where we pooled and sequenced 4, 6 and 12 test
samples, respectively, labeled with different barcodes.
Materials and methods
Samples
A total of 48 samples from Danish childhood ALL patients (aged
between 1 and 15 years at the time of diagnosis) diagnosed with
B-cell precursor or T-lineage ALL and enrolled in the Nordic Society
for Pediatric Hematology and Oncology (NOPHO) ALL-2000
protocol were included. For the pilot study, four human DNA and
two HapMapDNA test samples were used in different combinations
(Supplementary Table 1). The study was approved by The Danish
Data Protection Agency (2007-41-1289) and The Committee on
Biomedical Research Ethics (H-D-2007-0100, KF 01 265848).
Library preparation, pooling, target enrichment
and sequencing
DNA shearing and library preparations were performed accord-
ing to the SureSelect Target Enrichment System protocol versionReceived 21 December 2010; accepted 11 January 2011
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1.2 April 2009 (Agilent Technologies, Santa Clara, CA, USA)
with minor modifications. Briefly, 3mg of genomic DNA was
sheared by Covaris S2 System (Covaris Inc., Woburn, MA, USA)
using 10% duty cycle, intensity of 5, cycles per burst of 200 for 6
cycles of 60 s, following purification of the DNA fragments by
QIAquick PCR purification spin columns (Qiagen, Hilden,
Germany). After each reaction, a purification step was
performed. Then end repair was performed (by applying T4
DNA polymerase, T4 phosphonucleotide kinase and Klenow
fragment enzyme) and 30 end A-overhangs were produced
(by applying Klenow 30–50exo minus). Custom-made adapters
containing unique barcodes of four bases each were prepared.
The complementary oligos (Supplementary Table 2; DNA
technology A/S, Risskov, Denmark) were dissolved in DNase-
free water to a final concentration of 300 mM. Complementary
oligonucleotide pairs were mixed in ratio 1:1 in 1! annealing
buffer (10! buffer contained 100mM Tris-HCL, pH 8.1; 0.5M
NaCl). The barcoded adapter mix was heated to 90 1C for 2min,
then cooled down to 30 1C at a rate of 2 1C per minute and
diluted to a working concentration of 15 mM. After ligation of the
adapters to the DNA fragments, the fragments were size selected
in the range of 150–250 bp by 4% agarose gel electrophoresis
and excised. The DNA libraries were amplified applying
Phusion High-Fidelity PCR Master Mix (Finnzymes, Espoo,
Finland) with a denaturation time of 30 s at 98 1C, followed by
14 cycles of denaturation at 98 1C for 10 s, annealing at 65 1C for
30 s and extension at 72 1C for 30 s. Final extension was
performed at 72 1C for 5min. DNA quantity and quality was
checked on a NanoDrop ND- 1000 UV-VIS Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100
Bioanalyzer using the Bioanalyzer DNA High sensitivity (Agilent
Technologies), respectively. The DNA libraries were mixed in
groups of 8 (or 4, 6 and 12 in the pilot study) in equimolar ratios
to yield a final concentration of 147 ng/ml of each pooled library.
The pooled libraries were hybridized with our custom-designed
SureSelect Oligo Capture Library SureSelect (Agilent Technol-
ogies; SureSelect Human X Chromosome Demo Kit was used for
the pilot study (Agilent Technologies)) for 24 h according to the
manufacturer’s instructions. After incubation, the selected
hybrids were purified using magnetic beads and desalted with
Qiagen minElute PCR purification column. Post-hybridization
amplification PCR with standard primers from SureSelect Target
Enrichment System kit and Herculase II Fusion DNA Polymerase
(Stratagene, Agilent Technologies) was performed with a
denaturation time of 30 s at 98 1C, followed by 18 cycles of
denaturation at 98 1C for 10 s, annealing at 57 1C for 30 s and
extension at 72 1C for 30 s. The final extension was performed at
72 1C for 7min. After purification, DNA quantity and quality
was checked. A 75-nucleotide (nt) single-end run on the
Illumina GAIIx Genome Analyzer (Illumina Inc., San Diego,
CA, USA) was performed following the manufacturer’s recom-
mendations.
SNP selection and bait design
SNPs were selected to cover all known and putative clinically
relevant variations with regard to childhood ALL treatment
(Figure 1). First, a list of clinically relevant genes and SNPs was
curated, and their influence (known and suspected) in terms of
effect on metabolism, transport or drug targets interactions for
the 13 most administered chemotherapeutic drugs and their
clinical consequences in childhood ALL were evaluated.2 To
extend the list of genes/proteins connected to these drugs, drug–
protein associations from different sources such as DrugBank
(version 2008)8 and PharmGKB (version 2008)9 were gathered.
The resulting protein drug targets (from binding data), metabo-
lizing enzymes and drug transporters were integrated into the
previous list.
The list of clinically relevant genes and SNPs was further
expanded by including their known first-order protein–protein
interaction partners using a high-confidence human interactome
and other genes participating in the same pathways.10 This
approach allows for investigating complex effects, where several
SNPs (potentially in different genes) could exert the same effect
through a common mechanism, for example, affecting the same
pathway. A list of 969 genes was generated and all genomic
variations associated with those genes were extracted using the
Ensembl API version 57 (Ensembl, EBI and WTSI, Hinxton, UK)
based on the Single Nucleotide Polymorphism Database
(dbSNP) 130. SNPs with potential functional impact on the
genes of interest were chosen by selecting SNPs resulting in
amino-acid changes or frameshifts, SNPs in annotated regula-
tory regions, variations affecting a stop codon or a splice site, as
well as variations within non-coding genes and within mature
microRNAs. Furthermore, the list was expanded by including
SNPs, which could potentially disrupt predicted microRNA
target sites of the listed genes found in Patrocles database.11
Baits for the SureSelect Target Enrichment System were
designed for all identified SNPs. Each variation was targeted
by two baits with a 50% overlap, where the variation was
positioned exactly in the middle of the overlap region
(Supplementary Figure 1). The physical and cross-hybridization
properties of the baits were explored using the oligonucleotide
design software OligoWiz12 and sequence-matching tools
Figure 1 SNP selection and bait design. The list of curated genes and drug targets was expanded with the systems biology approach, and known
SNPs in these genes were selected with potential functional significance. The baits targeting selected SNPs were designed to minimize the extent of
cross-hybridization and self-folding of the baits, as well as extreme levels of GC content.
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BLAST13 and SeqMap.14 The extent of baits prone to cross-
hybridization, self-folding, extreme levels of GC content or baits
targeting highly variable regions, which could decrease
specificity or efficiency of the baits, was limited to a minimum.
However, some potentially problematic baits were still included
in the design because of the clinical importance of their target
region (Supplementary Figure 2). To exploit the whole capacity
of the method and to probe for key deletions, additional baits
were designed tiling all the exons of ETV6, MTAP and OPRM1,
and the entire genomic regions of CDKN2A, GSTM1 and
GSTT1, allowing full sequencing of these genes of particular
importance in childhood ALL. The baits tiling the genomic
regions of the drug-metabolizing genes GSTM1 and GSTT1 were
used to detect the deletion state of those genes. To estimate copy
number, a depth ratio was calculated from the number of reads
in the targeted genomic region normalized by size of the region
and total number of reads for the sample. The final design
included baits targeting 25 602 clinically relevant SNPs, as well
as 1200 baits targeting the exons or the genomic regions of the
above-mentioned genes, with specific impact on the treatment
outcome in childhood ALL (Figure 1).
Barcodes
In the pilot study, 12 different barcodes (Supplementary
Table 2), with the last base being a thymidine (T) necessary
for ligation to chromosomal DNA fragments with a 30 adenosine
(A) overhang, were tested. These four base barcodes in
combination with 75 nt sequencing reads render high quality,
unambiguously mapped reads, while using only 5% of the read
length for sample identification.
Data analysis
The high-quality reads obtained from sequencing were aligned
to the NCBI37 reference human genome (version GRCh37)
using the Burrows–Wheeler Alignment Tool.15 The alignment
was refined by means of quality score recalibration and around
indel realignment using Genome Analysis ToolKit package.16
SNP calling was performed with SAMtools package17 using
default settings. The threshold set for SNP calling was minimum
10x sequencing depth; however, 4x was also accepted as a
threshold for high-priority SNPs when 10x depth was not
available. The data was further analyzed with help of SAMtools
and BEDtools18 packages and custom-written Perl scripts.
Results
Pilot study
The applied baits from the SureSelect Human X Chromosome
Demo Kit were designed to capture 85% of the human X
chromosome exons, tiling exons with a 50% overlap between
consecutive baits. In an attempt to reflect the application of this
method to custom-genotyping purposes, the performance was
assessed on a set of target positions defined as base pairs
positioned exactly in the middle of the 50% overlap region of
two consecutive baits (Supplementary Figure 1). The average
sequence depth achieved with this approach is higher and more
uniform in the immediate surrounding of the target position
when compared with placing the target position in the middle of
a single bait.
The results of the pilot study showed that average sequence
depth decreases with an increasing number of pooled samples;
however, the distribution of reads is well balanced and sufficient
for genotyping even with 12 pooled samples (Supplementary
Figure 3). Each sample had between 55 and 65% sequencing
reads mapped to the targeted regions and between 65 and 75%
of the reads mapped to targeted regions plus/minus 100 bp of
target (Supplementary Figure 4), indicating that sample compe-
tition during hybridization was not an issue. An average depth of
at least 10x was achieved forB88% of the target positions, with
a standard deviation of 10% when pooling 12 samples
(Supplementary Figure 5). Increased pooling affected the
number of detected target positions. However, depending on
the desired depth of sequence reads and required target size
(number of SNPs for genotyping studies), the amount of pooling
can be adjusted appropriately. Genotyping using depths from
4x to 12x has recently been tried19,20 and consensus for 10x
SNP calling is relatively high, while mapping against a known
reference genome such as the human.
SNP calls from the targeted sequencing approach were
compared with genotype calls using in-house Affymetrix
Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara,
CA, USA) and public HapMap data. The comparison was
restricted to all probes on the array matching SNP calls within
targeted regions from the sequencing kit. The accuracy of the
multiplexed targeted sequencing approach was assessed on 12-
pooled samples based on concordance for sequencing and
array-based genotype calls. SNP calls with the coverage depths
of 4x, 10x and 20x were compared with the SNP calls obtained
from the array, and the percent concordance for each sample
was calculated as the percent of calls that were the same for
each depth (Supplementary Figure 6). As expected, the number
of compared SNPs decreased with increasing depth required;
however, it did not affect the concordance rates significantly. In
this study, calling SNPs at 4x depth appeared acceptable when
10x depth was not available. All samples achieved concordance
well above 95% at 10x coverage depth (the same holds for 4x
coverage, with an exception of the CGCT labeled sample).
Examining regions that had 20x or better sequence depth, 9 out
of the 12 samples were 100% concordant; however, the number
of SNPs decreased by B38% because of minimum sequencing
depth requirement (20x) as compared with 10x coverage depth.
Childhood ALL samples
Sequencing of the 48 samples generated a total of 39Gb of data
in FASTQ format and 32Gb passed the default Illumina quality
filter. Out of those, 23.2Gb were uniquely mapped to the
reference genome (Table 1). On average, 53% (sd of 9%) of the
high-quality sequencing reads were mapped to the target
regions, which shows that the distribution of reads was relatively
balanced. In addition, on average, 94% of the targeted SNPs
were covered at least with one sequencing read for each sample,
and B73% of those SNPs achieved at least 10x sequencing
depth. The average sequence coverage for the covered
variations from the list of targeted SNPs was 23x across all
samples. The average depth coverage for the targeted exons of
ETV6, MTAP and OPRM1 genes was 32x, whereas the average
coverage for the genomic region of CDKN2A gene was 31x.
Average depth coverage for GSTs could not be estimated, as it
varies with the deletion state of the genes.
Bait design
The performance of capturing baits depends on their physical
and cross-hybridizational properties (Supplementary Figure 2).
Baits used in the design were explored using the OligoWiz
program for their probability of self-folding and cross-hybridiza-
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tion for the presence of low-complexity regions and their GC
content. All the tested parameters seem to influence bait
performance; therefore, these properties should be taken into
consideration during bait design. If required, higher depths for
regions of particular interest can be obtained by targeting them
with higher numbers of overlapping baits. In this study, for a list
of high-priority SNPs with known significant impact on
the treatment outcome in childhood ALL,2 four different baits
(instead of two) have been designed for each SNP. The obtained
average coverage for those was 35x, as compared with the
average coverage of 23x for the whole list of SNPs. Special care
must be taken when targeting regions on a human mitochondrial
genome, as these DNA fragments are overrepresented in a
genomic DNA sample. Mitochondrial regions will attract
significantly more reads, and might therefore dominate the
sequencing results. In our study, 66 baits targeting regions on the
mitochondrial genome were included, achieving an average
depth of 4350x and the reads corresponding to those constituted
15% of all the mapped sequencing reads.
Genotype validation
Genotype data from the 48 childhood ALL samples on seven
SNPs and two gene deletions were used for validation of the
sequencing results (Table 2). Patients were previously genotyped
for CYP3A5*3 6986A4G (rs776746), RFC1 80G4A
(rs1051266), TPMT*3B 460G4A (rs1800460), TPMT*3C
719A4G (rs1142345), MTHFR 677C4T (rs1801133) and
MTHFR 1298A4C (rs1801131) by allelic discrimination5,6
(and unpublished data). GSTP1 313A4G (rs1695), GSTM1
and GSTT1 deletions were genotyped by multiplexing PCR,
which simultaneously detects GSTT1 and GSTM1 gene copy
number and GSTP1 313A4G.21 Based on the calculated
coverage depth ratio for the genomic regions of GSTM1 and
GSTT1, it was possible to distinguish three distinct clusters
corresponding to homozygous deletions, heterozygous deletions
and the wild type (Figure 2). Concordance for the seven SNPs
was between 91 and 100%, and 100% for the two gene
deletions (Table 2).
Discussion
In recent years, clinically important genetic variations have been
thoroughly investigated in childhood ALL.2 Even though
minimal residual disease monitoring22 and extensive toxicity
scoring have been established in some treatment protocols,1 still
very few groups include genetic variations in their treatment
strategies.6 This primarily reflects the lack of extensive targeted
analyses of genetic variants and the costs associated with such
analyses. Multiplexing before capture, target enrichment and
sequencing allows screening ofB25000 custom-selected SNPs
simultaneously and could therefore be a solution. As shown in
the pilot study, pooling of 4–12 samples in a single lane of an
Illumina GAIIx with 75 nt single-ended reads is sufficient to
generate 10–20x sequence depth over more than 80% of the
target region per sample (Supplementary Figure 3). If a 10–20%
drop in coverage (or target size) is allowed, pooling 6 or 12
samples can easily be achieved. Pooling of up to 12 samples
showed relatively balanced results, but larger dispersion at
higher depth. To reduce this variation, we hypothesized that in
case of pooling 8–10 samples, an average sequence depth of
10x for B80% of the intended regions could be expected. The
amount of pooling was therefore adjusted to eight samples at a
time because of the large size of the desired target and need for
high sequence depth. The next-generation sequencing technol-
ogy is rapidly evolving; hence, in future studies, it will be
possible to either pool more samples or obtain higher coverage.
It was observed in different sequencing runs that not all
barcodes performed equally well. For example, we found that
barcode CGCT had a lower performance compared with the rest
(Supplementary Table 1, Supplementary Figures 5 and 6). This
could be inherent to the barcode itself, but also influenced by
experimental variation (for example, small differences in the
amount and quality of the different adapters and variation in
library preparation). Additional studies exploring this and the
individual barcodes could provide information to further
improve the study design.23
Table 2 Genotype concordance for the 48 childhood ALL samples analyzed by single PCR and by multiplexing sequencing
CYP3A5*3
6986A4G
TPMT*3B
460G4A
TPMT*3C
719A4G
RFC1
80G4A
MTHFR
677C4T
MTHFR
1298A4C
GSTP1
313A4G
GSTM1
deletion
GSTT1
deletion
Single PCR/sequencing (N) 48/47 30/48 30/47 46/48 29/46 29/48 42/48 42/48 42/48
Analyzed by both methods (N) 47 30 29 46 28 29 42 42 42
Concordant (N) 46 28 28 42 26 28 42 42 42
Concordance (%) 98 93 97 91 93 96.55 100 100 100
Abbreviation: ALL, acute lymphoblastic leukemia.
Table 1 Summary of the sequencing of the childhood ALL samples
Total samples 48
Total sequencing lanes 6
Total samples per lane 8
Total raw reads (Gb)a 39
Total high-quality reads (Gb)a 32
Total mapped reads (Gb)a 23.2
Mean percent on target (%) 53
Mean mapped depth on target (x) 35
SNPs with read depth (%)
X1x 94
X4xb 90
X10xb 73
X20xb 48
Mean variant SNP sites per individual (at X10x) 3896
Novel (not in dbSNP130; %) 9.5
Mean variant indel sites per individual 1024
Abbreviations: ALL, acute lymphoblastic leukemia; SNP, single-
nucleotide polymorphism.
In all, 94% of the targeted SNPs were covered by at least one read; of
these, 73–90% could be called at 4x or 10x depth. With eight samples
per capture and per sequencing lane, the per sample cost was in the
$200–300 range at 2010 prices.
aFiles in FASTQ format.
bOf SNPs covered by at least one read.
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We here demonstrate that it is possible to reliably genotype
childhood ALL patients for a large number of SNPs simulta-
neously using multiplexed target enrichment, followed by
sequencing. Sequencing data for B94% of the targeted SNPs
for each sample was obtained, and for 73% of those, the
achieved coverage depth was sufficient for high-confidence
genotype calling (at least 10x). In addition, this methodology is
easy to adapt in a sequencing lab and has a low entry level
(80–100 samples), thus allowing redesign of content during the
course of large sample projects. In a single design, exon tiling
can be combined with SNP or somatic-mutation detection, and
we show here that copy number can be reliably inferred through
sequencing. Whole-exome sequencing is gaining popularity
among targeted sequencing efforts as a way to improve
sequence depth and reduce cost compared with whole-genome
sequencing, as exons span only B1.2% of the whole human
genome. This is a valuable approach and it has recently been
shown that some multiplexing (3–5 samples) can be accom-
plished.24 However, when sequencing the exons only, many
regions are missed that may have important biological functions
such as transcriptional or translational regulation of the protein-
coding sequences. Many studies indicate non-coding SNPs to be
clinically relevant; therefore, it is crucial for pharmacogenetic
studies to also investigate regions outside of the protein-coding
parts of the genome. We demonstrate that a more targeted
hypothesis-driven panel can be constructed, assayed reliably
and at much lower costs than exome sequencing. Pooling of
eight patient samples before capture reduces the costs of the
capture library, hybridization reagents and, none the least, the
costs of sequencing by eight times. Furthermore, the patients are
genotyped for 25 000 targeted SNPs simultaneously, reducing
the cost per SNP per patient even further compared with
conventional methods.
The presented method for performing high-throughput, low-
cost, customized genotyping will allow wider application of
studying clinical impact of genomic variations. Immediate
applications include validation of GWAS, assaying somatic
mutations or a panel of SNPs such as in drug toxicology studies.
Furthermore, the flexibility of the bait design enables researchers
to adapt the SNP content as new knowledge emerges. Future
applications of this method in upcoming childhood ALL studies
will move us closer to pharmacogenetic-based personalization
of therapy in childhood ALLFand possibly other cancers. Such
studies are currently ongoing in the NOPHO Study Group.
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Chapter 7
Integrative variation analysis
This chapter presents some of the integrative analyses methods applied in
Papers III, IV and V, as well as the unpublished analysis of the individual
disease risk based on genome sequence of an Aboriginal Australian.
7.1 Single SNP associations
Conventionally in association studies involving cases and controls one com-
pares the allele frequencies at all the genotyped loci between the two groups
of individuals to determine whether there is a statistically signiﬁcant associ-
ation between the genotype at a given locus and the phenotype under inves-
tigation. There exist several models of genetic penetrance of the phenotype,
including additive, multiplicative, recessive and dominant, which determine
the risk of developing the phenotype dependent on the present number of
risk alleles. Testing for association with phenotype is usually performed for
each SNP separately by means of chi-squared test, which tests independence
of the rows and columns of a contingency table of counts of phenotype sta-
tus by genotype or allele count. As chi-squared test is an approximation of
the results of a Fisher’s exact test, the latter can also be used for associa-
tion studies and is the recommended choice for small sample sizes or in cases
when cell count less than 5 can be expected. When it is necessary to adjust
the association for possible confounding covariates like environmental factors
or population stratiﬁcation a logistic regression model can be used, and if
the phenotype is a continuous trait a linear regression model can be applied.
After performing multiple single SNP association test, one should correct the
signiﬁcance values for multiple testing to avoid incidental ﬁndings.
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7.2 Rare variant accumulation
Reasoning behind conducting GWA studies included the ”common disease
common variant” hypothesis suggesting that common diseases are caused by
multiple common variants. However, when the majority of GWAS ﬁndings
turned out to be associations with only modest eﬀect sizes and explaining
only small fraction of heritability, the focus has been shifted to investigation
of rare variants [78]. This gave rise to the ”multiple rare variant” hypothesis
suggesting that common inherited diseases are caused by aggregation of
multiple rare variants with larger eﬀect sizes [13]. Diﬀerent scenarios of
common and rare variant attributing to phenotype are illustrated in Figure
7.1. The studies of rare variants have recently been made possible due to
a continuing decrease in NGS technologies cost and completion of 1,000
Genomes Project serving as a public rare variant catalogue.
There exist several methods for investigating eﬀects of rare variants, which
can be summarized as: single marker tests, multiple marker tests, collapsing
methods and approaches based on similarities among individual sequences
reviewed in an article by Bansal et al. [10]. While single marker tests like
Fisher’s exact test can be applied to study rare variants, they are usually
underpowered even in very large samples and alternative approaches consid-
ering multiple markers are required. Even though the individual frequency of
rare variant is low, collectively their abundance makes them quite common,
occurring on average every 17 bases as reported by a recent study by Nelson
et al. [86]. This is the assumption for collapsing methods, which simply test
for accumulation of rare minor alleles in the case group at a speciﬁc asso-
ciated genomic site. This method was applied to study eﬀects of multiple
variants in Paper III by performing the cumulative minor-allele test (CMAT)
[136] on the coding SNPs grouped by their genic regions or protein-protein
complexes. The obvious limitation of this type of methods is that investigat-
ing accumulation of rare variants requires large sample sizes and the result
is largely inﬂuenced by the size of investigated genomic region. Alternative
methods include inspecting the local similarity of the DNA sequences be-
tween individuals motivated by phylogenetic analyses or multiple regression
methods allowing for adjusting for additional predictor variables like covari-
ates or common variants. Overall, numerous methods for studying the eﬀects
of rare variants exist, however there is no consensus on which of them are
most applicable and what is their power and robustness in diﬀerent contexts.
Despite that, increasing amount of studies report and discuss the importance
of rare variants, including a recent study demonstrating that rare variants in
SLCO1B1 have greater eﬀects on methotrexate clearance in childhood ALL
patients than common variants and thereby showing that rare variants aﬀect
traits beyond the disease susceptibility [101].
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Figure 7.1. Scenarios in which DNA sequence variants distin-
guish cases and controls. The blue lines indicate genomic regions;
red boxes indicate variants. a | Variants at a single locus with com-
mon alleles are more frequent in cases then controls. b | Multiple
rare variations contribute to the phenotype such that the collec-
tive frequency of these variations is greater in cases. This would
create a greater diversity of haplotypes or DNA sequences among
the cases. c | Multiple rare variations contribute to the phenotype
but act in a synergistic fashion, such that cases are likely to have
more similar DNA sequences compared to controls. d | Multiple
rare variations contribute to a phenotype but the variations con-
tributing to the phenotype reside in speciﬁc genomic regions. This
situation would create greater sequence diversity among the cases,
as in part b, but only in the relevant genomic regions. Source of
ﬁgure and legend: Bansal et al. 2010 [10].
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7.3 Pathways analysis
While many association studies concentrate on detecting single marker asso-
ciation signals, it is important to remember that genes do not act alone. The
interactions between various cellular components such as genes, proteins,
small RNAs or metabolites create complex networks, which together aﬀect
the phenotypes. Often perturbation of diﬀerent interacting components of
the same network result in disruption of the same molecular mechanism and
give rise to the same observable trait. While studying associations of genomic
variations to a phenotype, one can examine the collective eﬀects of multiple
SNPs acting in the same biological pathway, serving as a simpliﬁed model
of the complex cellular interactions. This kind of integrative analysis may
yield more robust results and is more sensitive to detect a sum of modest but
not independent eﬀects in a group of individuals. Finally, pathway analyses
can aid translation of the ﬁndings into clinical setting, as other pathway
members might be more suitable drug targets than the most associated gene.
Several methods have been developed to study pathway-mediated eﬀects
in GWA studies inspired by the success of gene-set enrichment analysis for
gene expression data [122]. The most popular of those methods are described
in a review by Wang et al. 2010 [130]. One of the major diﬃculties in con-
ducting pathway-level associations for GWAS is mapping the SNPs to their
respective genes, as most of the variations included on the widely-used SNP
arrays reside in non-coding regions. Further, the amount of genotyped SNPs
is too large to include in the analysis, so diﬀerent search space reducing
techniques are used, including ﬁltering out SNPs in high LD or only consid-
ering one SNP per gene with the lowest p-value. These practices may lead
to loss of information, as in the case when association tests only consider
the individual SNPs p-values rather than the SNP genotype. On the other
hand, limiting the investigations to only the most signiﬁcant SNPs can lead
to missing eﬀects mediated by multiple genetic variants acting in a concert
but individually having only small eﬀects. So far pathway analyses for
NGS based studies are rather limited and concentrate mostly on detecting
overrepresentation of mutations within deﬁned pathways without taking into
account the more common variants.
This was the motivation behind the pathways association analyses pre-
sented in Papers III and IV in this thesis. Due to unique design of the assay
used in these studies, the number of genotyped SNPs was much lower than
in a typical GWA study and the assayed SNPs were selected to reside in
coding or regulatory regions, hence the biggest diﬃculties of GWAS based
pathway analyses were not an issue in this case. In these two papers the in-
vestigated SNPs have been grouped by all pathways from Reactome database
[31] and eleven drug metabolic pathways from PharmGKB [54] relevant to
drugs administered in childhood ALL. Only SNPs observed at a minimum
MAF of 0.5 % and likely to aﬀect the protein function were included: non-
synonymous coding, frame-shift coding, as well as SNPs aﬀecting the stop
7.3. PATHWAYS ANALYSIS 61
codons and splice sites. The association testing of groups of SNPs was per-
formed by artiﬁcial neural network training with three-fold cross-validation
to avoid overﬁtting. All the SNPs were encoded by 3 values corresponding
to likelihood of each genotype derived from the VCF ﬁle produced during
the SNP calling step. In case of lack of sequencing coverage at a given posi-
tion the values used to encode the SNP were the observed frequencies of the
genotypes in remaining samples. Since it is not computationally feasible to
train neural networks on all possible combinations of SNPs, even when di-
vided into smaller sets deﬁned by pathways, the selection of informative SNPs
for each pathway followed a simple two step procedure: 1) all the possible
combinations of up to 3 SNPs were tested for each pathway and 2) the com-
binations were iteratively increased up to 15 SNPs by adding another SNP to
top 20 previous combinations of SNPs. The performance of neural networks
models was assessed by Matthew’s correlation coeﬃcient (MCC), which takes
into account the numbers of true and false positives and negatives. MCC is
calculated according to the following formula:
MCC =
TP  TN   FP  FNp
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
where:
TP = number of true positives
TN = number of true negatives
FP = number of false positives
FN = number of false negatives.
This approach validated the hypothesis presented in Paper III that
inter-individual variation in drug disposition is largely eﬀected by the host
genomic background at pharmacogenomic domains. For both investigated
phenotypes (MRD levels after remission induction therapy and risk of re-
lapse) pathways comprising of transporter genes were found among the top
associated collections. Additionally, using this method the most important
biological mechanisms contributing to phenotypes can be identiﬁed and
used together with other predictive variables in prediction of the treatment
outcome.
Pathway-level analysis is becoming a popular method for complementing
single SNP associations, however there are several challenges to be faced.
Studying phenotypes by means of pathway associations has the obvious
drawback that many human genes are not studied well enough to be in-
cluded in known pathways, so the eﬀects of variations of those genes would
not be accounted for in pathway analysis. Moreover, the pathway represen-
tations collected by public databases are often not complete and are limited
by current understanding of the biological processes. Lastly, diﬀerent path-
way resources contain diﬀerent descriptions of the same biological pathways
diﬀering in levels of complexity and numbers of included components. There-
fore, comprehensive, consistent and reliable pathway resources are needed in
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the future to conduct unbiased association analyses on pathway level.
7.4 Individual disease risk
GWA studies provide an excellent way of identifying variants contributing
to disease susceptibility. This information can be further used to predict the
susceptibility to a given disease for an individual and is used for instance
by direct-to-consumer genetic testing provided by companies like 23andMe,
deCODEme or Navigenics as described in Chapter 1.4. The usefulness of
combining genomic information together with patient’s clinical characteris-
tics for disease risk estimation and genetic counselling was also demonstrated
by Ashley et al. 2010 [7].
Motivated by that, we have attempted to estimate the disease risk suscepti-
bility of an aboriginal Australian sequenced in a study by Rasmussen et al.
2011 [102]. The genome was sequenced from a lock of hair collected a century
ago, therefore no additional information of the health status or family disease
history was available for the individual and the disease risk prediction had to
be based solely on genomic information. The GWA studies are usually per-
formed on individuals with European ancestry, therefore their ﬁndings might
not be directly applicable to studying disease risk of a member of a much
diﬀerent isolated population of aboriginal Australians. However, the overall
disease mechanisms and associated genes are not expected to diﬀer between
the populations, therefore this analysis concentrated on known genes associ-
ated to diseases known to be more prevalent in the aboriginal Australians.
The burden of disease suﬀered by Australians with aborigine ancestry is es-
timated to be two-and-a-half times greater than that of the entire Australian
population [11]. The increased risk is seen for a variety of disorders in-
cluding cardiovascular, respiratory and kidney diseases, as well as diabetes
and diﬀerent types of cancer. To study the disease risk of the aborigine we
examined the genetic variant enrichment in a set of functional modules as-
sociated with diseases. The investigated collections of genes were compiled
using KEGG [92] and Reactome [31] pathways, Gene Ontology categories [6],
OMIM [50], GeneCards [104] and protein-protein complexes, including dis-
ease associated protein-protein complexes curated from phenome-interaction
networks [68, 67]. Functional modules not appearing signiﬁcant in other
modern day genomes were prioritized. The enrichment score was calculated
based only on the high-conﬁdence missense and nonsense variations, since
those have the most potential for functional eﬀects. The simple assumption
here is that genetic changes causing functional, especially deleterious changes,
to a protein in a disease associated complex or network, would impact disease
development. Enrichment of such functional eﬀects in a complex increases
the likelihood of impact. The scoring used here was very similar to gene set
enrichment techniques used in prior literature [36, 38, 95, 122]. Each disease-
associated set of genes was scored using hypergeometric testing following the
formula:
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where:
k - number of genes related to a given disease in which aborigine had poten-
tially deleterious variants
m – total number of genes in a given disease module
n – total number of genes in which the aborigine had potentially deleterious
variants
N – total number of genes included in all the considered disease modules.
All numbers were corrected for sequencing coverage, e.g. genes with no
sequence coverage were not included in numerator or denominator.
The ﬁnal enrichment score was calculated as S=1-log (P), where P was
derived from the hypergeometric distribution. These enrichment scores were
plotted as the length of the disease cones in the half-circular plot (Figure
7.2).
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Figure 7.2. Disease risk for aborigine.
To bring the P-values to a graphable scale, -log (P-value) was used and
the output was linearly rescaled to lie between 0 and 1. To prioritize dis-
eases to display, prior knowledge from the Australian Bureau of Statistics
and the Australian Institute of Health and Welfare [11] was used. The ratio
of age-standardized incidence in people of Aboriginal Australian descent rela-
tive to those of non-Aboriginal Australian background was used as a measure
of ”interestingness” to select diseases to focus on. Overall, diseases with a
higher occurrence in indigenous Australians, like diabetes, lung cancer and
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coronary heart disease, also obtained a higher enrichment score in the as-
sociated disease complexes. Accordingly cancer types with a less increased
risk in indigenous Australians, like lymphomas, colorectal cancer or prostate
cancer, show lower enrichment scores.
A single aborigine genome does not have the statistical rigor of genome wide
disease association studies. However, it can still pinpoint areas of further
research interest, especially as the genome shows no signatures of recent ad-
mixture. Disease risk inference has previously been shown to be successful
even when applied to a genome of a single individual [7]. This kind of ana-
lysis could be performed having the results of various association studies
performed in the Aboriginal Australian population, or one closely related to
it, otherwise the results cannot be directly compared. The ﬁndings of this
study have also demonstrated that rare and novel mutations are abundant in
the genes known to be associated with disease. Therefore even without know-
ing the exact causative variants in a given population, we can use missense
variants accumulation analysis to identify subjects at risk of showing severe
phenotypes, using an approach similar to strategies applied before in other
studies [62]. This kind of analysis goes few steps beyond the current state of
art in this ﬁeld. A recent paper by Fujimoto et al. [43] shows enrichment of
the functional polymorphisms in olfactory receptors by gene ontology cate-
gories enrichment analysis. However these ﬁndings lack comparison to other
modern genomes, which were found in this analysis to show similar enrich-
ment patterns. This stresses the necessity to compare the trends across the
genomes, therefore in this work the modules not appearing to be signiﬁcantly
enriched in other modern genomes were prioritized, and prior knowledge of
disease incidence ratio was included to verify the ﬁndings. This approach
also integrates diﬀerent sources of gene-phenotype information making the
analysis more comprehensive. Similar approaches have been applied before
to rank overrepresented sets of genes [36, 38, 95, 122], however this kind of
analysis has not been applied before to genome wide genotype data in context
of inferring a disease risk.
7.5 Subgrouping patients
Copy number variations are another common type of genomic variation and
can contribute to disease susceptibility. Changes in copy number have been
implicated in susceptibility to among others inﬂammatory autoimmune dis-
orders [2], autism and schizophrenia [27], however the most common CNVs
have been shown to not play a signiﬁcant role in causing disease [30]. On the
other hand copy number alterations (CNAs) are commonly acquired in cancer
and by altering the expression of involved genes might contribute to cancer
heterogeneity between patients. In Paper V in this thesis we investigated
CNAs in a subgroup of childhood ALL cancers with a t(12;21) transloca-
tion. This group of patients is characterized by very good prognosis, however
cases of relapse or other events can also occur in patients with this translo-
cation. This observation leads to hypothesis that t(12;21) childhood ALLs
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should not be treated as a homogeneous group and diﬀerent subgroups can
be distinguished within those patients with diﬀerent prognosis.
Figure 7.3. Heatmap clustering of patients and their recurrent
aberrations summarized in cytoband, chromosome arm or whole
chromosome regions. Source: Supporting Figure 1 from Paper V.
Conventional heatmap analysis of recurrent aberrations did not reveal any
obvious patterns of patient subgrouping (Figure 7.3), therefore the detected
CNAs were mapped to protein-protein interaction complexes which they are
likely to aﬀect to identify speciﬁc biological mechanisms aﬀected. The per-
formed analysis was limited to losses of genetic material as these are likely
to result in a direct loss of function and hence are most disruptive to the
complexes. All possible combinations of 2-5 diﬀerent complexes were created
and tested to ﬁnd a set of complexes aﬀected in the largest possible group
of patients with the smallest possible overlap between diﬀerent complexes.
The resulting list of top combinations was ﬁltered based on expression data
to include only genes highly expressed in B lymphoblasts and further prior-
itized based on annotations of the participating genes related to leukaemia.
The three protein-protein complexes that best discriminated between the pa-
tients were seeded from genes CD2, CDKN1A and PPP2R1B (Figure 7.4) and
aberrations in those complexes enabled identiﬁcation of four distinct groups
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Figure 7.4. Protein-protein complexes distinguishing subgroups
of patients. A. Table listing genes aﬀected by CNAs in each com-
plex together with Gene Ontology annotations of the biological
process in which the complex is involved. B. Heatmap showing
distinct groups of patients identiﬁed through protein-protein com-
plex analysis. Sidebars show age and white blood count (WBC) of
patients with lighter colours representing values below mean and
darker colours represent values above mean. C. Graphical represen-
tation of the protein-protein interactions within complexes. Yellow
nodes represent genes aﬀected by CNAs in this study. Source: Sup-
porting Figure 2 from Paper V.
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of patients with potentially diﬀerent biological mechanisms underlying the
leukaemogenesis.
The three complexes are involved in diﬀerent biological processes and
mechanisms, potentially reﬂecting the diﬀerent aetiology of leukaemia in
diﬀerent groups. Brieﬂy, the protein-protein complex seeded from CD2 is in-
volved in immune system processes, including regulation of T cell activation,
and has been associated with various types of leukaemia and lymphoma. The
CDKN1A complex is mainly involved in regulation of cell cycle and ﬁnally
the PPP2R1B complex plays a role in regulation of the Wnt receptor sig-
nalling pathway and in negative regulation of the JAK-STAT cascade, both
pathways are known to be of high relevance to leukemia. Interestingly, this
patient classiﬁcation also shows some agreement with clinical characteristics
of the patients, e.g. patients with deletions in CD2 complex are generally
older and have high WBC, patients with single deletion of CDKN1B are
young and have high WBC, while patients with no deletions or deletions
other than CDKN1B in the CDKN1A complex and patients with deletions
in PPP2R1B have low WBC. This observation further strengthens the pre-
sented hypothesis and provides additional evidence of patient subgroups
observable beyond the CNAs occurrence.

Part III
SNP proﬁling of treatment
eﬃcacy in childhood ALL
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Chapter 8
Paper III - Extensive targeted
SNP proﬁling predicts early
treatment response and risk of
relapse in 864 childhood ALL
patients
The overall current cure rate for childhood acute lymphoblastic leukaemia is
approximately 80%, thus around 20% of treated children die from resistant
disease, relapse or treatment toxicities. Several SNPs are known to be key
determinators for inter-individual diﬀerences in treatment resistance and
toxic side eﬀects. Several studies addressed this hypothesis before, however
they concentrated either on single candidate polymorphisms [120, 109, 34],
or GWAS approaches without prior knowledge of clinical relevance [134, 133].
Due to the fact that childhood ALL treatment protocols include up to 13
diﬀerent chemotherapeutic agents, it is hard to evaluate the impact of indi-
vidual SNPs. In order to progress from the non-targeted GWA studies and
limited candidate-gene studies to future clinical trials and further implemen-
tation of routine pharmacogenetic screening in childhood ALL, extensive
targeted genetic analyses are needed.
In this paper we applied multiplexed targeted sequencing method (described
in Paper II) for genotyping of three independent cohorts of childhood ALL,
treated on similar protocols. The contribution of inherited genetic variation
to treatment response was investigated by associating targeted germline
single nucleotide polymorphisms (SNPs) with risk of high minimal residual
disease (MRD) levels after remission induction chemotherapy and risk of
relapse. We also investigated the eﬀects of several SNPs within the same
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CHAPTER 8. PAPER III - EXTENSIVE TARGETED SNP PROFILING
PREDICTS EARLY TREATMENT RESPONSE AND RISK OF
RELAPSE IN 864 CHILDHOOD ALL PATIENTS
gene, protein-protein complex or biological pathway in relation to studied
phenotypes. Multiple evidence from associations representing diﬀerent levels
of molecular complexity associate outcome with glucocorticosteroid treat-
ment, immune system functions, signalling pathways and pharmacogenomics
of in particular methotrexate and doxorubicin. Results from subsequent
analyses were combined together with clinical information in classiﬁcation
and regression tree (CART) analysis, providing a framework for developing
an algorithm predicting treatment response based on individual patient SNP
proﬁles.
This study presents ﬁrst large scale hypothesis-driven screening of thousands
of polymorphisms in childhood ALL. The design of the study sets new
directions for future pharmacogenetic studies and might serve as a model
for other oncology areas. We combined the current state-of-art knowledge
of ALL disease mechanisms and pharmacogenetics of the administered drugs
curated from a variety of available pharmacogenomics, pathway and protein
interaction resources for target selection with a novel, cost-eﬀective method
of genotyping by next-generation sequencing. The data analysis in this paper
goes beyond analysing the impact of single SNPs, and integrates genotype
data across diﬀerent levels of molecular complexity. This knowledge in
the future can be used to help identify patients at risk of relapse at the
moment of diagnosis from their individual SNP proﬁle and to adjust their
chemotherapy accordingly to prevent treatment failure.
The manuscript presented in this chapter has been submitted to the
New England Journal of Medicine and has been formatted according to the
journal’s speciﬁcations. Due to limited amount of text, ﬁgures and tables
allowed by the journal, additional information was compiled into Supple-
mentary Online Material. Selected ﬁgures from the supplementary material
are included here after the manuscript.
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ABSTRACT
Background: Despite uniform treatment for childhood acute lymphoblastic leukemia (ALL), considerable
interindividual variability exists in treatment response, potentially explained by host genetic variation.
Earlier pharmacogenetic studies have concentrated either on single candidate polymorphisms or data-driven
genome-wide association studies.
Methods: We applied a novel, cost-effective sequencing-based platform for genotyping thousands of pres-
elected polymorphisms in 864 childhood ALL patients from Nordic NOPHO ALL-92 (n = 143), NOPHO
ALL-2000 (n = 232) and German ALL-BFM 2000 (n = 489) cohorts. We explored association of germline
single nucleotide polymorphisms (SNPs) to minimal residual disease (MRD) levels after remission induction
chemotherapy and relapse risk.
Results: We found 23 and 11 SNPs significantly associated with MRD and relapse, respectively, cross-
validated between cohorts. Most significant were rs12546582 (TNFRSF10A), rs113708938 (AKR1C3) and
rs34305100 (UTS2) for MRD and rs10502001 (MMP7), rs10795242 (AKR1C3) and rs28730837 (MPO)
for relapse risk. Multiple evidence from SNP, gene, protein complex and biological pathway level analyses
associate outcome with glucocorticosteroid treatment, immune system functions, G protein-coupled receptor
(GPCR) signaling and pharmacogenomics of Methotrexate and Doxorubicin. Categorical regression tree
analysis identifies three patient groups with distinct outcome profiles, ranging from 2.5% relapse risk for the
best and 77.2% for the worst group, constituting 72% and 7.5% of analyzed patients (P < 0.001).
Conclusions: Extensive hypothesis-driven screening of thousands of polymorphisms allows integrative
analyses of multiple genotypes grouped by functional modules providing multiple layers of evidence for the
hypotheses. This study sets new directions for future pharmacogenetic studies in cancer - moving us closer to
the era of personalized medicine.
Corresponding author: Kjeld Schmiegelow, Department of Pedi-
atrics, The Juliane Marie Centre, The University Hospital Rigshospi-
talet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Telephone +45
35451357, Fax +45 35454524, e-mail: kschmiegelow@rh.dk
1. Introduction
The current cure rates for childhood acute lymphoblas-
tic leukemia (ALL) after first-line therapy approach 80-
85% in the developed countries [13, 11]. However, even
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within risk-adapted treatment groups, there is a wide di-
versity in the patients‘ treatment response potentially ex-
plainable by genetic variation of both tumor- and host-
related factors [11, 4]. One of the strongest, indepen-
dent predictors of relapse in childhood ALL is high mini-
mal residual disease (MRD) levels at the end of remission
induction therapy [13, 11, 4, 2, 10]. Several candidate
gene studies demonstrate associations of inherited poly-
morphisms with post-inductionMRD levels and cure rates
in childhood ALL [14, 5, 12]. Recent genome-wide asso-
ciation studies (GWAS) identified 102 SNPs associated to
MRD levels [18] and 134 SNPs associated to relapse risk
[17], however the biological relevance and interpretation
of most of those polymorphisms remains unclear. This
hinders the translation of such findings to routine pharma-
cogenetic screening and treatment stratification in child-
hood ALL. Recently, we reported a novel cost-effective
multiplexed targeted sequencing method for screening of
approximately 25,000 targeted clinically relevant SNPs in
multiple samples simultaneously [16]. This extends the
candidate-gene approach to thousands of polymorphisms,
focusing a genome-wide approach on the important bio-
logical domains. We here apply this method in screening
of all Danish childhood ALL patients treated according
to the NOPHO ALL-1992 and NOPHO ALL-2000 proto-
cols to explore the genetic components of early treatment
response (MRD) and relapse risk, and cross-validating re-
sults in ALL-BFM 2000 cohort. Beyond conventional sin-
gle SNP associations, we present integrative analyses of
multiple SNPs acting in the same genes, protein-protein
complexes or pathways and define the most important bio-
logical mechanisms and drugs influencing the phenotype.
2. Materials and Methods
We genotyped 864 patients from three childhood ALL co-
horts (Table 1) for a panel of potentially clinically rel-
evant SNPs by means of multiplexed targeted sequenc-
ing as described previously [16]. The genotyping panel
consisted of approximately 25,000 SNPs applied for the
NOPHO ALL-2000 cohort, later updated to 34,000 SNPs
for genotyping of the NOPHO ALL-92 and ALL-BFM
2000 cohorts (Supplementary Figure 1). The selection of
genes and polymorphisms involved those previously as-
sociated with treatment response, genes influencing phar-
macogenomics of drugs administered in ALL treatment,
and genes involved in additional aspects of response to
chemotherapy including immune system, apoptosis or DNA
repair genes. The list was then expanded with first-order
protein-protein interactions to a total of 2,349 investigated
genes with SNPs residing in their coding and regulatory
regions selected for assay. The remission induction ther-
apy in the ALL-BFM 2000 protocol involves a combina-
tion of four drugs (Vincristine, Doxorubicin, glucocorti-
costeroid, L-Asparaginase), while in the NOPHO proto-
col three drugs are used (no L-Asparaginase) with 30%
lower doses of Doxorubicin. Accordingly, the MRD lev-
els are lower in the BFM cohort. To allow integrative
association analyses of polymorphisms with MRD lev-
els across ALL cohorts, we used as cut-off the approxi-
mate median value for each cohort (MRDmedian NOPHO
= 10-3, MRDmedian BFM = 10-4), resulting in similar
distribution of patients into high and low MRD groups.
Due to differences in cohort sizes, treatment protocol, and
measurement methods, we considered SNPs associated to
MRD levels if they reached P-values below 0.05 in the
BFM cohort and if observed allele frequencies and odds
ratios in the NOPHO cohort were consistent with those
observed in the BFM cohort. Since occurrence of relapse
is a more precisely defined phenotype, we required P-
values below 0.05 in both cohorts to consider the SNPs as-
sociated. Besides investigating contribution of individual
variations to phenotype, the effects of multiple SNPs act-
ing in the same gene, protein-protein complex or biolog-
ical pathway were investigated using the CMAT [19] test
and neural network models, and subsequently combined
with clinical information in classification and regression
tree (CART) analysis. Detailed methods are outlined in
the Supplementary Online Material (SOM).
3. Results
A total of 864 childhood ALL patients from three cohorts
were genotyped for between 25,000 to 34,000 SNPs by
size-controlled DNA fragmentation, sample-specific bar-
coding, sample pooling before SNP-targeted DNA frag-
ment capture, and sequencing. Of the genotyped patients,
820 fulfilled the quality control (QC) criteria and Euro-
pean ancestry requirement (Supplementary Figure 2 & 3).
Majority of genotyped variants had very low minor al-
lele frequencies (MAF) and were excluded from the sin-
gle SNP analysis. Finally, 3,274 SNPs fulfilling the QC
were tested for association with post-induction MRD sta-
tus in 172 NOPHO patients and 4,101 SNPs in 420 BFM
patients, respectively. The relapse risk was investigated
using 4,260 SNPs in the NOPHO cohorts and 3,865 SNPs
in the BFM cohort (in 351 and 424 patients, respectively).
3.1 Single SNP associations
The Manhattan plots for both analyses demonstrate sev-
eral loci associated with treatment response (Figure 1).
The associated QQ plots show good agreement with the
Manuscript 3
null distribution and absence of genomic inflation (Sup-
plementary Figure 5). After correcting for multiple testing
using up to one million adaptive permutations [1], a total
of 88 and 82 SNPs were associated with MRD levels in
the NOPHO and BFM cohorts, respectively, and 188 and
152 SNPs were associated to relapse risk with p-values
below 0.05 (data not shown). The 23 SNPs for MRD lev-
els and 11 SNPs for relapse risk, cross-validated between
cohorts, are listed in Table 2 and 3. For the replicated
relapse-associated SNPs Kaplan-Meier survival analysis
was performed showing a general tendency of gene dose
effects with the P-values for the log-rank trend test rang-
ing from 4.76*10-6 for rs3216144 (MMP7) to 0.025 for
rs35721373 (DYSF) (Supplementary Figure 6).
3.2 Multiple SNP associations
Subsequently we investigated the effects of multiple cod-
ing SNPs residing in the same genes by testing for accu-
mulation of variants in the 446 and 388 genes with at least
two sequenced variants in association with MRD level
and relapse risk, respectively. In MRD analysis 12 genes
achieved P-values lower than 0.05 after one million per-
mutations in the CMAT test. After manual inspection of
the contributing variations, excluding results driven by
single SNPs, two of the genes presented meaningful as-
sociations contributed by five polymorphisms in the gene
SLCO1A2 and nine in ABCB5 (Table 4). In relapse risk
analysis 19 genes achieved P-values lower than 0.05, and
after manual inspection of the contributing variations only
gene AKR1C4 presented meaningful association contributed
by three SNPs (Supplementary Table 1).
Similarly we tested the effects of multiple coding SNPs
in genes forming a protein-protein complex. A total of
196 and 170 virtual pull-down protein-protein complexes
were assessed for association to MRD levels and relapse
risk respectively, resulting in 11 and 6 associated com-
plexes with permutation P-values below 0.05. After man-
ual inspection of the contributing variations, two com-
plexes presented meaningful associations contributed by
multiple SNPs in different genes to MRD levels: a com-
plex of CASP7 andMVK (P = 0.001) and a complex com-
prising of SLCO1B1, ABCB11 and ABCB3 (P = 0.014),
but none for risk of relapse (Supplementary Table 2).
Finally, we grouped functional SNPs by the biological
pathways and assessed the relevance of the pathways to
phenotypes by training artificial neural networks on dif-
ferent combinations of SNPs from each pathway, allowing
non-linear correlations between SNPs (details in SOM).
The top associated Reactome [3] pathways ranked byMatt-
hew‘s correlation coefficient [9] (MCC, ranging from 0 to
1) were ‘Immune system‘ (MCC = 0.42, AUC = 0.73) for
MRD and ‘Metabolism of lipids and lipoproteins‘ (MCC
= 0.40, AUC = 0.62) for relapse (Supplementary Table
3 and 4). Similarly, we investigated 11 drug metabolism
pathways from PharmGKB [8] relevant for administered
drugs, and the top pathways for MRD analysis were the
‘Thiopurine pathway‘ (MCC = 0.34, AUC = 0.65), ‘Glu-
cocorticoid Pathway Transcription Regulation, Pharma-
codynamics‘ (MCC = 0.34, AUC = 0.66) and ‘Methotrex-
ate Pathway, Pharmacokinetics‘ (MCC = 0.33, AUC =
0.67), while for relapse risk ‘Glucocorticoid Pathway Tran-
scription Regulation, Pharmacodynamics‘ (MCC = 0.28,
AUC = 0.62), ‘Methotrexate Pathway, Pharmacokinetics‘
(MCC = 0.28, AUC = 0.63) and ‘Doxorubicin Pathway,
Pharmacokinetics‘ (MCC = 0.27, AUC = 0.63) (Supple-
mentary Table 5).
3.3 CART analyses
To evaluate and illustrate the combined significance of the
findings with respect to relapse risk, CART analysis was
applied to sequentially sub-classify the cohort in a mul-
tivariate modeling, including genotypes of 11 replicated
SNPs, number of variants in the AKR1C4 gene, pathway
profiles for top ten Reactome pathways and all investi-
gated PharmGKB pathways and clinical information on
MRD levels, white blood cell count, cytogenetics, age
and sex (Figure 2). Post-induction MRD levels and white
blood cell count (WBC) were the strongest predictors of
outcome, and combined with the genomic background in-
formation we identified three groups of patients signifi-
cantly (P < 0.001) differing in their risk of relapse. Es-
pecially for the group of patients with low MRD levels
pathway profiles improved outcome prediction. By this
approach we identified two extreme subgroups of patients
with a 6-years cumulative risk of relapse of 2.5% (CI95%:
0.5 4.5%) for the best outcome group (72% of all ana-
lyzed patients with available MRD) and 77.2% (CI95%:
50.2 89.5%) in the worst outcome group (7.5% of all an-
alyzed patients).
4. Discussion
This study of three independent ALL cohorts using cost-
effective targeted genotyping and front-line bioinformatic
analyses provides a novel biology- and pharmacology-driven
approach for outcome prediction. Treatment is the strongest
predictor of relapse in childhood ALL, and the selection
of SNPs based on current knowledge of pharmacogenomics,
disease mechanisms, and protein interactions allowed us
to explore the complete landscape of known relevant phar-
macogenomic domains together with their interactome.
The application of multiplexed targeted sequencing for
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genotyping significantly reduced costs and provided flex-
ibility to meet the needs of this hypothesis-driven study.
Such a large-scale candidate gene and SNP panel facil-
itates not only single SNP investigations, but also asso-
ciations of multiple variations grouped by their putative
function. This allowed us to test for overrepresentation
of variants within genes or protein-protein complexes in-
cluding rare variants, which are normally excluded from
association analyses, but have been shown to accumulate
in disease-related genes [19]. Additionally, associations
of combinations of SNPs grouped by biological pathways
are tested with neural network models, enabling detec-
tion of meaningful non-linear SNP interactions by reduc-
ing the search space. The results obtained through those
strategies provide conclusions at different levels of ge-
nomic complexity, collectively emphasizing the impor-
tance of the same biological mechanisms for the pheno-
type.
Most of the 23 SNPs associated to post-induction MRD
levels reside in genes involved in metabolism and trans-
port of steroids, Doxorubicin or Methotrexate, or inter-
act with those drugs (as detailed in SOM). Variant accu-
mulation test indicated importance of drug transporters:
SLCO1A2 involved in transport of steroid compounds and
ABCB5 in transport of doxorubicin, while the same test
performed on protein-protein complexes supported the afore-
mentioned findings by identifying two complexes that in-
cluded genes involved in the steroid transport and metabolism:
ABCB3, SLCO1B1 and ABCB11 in the first complex and
MVK and CASP7 in the second. Lastly, the Reactome
pathways important for MRD levels represented immune
system functions, signaling by G protein-coupled recep-
tor (GPCR), hemostasis, and transmembrane transport of
small molecules. The last pathway confirms the role of
pharmacogenetics in drug response including mostly mem-
bers of the ATP-binding cassette (ABC) transporters or
soluble ligand carrier (SLC) families involved in drug in-
flux and efflux, while GPCR signaling pathways empha-
size further the importance of glucocorticosteroid therapy
as the action of those drugs is triggered by the membrane-
associated GPCRs and activation of their downstream sig-
naling cascades [15]. Accordingly, these data provide im-
portant biological input to the many clinical studies of
glucocorticosteroid therapy [6, 7], and give credit to the
present targeted SNP exploration approach. Similarly, anal-
ysis of drug metabolic pathways from PharmGKB indi-
cated the metabolism of thiopurines (or endogenous purines),
pharmacodynamics of glucocorticosteroids and pharma-
cokinetics of Methotrexate (or folates) to be most predic-
tive of the outcome. Clearly, transport, metabolism and
downstream effects of glucocorticosteroid therapy com-
prise a consistent theme for all the associations.
Prediction of relapse risk resulted in 11 cross-validated
SNPs residing in genes previously suggested as markers
for leukemia aggressiveness, involved in steroid response
or implicated in resistance mechanisms or toxicities of
certain drugs (addressed in more detail in SOM). No rare
variant accumulation was observed for relapse analysis
potentially due to the relatively small numbers of affected
patients. However, we observed three non-synonymous
coding SNPs with MAF higher in relapse patients in the
steroid metabolism gene AKR1C4. Similarly, pathway
analysis revealed importance of the GPCR signaling, home-
ostasis and immune system, as well as metabolism of lipids
and lipoproteins and cell cycle. The top associated path-
way ‘Metabolism of lipids and lipoproteins‘ contained genes
involved in steroid metabolism, pointing again to impor-
tance of such drugs for outcome. Additionally, most of the
SNPs pointing to importance of cell cycle pathway reside
in genes related to methotrexate and doxorubicin. Not sur-
prisingly, the three top drug metabolism pathways for re-
lapse risk corresponded to the pharmacodynamics of glu-
cocorticoids and pharmacokinetics of Methotrexate and
Doxorubicin. Undoubtedly, this reflects the precedence
of glucocorticoid therapy, but also emphasizes the impor-
tance of the cell cycle arresting agents like Methotrexate
and Doxorubicin.
As risk factors linked to host genomics, leukemia biology,
treatment response markers, and drug pharmacokinetics
pile up, CART analysis allows integration of the differ-
ent layers of molecular complexity with patients’ clinical
characteristics to identify groups of patients with distinct
treatment outcomes and accordingly candidates for dif-
ferent treatment approaches. Among the identified three
groups of patients with a highly significant difference in
relapse risk, the group with a 2.5% projected risk of re-
lapse comprised 72% of analyzed patients, whereas the
group with a 77.2% risk of relapse included 45% of in-
cluded relapses. Not surprisingly, combining patients‘
genotypes with their clinical features can explain the treat-
ment outcome better than single SNPs. Further, in con-
trast to conventional multivariate Cox regression analyses,
CART approach yields classifications easier to perceive
and apply in the clinical setting. If additional independent
childhood ALL studies confirm these associations, these
findings are of sufficient power to be considered in future
treatment stratification.
Compared to other large-scale studies, this study has a
clear advantage of specifically targeting potential causative
variants, without need to investigate genomic LD patterns
or conduct follow-up fine-mapping studies. Functional
prioritization of genotyped SNPs eliminates the difficulty
of mapping variants to genes and the genotypes can be di-
rectly combined in functional analyses. Recently Yang et
al. published two papers on GWAS analysis of childhood
ALL patients with respect to MRD levels after remission
induction therapy [18] and risk of relapse [17]. All the
associated SNPs from the first study were included in this
analysis, however few of the SNPs were found associated
in either the NOPHO or BFM cohorts (Supplementary
Table 6), Only 1 of the 134 SNPs associated to relapse
risk was genotyped in this study, as all associated SNPs
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resided in non-coding regions, but it was not significant
in this study. We were not able to assess associations of
the other SNPs. However, lack of replication of MRD as-
sociated SNPs suggests that the results potentially could
reflect the applied treatment protocol or ethnicity of inves-
tigated patients. Moreover, since the associated SNPs in
the studies of Yang and coworkers in most cases were dif-
ficult to map to the gene on which they exert their effects,
it is difficult to elucidate the involved biological mecha-
nisms.
Our study combines large-scale genetic investigations of a
GWAS approach with the biological relevance of a candidate-
gene approach. The major strength of our approach is that
a panel of functional SNPs was selected with various prior
assumptions of relevance for childhood ALL. Therefore,
the results obtained through the method presented here are
easier to interpret, and thus implement in the clinic based
on existing knowledge of ALL disease mechanisms and
pharmacogenomics of administered drugs. Not covering
the scope of the whole genome potentially leads to over-
looking unknown important genetic components of treat-
ment response, and such exploration will require genome-
wide screening approaches such as GWAS or whole ex-
ome/transcriptome/genome sequencing, although the lat-
ter is still burdened by its relatively high costs, and re-
quired patient numbers for statistical significance.
In conclusion, this study introduces new potential targets
for future pharmacogenetic studies in childhood ALL. In
addition to potentially allowing future risk grouping based
on individual SNP profiles, using a similar approach for
the multiple toxicities burdening childhood ALL patients
could pave the way for higher cure rates with less toxicity.
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Figure S1. Genomic target of two SNP panels. 
The genomic coverage of targeted regions with first and second target capture designs 
is plotted in blue and green, respectively. Each line represents a 100,000 base pairs, 
and the maximum value shown here corresponds to 5% coverage in this genomic 
region. 
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Figure S3. Identity by state for NOPHO ALL-2000 cohort.  
In order to investigate the ethnicity of the patients we performed this identity by state 
analysis. For this purpose 4,295 SNPs genotyped in NOPHO ALL-2000 cohort and 
overlapping with the HapMap phase 3 data were analyzed by means of principal 
component analysis. The first two principal components are plotted and the childhood 
ALL patients are shown in red and the HapMap-CEU population in blue. All the 
samples, except for one, are grouped together with other individuals of European 
ancestry. The one sample of Asian origin was excluded from further analysis. 
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Figure S4. Identity by state for NOPHO ALL-92 and BFM ALL2000 cohorts.  
In order to investigate the ethnicity of the patients we performed this identity by state 
analysis. For this purpose approximately 3,862 SNPs genotyped in NOPHO ALL-
1992 and German cohorts and overlapping with the HapMap phase 3 data were 
analyzed by means of principal component analysis. The first two principal 
components are plotted and the childhood ALL patients are shown in red and the 
HapMap-CEU population in blue. Majority of the samples are grouped together with 
other individuals of European ancestry. The one sample of African origin was 
excluded from further analysis, as well as the 18 samples presenting as outliers in the 
plot. 
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Figure S5. MAF comparison. 
Minor allele frequencies (MAF) comparison of the SNPs genotyped in childhood 
ALL patients with overlapping SNPs genotyped in HapMap and 1000 genomes 
projects samples. Fisher’s exact test was performed for all the SNPs to assess 
deviation from expected distribution, the SNPs showing slight deviation from that are 
plotted in blue, while most deviating SNPs are shown in red. 
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Figure S8. CART analysis – pathways. 
CART analysis of relapse risk by pathway profiles from neural network models. This 
model gives a general idea of involved biological processes, however since each 
pathway profile consists of up to 15 SNPs, the model is too complex to be used in 
treatment response predictions. Arrows going to the left represent favourable pathway 
profiles, while arrows going to the right represent unfavourable pathway profiles. 
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Chapter 9
Paper IV - Variation in host
genetics and infections during
induction treatment in
childhood acute lymphoblastic
leukaemia
Infections remain a signiﬁcant challenge in treatment of childhood ALL
sometimes causing treatment related death [75]. Since relapse rates are
decreasing due to more risk adapted and, for some groups, more toxic ther-
apy, focus on toxic events is increasingly essential. Among patients dying
from toxicity, infections are the most common cause in which a majority
happen during the ﬁrst months of treatment. Inherited genetic variants may
inﬂuence the susceptibility to infections during treatment. In this paper
we describe the factors inﬂuencing the risk of infections and the patients
outcome in infectious events (Figure I, Paper IV). We then focus on studying
patients’ genetic background to identify the risk proﬁles.
We used the multiplexed targeted sequencing method (described in Paper
II) for genotyping of 69 patients for a set of approximately 34,000 genomic
variations selected based on prior knowledge of ALL disease mechanisms,
pharmacogenetic of administered drugs and immune system functions (SNP
selection is described in more detail in Chapter 6.1).
The 69 patients included in the study were treated according to NOPHO
ALL-92 protocol at a single centre in Denmark and all the infectious events
were registered during the ﬁrst 7 weeks of treatment constituting the remis-
sion induction therapy. The phenotypes used in the study are occurrence
of at least one infectious event during induction therapy and positive blood
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culture. The investigated cohort is very small and single SNP association
analysis yields many results probably burdened by many false positive ﬁnd-
ings. However, by integrating SNP eﬀects in well deﬁned biological pathways
we were able to deﬁne the most important mechanisms of susceptibility to
infectious events and classify patients into two risk groups with signiﬁcantly
diﬀerent risk of infections. Certainly, in order to be translated into clinical
settings, these ﬁndings have to be validated in a larger cohort of patients,
however the study demonstrates that host genomic risk proﬁling is possible
even in relatively small sample sizes. The results of this study indicate
that susceptibility to infections is a well-deﬁned phenotype with considerate
genetic component and therefore genetic screening provides a promising way
of identifying patients at risk and adapting individualised supportive care
and treatment protocols accordingly.
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Variation in host genetics and infections during induction treatment in
childhood acute lymphoblastic leukemia
Bendik Lund1,2,*, Agata Wesolowska-Andersen3,*, Birgitte Lausen4, Louise Borst5, Kirsten Kørup Rasmussen5, Klaus
Muller5, Helge Klungland5, Ramneek Gupta3 and Kjeld Schmiegelow5,6
1Dept. of Pediatrics, St Olavs Hospital, Trondheim, Norway
2Department for laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of
Science and Technology, Trondheim, Norway
3Center for Biological Sequence Analysis, The Technical University of Denmark, Copenhagen, Denmark
4Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark
5Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
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ABSTRACT
Purpose.To investigate host genomic variation and its association with risk of infections during induction
treatment of children with acute lymphoblastic leukemia.
Patients and Methods. A total of 69 patients aged 1 to 15 years treated at the University Hospital Rigshos-
pitalet, Denmark, from 1992 to 2000 were included. Approximately 34 000 candidate single nucleotide
polymorphisms (SNPs) related primarily to pharmacogenomics and immune function were analysed for each
patient and associations with infectious events during induction treatment were explored by testing individual
SNPs and multiple SNPs grouped by biological pathways.
Results. Forty-eight (70%) of the patients experienced an infectious event, and of these 23 (33% of total)
also had a positive blood culture. A total of 103 and 94 SNPs were associated with having an infectious
event or having a positive blood culture, respectively. CART analysis demonstrated rs11033797 (OR51F1),
rs2835265 (CBR1), rs28627172 (POLDIP3) and rs1129844/CM072923 (CCL11) to be highly predictive
of outcome characterizing 40 of 45 (89%) infectious event-patients with 98% accuracy. Pathway analysis
identified variations in GPCR downstream signalling, Bile acid and bile salt metabolism (both involved
in glucocorticosteroid pharmacokinetics and -dynamics) and Class I MHC mediated antigen processing &
presentation pathways to be predictive of infectious events.
Conclusion. Our data indicate that host genomic profile prediction of the risk of infectious events during
induction therapy could be helpful in developing individualised supportive care and leukemic treatment
strategies.
1. Introduction
Infections remain a significant challenge in treatment of
childhood acute lymphoblastic leukemia (ALL) [24, 19,
2, 29, 4, 31] with known risk factors such as use of central
venous catheters [3], mucositis [9], neutropenia [6] and
treatment intensity [33]. Inherited genetic variation may
influence the immune-inflammatory response in patients
with compromised immune function such as children un-
dergoing ALL treatment. A few studies testing single
SNPs (single nucleotide polymorphisms) have shown as-
sociations between genetic variation and severity of in-
fections during childhood leukemia treatment both within
immunogenetics [17, 28, 20] and pharmacogenetics [10].
Corresponding author: Kjeld Schmiegelow, Department of Pedi-
atrics, The Juliane Marie Centre, The University Hospital Rigshospi-
talet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Telephone +45
35451357, Fax +45 35454524, e-mail: kschmiegelow@rh.dk
However, in children who were otherwise healthy prior
to the diagnosis of ALL, severe infections are unlikely to
be determined by single SNPs, since the complex factors
precipitating these infections involve the interplay of mul-
tiple genes and their signalling molecules [15, 25]. In ad-
dition, significant single SNP associations generally have
only mild effects on outcome [21]. Genome-wide asso-
ciation studies (GWAS) provide the opportunity to link
new genes to well-defined outcomes such as response to
treatment, toxicities, or other events. The biggest limita-
tion of GWAS is that the majority of SNPs included on
commercially available microarray platforms are located
outside protein-coding genes or functionally annotated re-
gions. Consequently, many significant SNPs in such stud-
ies are difficult to map to a specific gene, and causal rela-
tionships of significantly associated SNPs is often unclear
[37, 11]. A hypothesis-driven extended candidate gene
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approach including pathway-analysis and protein-protein
interactions can provide more insight into the complex
interplay between genes in complex diseases. We have
also recently developed a cost-effective next-generation
sequencing capture assay for SNP analysis allowing pool-
ing and simultaneously genotyping of several samples for
a large number of variants [36]. Aiming at exploring host
genomic patterns of possible influence on infections dur-
ing induction therapy, we expanded our earlier study on
mannose binding lectin gene (MBL) polymorphisms and
infections [19] to include approximately 34 000 target SNPs
in candidate genes of possible relevance for childhood
ALL treatment efficacy and toxicity.
2. Materials and Methods
The patient population has previously been described in
detail [19]. Briefly, the included patients were i) diag-
nosed and treated according to the NOPHO ALL92 proto-
col [13, 32] for non-BALL at University Hospital Rigshos-
pitalet, Copenhagen, Denmark, in the period January 1,
1992, to December 31, 2000, and ii) between 1.0 -14.9
years of age at diagnosis. A total of 137 patients ful-
filled these criteria and were included in the earlier study
of MBL SNPs in relation to infections during the first 50
days of antileukemic therapy [19]. Of these, blood sam-
ples for extended SNP profiling were available for 72 pa-
tients. We excluded three patients because of too little
amount of DNA resulting in 69 patients, who then con-
stituted the study cohort (Table1). Patients were treated 
Table I. Patient characteristics 
 
Patients Original cohort 
(n=137) (%) 
Multiple SNP-cohort 
(n=69) (%) a 
p-value for 
relation to 
“infectious event” b 
(48/69) 
p-value for relation 
to “positive 
culture” b 
(23/69) 
Sex   0.78 0.56 
    Female 50 (36.5) 18 (26.1)   
    Male 87 (63.5) 51 (73.9)   
Age   <0.01 0.24 
    1-5 86 (62.8) 49 (71.0)   
    6-10 32 (23.4) 14 (20.3)   
    11-14 19 (13.9) 6 (8.7)   
Risk group   0.12 0.31 
    Low risk 95 (69.3) 53 (76.8)   
    High risk 42 (30.7) 16 (23.2)   
Immunophenotype   0.71 0.47 
    Non-B cell 113 (82.5) 60 (87.0)   
    T-cell 24 (17.5) 9 (13.0)   
Infectious eventc     
    Yes 99 (72.3) 48 (69.6)   
    No 38 (27.7) 21 (30.4)   
Positive culturec     
    Yes 43 (31.4) 23 (33.3)   
    No 94 (68.6) 46 (66.7)   
a Original SNP-cohort was 72 patients, but it showed up that 3 patients had too low DNA concentration for multiple SNP analysis 
b Association between patient characteristics and event (infectious event or positive culture), Pearson Chi-Square test or Fisher’s exact 
test, for the multiple SNP-cohort 
c At least 1 infectious event/positive blood culture during induction treatment 
 Table 1: Patient characteristics. a. Original SNP-cohort was
72 patients, but 3 patients were excluded due to too low DNA
concentration. b. Association between patient characteristics
and event (infectious event or positive culture), Pearson Chi-
Square test or Fishers exact test, for the multiple SNP-cohort. c.
At least 1 infectious event/positive blood culture during induc-
tion treatment.
according to the following risk criteria: a) low risk crite-
ria included WBC at diagnosis < 50x109/L and no other
high-risk criteria; b) high risk criteria included at least one
of the following: i) WBC > 50 x109/L, ii) T-cell disease,
iii) a mediastinal mass, iv) t(9;22) and/or t(4;11), v) pres-
ence of CNS-disease and/or testicular involvement and/or
lymphomatous leukemia, and vi) a M3 bone marrow day
15 and/or M2 bone marrow day 29.
The four-weeks induction therapy and three-weeks post-
induction period included in this study encompassed oral
Prednisone 60mg/m2/d days 1-36 and then tapered, weekly
i.v. Vincristine 2.0 mg/m2 (six doses, maximum 2.0 mg
per dose), i.v. Doxorubicin 40mg/m2 (days 1, 22 and 36;
with the addition of one dose on day 8 for the high risk pa-
tients), Erwinia L-Asparaginase 30 000IE/m2 daily days
36-45, and age adjusted intrathecal Methotrexate (four doses)
[13].
Fever was defined as a single temperature above 38:5 C.
Neutropenia was defined as an absolute neutrophil count
(ANC) less than 0.5x109 /L. In this retrospective analy-
sis, an infectious event was defined as the combination of
fever or other signs of infection and initiation of antimi-
crobial therapy after the initiation of antileukemic therapy.
In addition, a fraction of patients with an infectious event
had positive blood cultures. Data for each new infectious
event were collected for the first 50 days of treatment.
2.1 Clinical endpoints and grouping of pa-
tients
Clinical parameters were collected from the patient files
and included all blood counts, days of neutropenia, febrile
episodes, infectious events and microbiological data. For
SNP association analyses patients were grouped twice.
The first grouping included as cases the patients who had
at least one infectious event (n=48) during the seven weeks
of antileukemic therapy while the remaining 21 patients
served as controls. The second grouping included cases
from the first grouping, who in addition had at least one
positive blood culture (n=23) with the remaining 46 pa-
tients serving as controls.
2.2 Candidate genes and SNP selection
Polymorphisms included in our multiple SNP analysis plat-
form belonged to 2,350 known genes with possible rele-
vance for childhood leukemia treatment efficacy and tox-
icity [36] covering the following areas/domains: i) phar-
macogenetics, ii) immunogenetics, iii) apoptosis, iv) neu-
robiology, v) toxicity, vi) thrombosis, vii) cell cycle con-
trol genes and viii) DNA repair and mitosis. Targeted
SNPs within candidate genes were selected based on their
consequence on their transcript (according to Ensembl [14]
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annotations): i) non-synonymous coding, ii) frame-shift
coding, iii) regulatory region, iv) stop lost, v) stop gained,
vi) splice site, vii) within non-coding gene, and viii) within
mature micro-RNA. This resulted in selection of approxi-
mately 34 000 targeted SNPs assayed in this study.
2.3 Library preparation
Blood samples were obtained during morphological re-
mission and DNA was extracted and purified by sodium
chloride and ethanol precipitation. Library preparation
was performed according to the SureSelect Target Enrich-
ment System protocol version 1.2 April 2009 (Agilent Tech-
nologies, Santa Clara, CA, USA) with minor modifica-
tions as described earlier [36]. Briefly, three g genomic
DNA was sheared by Covaris S2 System (Covaris Inc.,
Woburn, MA, USA) followed by DNA purification and
end-repair. For multiplexing, patient specific barcodes of
four bases were ligated to the DNA fragments. The library
samples were then pooled in groups of three to eight sam-
ples and hybridized to custom designed baits (Sure Select
Oligo Capture Libray, Agilent Technology) with two baits
(or four in case of high priority SNPs) targeting each SNP.
After PCR amplification the library were sequenced us-
ing Illumina HiSeq 2000 (Illumina Int., San Diego, CA,
USA).
2.4 Sequence analysis
The high quality reads obtained from sequencing were
mapped to the reference human genome build 37 (GRCh37)
using Burrow-Wheelers Alignment (BWA) algorithm [22].
The alignment was refined by means of quality score re-
calibration and around indel realignment using Genome
Analysis ToolKit package [26]. SNP calling was performed
with SAMtools package [23] using default settings. The
variants were filtered using the vcfutils.pl script from SAM-
tools package and only genotypes at a minimum of 10x
sequencing depth were included in the analysis. SNP call-
ing with our multiplexing technique have earlier been val-
idated with PCR [36]. Variant annotation was done with
Ensembl Variant Effect Predictor script [27].The data was
converted into .ped and .map file formats readable by Plink
[30] using vcftools package [8].
2.5 Single SNP association
The single SNPs associations to a risk of infection and
chances of having a positive culture were performed by
Fishers exact test implemented in PLINK. Only the SNPs
with observed minor allele frequency (MAF) above 5%
and at least 50% of non-missing genotypes above 10x se-
quencing depth were used in the analysis. The obtained
p-values were adjusted for multiple testing with up to one
million adaptive permutations [5]. The adjusted p-values
were plotted on quantile-quantile (QQ) plots (Supplemen-
tary figure 1) using publicly available R script [1] and on
Manhattan plot (Figure 1) using Circos software version
0.52 [18].
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Figure 1: Circular Manhattan plot showing the association
of SNPs with 1) having an infectious event (inner gray-shaded
ring), and 2) having a positive culture (outer gray-shaded ring).
Each section (HS1, HS2, ...) represents the chromosomes (chr1,
chr2,...). The radius (y-axis) represents the log10 of p-values
and each SNP is plotted based on its position in the chromo-
some and as a function of its p-value. Red dots represents SNPs
with p-values < 0.0001. Green tickmarks represent positions of
baits used for target capture.
2.6 Pathway analysis
All functional (non-synonymous coding, frame-shift cod-
ing, stop codon and splice site) SNPs genotyped in this
study with MAF > 0.01 residing in the pathways genes
were retrieved for Reactome pathways [16] excluding the
top two pathway levels. In order to discover pathways
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related to outcome, machine learning was performed to
predict outcome using combinations of SNPs within path-
ways. Number of SNPs per pathway ranged from 1 to
82 SNPs, and each SNP was encoded by three values be-
tween 0 and 1 corresponding to likelihood of each geno-
type calculated fromVCF file produced by SAMtools [23].
Missing variants were encoded as observed population fre-
quencies for the three genotypes. Associations to infec-
tious event and positive blood culture were performed by
training artificial neural networks on subsets of SNPs from
each pathway with 3-fold cross validation. For each path-
way all combinations of up to three SNPs were assessed,
and the tested combinations of SNPs were ranked byMatthews
correlation coefficient (MCC) calculated as:
MCC =
TP  TN   FP  FNp
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
where TP is the number of true positives, TN the num-
ber of true negatives, FP the number of false positives,
and FN the number of false negatives. For each result-
ing best combination of SNPs for each pathway the neu-
ral network parameters were optimized by testing multi-
ple settings of hidden neurons and training cycles. Path-
ways were then ranked by MCC of the best combination
of SNPs for each pathway. For all best combinations the
area under receiver-operator curve (AUC) was calculated
with 95% confidence intervals with the ‘pROC‘ R pack-
age.
2.7 CART
Classification and regression tree (CART) analyses were
performed using rpart R package applying 3-fold cross-
validation [35] using the genotypes of the SNPs associ-
ated to risk of infection and positive culture together with
the patients‘ age, sex, risk group, immunophenotype and
white blood cell count (WBC) at diagnosis. Only the
SNPs with permutation corrected P-values below 0.01 were
used in the analysis. The same analysis was repeated in-
cluding also pathway-based predictions achieved from the
top ten artificial neural network classifiers from pathway
analysis.
2.8 Additional statistics
In addition to the above mentioned bioinformatics approaches,
Chi-Square or Fishers Exact Test were used for univari-
able analysis. For “time-to-event“ analysis, KaplanMeyer
analysis was done for univariable comparison with log-
rank test and proportional Hazard ratios calculated for mul-
tiple regression analysis. The software package used was
IBM SPSS statistics version 20.
2.9 Ethics
The study was approved by the Committee for research
ethics in the Danish Region H and performed in accor-
dance of Declaration of Helsinki.
3. Results
Of the 69 included patients in the SNP cohort, 48 (70%)
experienced at least one infectious event during the 7 weeks
induction period (Table I). Of these, 23 (33A total of 103
and 94 SNPs were found to be associated with infectious
event and positive culture, respectively (p<0.05 for all as-
sociations) (Supplementary tables I and II). The QQ plots
for the single SNP association analysis followed the null
distribution, but showed a few SNPs above the expected
distributions, suggesting true biological signals (Supple-
mentary figure 1). Manhattan plots for both analyses indi-
cate that several loci were associated to both risk of hav-
ing an infection and positive culture (Figure 1). The most
significantly associated SNP was a synonymous coding
SNP rs11033797 in ORF51F1, while the top SNP asso-
ciated to positive blood culture was a non-synonymous
coding SNP rs12632456 in FLNB gene. Pathway analysis
identified ‘GPCR downstream signaling‘ (MCC = 0.72,
AUC = 0.88), ‘Bile acid and bile salt metabolism‘ (MCC
= 0.71, AUC = 0.89), and ‘Class I MHC mediated anti-
gen processing & presentation‘ (MCC = 0.68, AUC =
0.83) among the pathways most predictive of an infec-
tious event. ‘Interferon Signaling‘ (MCC = 0.70, AUC =
0.85), ‘Rho GTPase cycle‘ (MCC = 0.62, AUC = 0.86)
and ‘G alpha (i) signaling events‘ (MCC = 0.60, AUC =
0.85) pathways were the most predictive of having a pos-
itive blood culture. The top ten pathways together with
selected combinations of SNPs for risk of infectious event
are listed in Supplementary Table III and for positive cul-
tures in Supplementary Table IV.
CART analysis demonstrated rs11033797 (SNP1,OR51F1),
rs2835265 (SNP2, CBR1), rs28627172 (SNP3, POLDIP3)
and rs1129844/CM072923 (SNP4, CCL11) to be highly
predictive of infectious event (Figure 2). Patients were
classified as “SNP profile-positive“ (P+) according to the
following SNP-pattern: either i) SNP1(GA, GG) or ii)
SNP1(AA) and SNP2(TC), or iii) SNP1(AA) and SNP2(CC)
and SNP3(GG) and SNP4(GG). The remaining patients
were classified as “SNP profile negative“ (P-). Data for
all four SNPs in the profile were available for 61 out of
69 patients. Of these 61 patients, 45 experienced at least
one infectious event. Of the P+ patients, 40 (97.6%) out
of 41 experienced an event compared to only 5 (25%) out
of the 20 P- patients (Figure 3, Table III). In a time-to-
event analysis, the risk of having an infectious event for
P+ patients compared to P- patients was 8.9 (95% CI:
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Figure 2: CART (Classification and regression tree) diagram
showing the most predictive SNP-sequences (all SNPs p<0.01).
Text-boxes: G: gene S: SNP (SNPs are termed SNP1-4 for sim-
plicity).
3.2-23.5, Cox regression). Adjusting for the mean ab-
solute neutrophil counts and age did not change the risk
significantly. The age group 1-5 years came out signif-
icantly in simple regression with a risk of 9.4 (95% CI:
1.3-69.0), but after adjustment for SNP-profile and ANC,
age lost statistical significance (Table III). For the “cul-
ture positive“ patients, CART analysis was less predictive
and SNPs rs12632456 (FLNB) and rs1171218 (TOPBP1)
were predictive for only 10 of 23 (43%) culture positive
patients with 77% accuracy (Figure 2).
CART analysis including pathway profiles demonstrated a
combination of variations in ‘GPCR downstream signal-
ing‘, ‘Bile acid and salt metabolism‘ and ‘Class I MHC
antigen processing & presentation‘ to be highly predictive
of infectious event (Supplementary Figure 1), while com-
binations of variations within ‘Interferon signaling‘ and
‘Platelet Aggregation (Plug Formation)‘ pathways were
predictive of a positive blood culture (Supplementary Fig-
ure 2).
4. Discussion
The cure rates of childhood ALL are approaching more
than 85-90%, but many of the 10-15% of patients that die,
do so from treatment related toxicity rather than from ac-
tive cancer. Since relapse rates are decreasing because of
better risk adapted but also more intensive therapy, focus
on toxic events has become increasingly essential. Among
patients dying from toxicity, infections are the most com-
mon cause, and the majority of these occur during the first
!"#$%&'()'!"#$%&'()*+,-./,0)1+,0',()&20,).(+30)'42,+5+.06,
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Figure 3: SNP profile and time to first infectious event. Total
number of patients: 61, total number of events: 45. The figure
illustrates the risk of having an infectious event with positive
(97.6% + 2.4%, 40/41) vs. negative (25% + 9.7%, 5/20) SNP
profile (p<0.001,Log Rank). 
Table III. Multiple regression analysis showing risk factors for having an infectious event.   
 
Risk factor Events 
n=45 
All patients 
n=61 
HR 
(95% CI) 
Simple regr. 
Adjusted HR 
(95% CI) 
Multiple regr. 
SNP profile     
    Positive 40 41 8.9 (3.2-23.5)* 7.5 (2.8-20.1)* 
    Negative 5 20 1.0 1.0 
wmANC     
    <median 25 32 1.2 (0.7-2.2) 0.8 (0.5-1.5) 
    >median 20 29 1.0 1.0 
Age     
    1-5 38 43 9.4 (1.3-69.0)* 4.9 (0.6-38.1) 
    6-10 6 13 2.7 (0.3-22.7) 1.6 (0.2-13.3) 
    11-14 1 5 1.0 1.0 
HR: Hazard ratio 
wmANC: weighted mean of ANC 
Only patients with sufficient SNP profile sequenced was included 
*significant 
Table 2: Multiple regression analysis showing risk factors for
having an infectious event.
months of treatment [24, 29]. It remains unknown, why
some patients develop severe, even life-threatening infec-
tions during treatment, while others, within the same sex,
age and risk group only experience mild infections. Many
factors influence the risk of severe infections during ALL
treatment (Figure 4), however, the role of inherited ge-
netic factors has to date not been investigated extensively.
The present study strongly indicates that common host
genomic variants that influence immune function and drug
disposition and effector mechanisms may play a critical
role. However, infectious events constitute a clinically
heterogeneous group spanning frommild clinical episodes
of fever of unknown origin to severe infectious episodes
requiring intensive care. Accordingly, the retrospective
nature of this study and the definition of an infectious
event (fever or other signs of infection and start of antibi-
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Figure 4: Factors influencing infectious events during ALL
treatment. §= Supportive care
otics) may have both under- and overestimated the impact
of host genomics.
Because of the complex nature of infections, a multiple
gene and SNP profiling approach is more likely to yield
biologically relevant results when compared to single SNP
analysis. Importantly, our findings of 103 and 94 SNPs
significantly associated with the risk of an infectious event
or a positive culture, emphasize that application of such
a candidate gene approach can yield potentially relevant
results, not least when the SNP data are integrated into
pathway explorations. Still, the results of this study need
to be validated in independent cohorts.
Integrative analysis of effects mediated by multiple SNPs
grouped by their function, e.g. acting in the same bio-
logical pathway, can provide robust results identifying the
most important underlying biological mechanisms. The
two pathways most predictive of infectious event ‘GPCR
downstream signaling‘ and ‘Bile acid and salt metabolism‘
are connected to steroid drugs that constitute an impor-
tant component of induction therapy [12]. Variants in
the second pathway are within genes involved in steroid
metabolism, while GPCR signalling reflects the mode of
action of those drugs [34]. Finally, ‘Class I MHC anti-
gen processing & presentation‘ is a critical pathway in re-
sponse to viral and other infections, as are the two path-
ways most predictive of positive blood culture ‘Interferon
signaling‘ and ‘Rho GTPase cycle‘.
Although the hierarchical approach of CART analysis re-
duces the true complexity of the biological and environ-
mental (including instrumental) factors leading to infec-
tions, its simplicity makes the risk profile data more com-
prehensible and clinically applicable than complex path-
way interactions. The CART approach identified a SNP
risk profile, which predicted the occurrence of an infec-
tious event for 40 (89%) out of 45 patients with 98% ac-
curacy. The SNPs selected by CART algorithm to collec-
tively predict the infection risk resided in genes involved
in olfactory functions (OR51F1), steroid and anthracy-
cline metabolism (CBR1), cell growth (POLDIP3) and
chemokine signalling (CCL11). When including pathway
profiles in the analysis, variants affecting GPCR down-
stream signalling (including another olfactory geneOR51T1)
and steroid metabolism (‘Bile acid and salt metabolism‘)
were most predictive of outcome. In case of positive blood
culture, CART analysis identified the SNP in the FLNB
gene to best separate cases from controls, which was also
the top associated SNP in Fishers exact test. CART anal-
ysis including pathway profiles indicated ‘Interferon sig-
nalling‘ (including the variant in FLNB gene) and ‘Platelet
Aggregation (Plug Formation)‘ to predict the phenotype
best.
The results of this study reflect the suspected pharmacoge-
nomic and immune systemmechanisms of infections. Glu-
cocorticosteroids act by suppressing the immune system,
and the risk of infection has been shown to increase with
dose and duration of treatment with those drugs [7]. Class
I MHC antigen presentation mediates recognition of in-
fectious pathogens, and this process is upregulated by in-
terferon signalling which triggers the immune system re-
sponse, while aggregation of platelets is a mechanism ac-
tivated in response to inflammatory reactions caused by
e.g. infection. These results suggest that patients with in-
creased risk of infectious events are likely to experience
higher systemic exposure of glucocorticosteroids and/or
have impaired certain immune system functions due to
their genomic background.
Our study had several limitations, including a small num-
ber of patients, and a risk of false positive results. Ad-
ditionally, investigations of a set of candidate polymor-
phisms, even when conducted on a large scale, a priori
exclude identification of other important biological mech-
anisms. Such hypothesis generating exploration will re-
quire less supervised genome wide analyses such as GWAS
and exome or whole genome sequencing. Finally, DNA
was available for only 60% of the originally patient co-
hort and the influence of this bias remains unclear.
Despite the small size of the cohort, the presented re-
sults indicate that host genomic profile can predict the risk
of infectious events during induction therapy in children
with ALL. Such knowledge might be helpful in adapting
more individualised supportive care and treatment proto-
cols. Furthermore, the study design used here can be used
for many other clinical endpoints, for instance other toxic-
ities such as toxic deaths, pancreatitis, thrombosis, and os-
teonecrosis. Such candidate SNP profiling and association
studies are ongoing as part of the Nordic/Baltic ALL col-
laboration on childhood and adult ALL, and results could
be applied for future altered treatment strategies by i) re-
ducing treatment intensity, ii) use of antimicrobial pro-
phylaxis, and iii) administration of immune therapy (im-
munoglobulins or specific immune therapy).
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Supplementary Table 1. SNPs associated with risk of infectious event with permutation corrected 
P-values < 0.01 
	  
rsID Perm 
p-val 
Genotypes – no event Genotypes - event SNP consequence HGNC 
rs11033797 6.00E-
06 
GG:0;GA:0;AA:20;00:1 GG:1;GA:25;AA:22;00:0 SYNONYMOUS_CODING OR51F1 
rs28627172 0.0001 AA:2;AG:8;GG:8;00:3 AA:0;AG:5;GG:40;00:3 NON_SYNONYMOUS_CO
DING 
POLDIP3 
rs35158358 0.0002 -/-:0;-/+C:9;+C/+C:10;00:2 +C/+C:6;+C/-:26;-/-:12/00:4 WITHIN_NON_CODING_G
ENE 
GDA 
rs73197348 0.0007 CC:0;CT:7;TT:13;00:1 CC:0;CT:2;TT:46;00:0 REGULATORY_REGION RUNX1 
rs1129844, 
CM072923 
0.001 AA:3;AG:7;GG:6;00:5 AA:0;AG:10;GG:34;00:4 NON_SYNONYMOUS_CO
DING 
CCL11 
rs2835265 0.004 TT:0;TC:0;CC:20;00:1 TT:0;TC:14;CC:34;00:0 NON_SYNONYMOUS_CO
DING 
CBR1 
rs11409972 0.004 +T/+T:1;+T/-:7; -/-:10;00:3 +T/+T:9;+T/-:24;-/-:12;00:3 REGULATORY_REGION MAGI1 
rs67155431 0.005 -/-:1;-/+A:4;+A/+A:7;00:9 -/-:0;-/+A:4;+A/+A:38/00:6 SPLICE_SITE SLCO1A2 
rs10653020 0.007 +CATC/+CATC:0;+CATC/
-:1;-/-:17;00:3 
+CATC/+CATC:0;+CATC/-
:17;-/-:27;00:4 
WITHIN_NON_CODING_G
ENE 
ACE 
rs1130435 0.007 TT:1;TC:5;CC:10;00:5 TT:8;TC:24;CC:10;00:6 NON_SYNONYMOUS_CO
DING 
FABP6 
rs76959009 0.007 CC:0;CT:2;TT:18;00:1 CC:0;CT:20;TT:26;00:2 WITHIN_NON_CODING_G
ENE 
C1orf112 
rs1136410, 
CM042761 
0.007 GG:0;GA:8;AA:3;00:10 GG:0;GA:10;AA:27;00:11 NON_SYNONYMOUS_CO
DING 
PARP1 
rs35710857 0.007 TT:0;TC:0;CC:21;00:0 TT:0;TC:13;CC:35;00:0 SYNONYMOUS_CODING CBR1 
rs2292572 0.007 TT:0;TG:2;GG:18;00:1 TT:5;TG:15;GG:28;00:0 REGULATORY_REGION GAB2 
rs2275287 0.007 TT:1;TC:4;CC:9;00:7 TT:8;TC:27;CC:9;00:4 SPLICE_SITE RYR2 
rs10841795 0.007 GG:0;GA:5;AA:10;00:6 GG:0;GA:3;AA:43;00:2 NON_SYNONYMOUS_CO
DING 
SLCO1A2 
rs12666401 0.007 AA:0;AG:0;GG:14;00:7 AA:0;AG:14;GG:27;00:7 REGULATORY_REGION SHFM1 
rs5367 0.008 GG:0;GA:2;AA:17;00:2 GG:0;GA:20;AA:25;00:3 SPLICE_SITE SELE 
rs12133666 0.008 TT:0;TA:2;AA:19;00:0 TT:0;TA:20;AA:28;00:0 WITHIN_NON_CODING_G
ENE 
SELE 
rs3917441 0.008 CC:0;CG:2;GG:18;00:1 CC:0;CG:20;GG:28;00:0 REGULATORY_REGION SELE 
rs77115118 0.008 TT:0;TA:2;AA:19;00:0 TT:0;TA:20;AA:28;00:0 WITHIN_NON_CODING_G
ENE 
SELE 
rs62471402 0.008 GG:0;GC:0;CC:15;00:6 GG:0;GC:14;CC:33;00:1 WITHIN_NON_CODING_G
ENE 
SHFM1 
rs4877837 0.009 AA:0;AG:6;GG:3;00:12 AA:0;AG:7;GG:26;00:15 REGULATORY_REGION SLC28A3 
rs2306825 0.009 AA:0;AG:1;GG:16;00:4 AA:0;AG:17;GG:28;00:3 SYNONYMOUS_CODING, 
SPLICE_SITE 
PSD3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. SNPs associated with positive blood culture with permutation corrected 
P-values < 0.01. 
	  
rsID Perm 
p-val 
Genotypes – positive 
culture 
Genotypes – no positive 
culture 
SNP consequence HGNC 
rs12632456 
7.36E-
05 AA:2;AG:14;GG:7;00:0 AA:0;AG:10;GG:35;00:1 
NON_SYNONYMOUS_CO
DING FLNB 
rs12638356 
9.12E-
05 GG:3;GA:14;AA:6;00:0 GG:0;GA:12;AA:34;00:0 REGULATORY_REGION FLNB 
rs61748935 0.0004 AA:1;AG:5;GG:15;00:2 AA:0;AG:0;GG:42;00:4 
NON_SYNONYMOUS_CO
DING C22orf40 
rs8464 0.0005 AA:1;AC:11;CC:11;00:0 AA:0;AC:5;CC:40;00:1 
INTERGENIC, 
REGULATORY_REGION NA 
rs8640 0.001 TT:1;TC:14;CC:6;00:2 TT:0;TC:11;CC:28;00:7 SYNONYMOUS_CODING FLNB  
rs74207980, 
rs9270773 0.003 GG:1;GA:12;AA:7;00:3 GG:0;GA:10;AA:28;00:8 INTERGENIC NA 
rs2070687 0.004 GG:0;GC:4;CC:19;00:0 GG:1;GC:21;CC:21;00:3 SPLICE_SITE SFTPC 
rs35709976 0.004 
-/-:0;-
/+TA:2;+TA/+TA:21;00:0 
-/-:0;-
/+TA:19;+TA/+TA:26;00:1 REGULATORY_REGION F11 
rs6065, 
CM032257 0.005 TT:0;TC:11;CC:12;00:0 TT:0;TC:6;CC:37;00:3 
NON_SYNONYMOUS_CO
DING GP1BA 
rs7577978 0.005 AA:2;AG:6;GG:8;00:7 AA:0;AG:4;GG:22;00:20 DOWNSTREAM ATIC 
rs238239 0.006 CC:3;CT:11;TT:9;00:0 TT:4;TC:27;CC:14;00:1 
NON_SYNONYMOUS_CO
DING ENO3 
rs10949870 0.006 AA:3;AG:14;GG:4;00:2 AA:0;AG:16;GG:17;00:13 REGULATORY_REGION ZNF727 
rs59337853 0.007 -/-:2;-/T:4/TT:15;00:2 -/-:0;-/T:2;TT:39;00:5 REGULATORY_REGION ALOX5 
rs35187157 0.008 
-/-:1;-
/+TT:8;+TT/+TT:14;00:0 
-/-:6;-
/+TT:28;+TT/+TT:11;00:1 REGULATORY_REGION TRBV30 
rs3787537 0.008 TT:2;TC:11;CC:10;00:0 TT:0;TC:12;CC:32;00:2 REGULATORY_REGION SLCO4A1 
rs9332119 0.009 CC:0;CG:10;GG:11;00:2 CC:0;CG:6;GG:35;00:5 
WITHIN_NON_CODING_G
ENE CYP2C9 
rs4298 0.009 TT:1;TC:5;CC:13;00:4 TT:0;TC:2;CC:31;00:13 SYNONYMOUS_CODING ACE 
rs6958588 0.009 TT:3;TC:13;CC:4;00:3 TT:0;TC:19;CC:17;00:10 
WITHIN_NON_CODING_G
ENE ZNF727 
rs976002, 
rs139555919 0.009 GG:4;GA:10;AA:8;00:1 GG:1;GA:15;AA:27;00:3 
NON_SYNONYMOUS_CO
DING 
TMPRSS1
1E 
rs2228539 0.009 CC:4;CT:11;TT:8;00:0 CC:2;CT:13;TT:31;00:0 
NON_SYNONYMOUS_CO
DING EMR1 
rs11712186 0.0098 CC:1;CT:8;TT:6;00:8 CC:0;CT:7;TT:22;00:17 REGULATORY_REGION TOPBP1 
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Chapter 10
Paper V - Genome-wide analysis
of cytogenetic aberrations in
ETV6/RUNX1-positive
childhood acute lymphoblastic
leukaemia
The following paper is a descriptive study of a sub-group of childhood
ALL patients with a t(12;21) chromosomal translocation resulting in
ETV6/RUNX1 fusion gene. It is the most frequent chromosomal aber-
ration in B-lineage ALL, occurring in approximately 25% of cases and it is
usually associated with a more favourable prognosis. In this paper 62 patients
with the t(12;21) translocation were analysed with Aﬀymetrix GeneChip
500K arrays to investigate the copy number alterations (CNAs) in this group
of patients.
One of the hypotheses presented by this study was that there might exist
diﬀerent subgroups of patients within the t(12;21) childhood ALL deﬁned by
their recurrent aberrations. Traditional classiﬁcation approaches were not
successful in identifying subgroups within the samples, possibly due to not
suﬃcient number of patients included in the study. Therefore an integrative
analysis of CNAs was applied in this study, investigating the protein-protein
complexes potentially disrupted by losses of genetic material. This resulted
in identiﬁcation of four distinct groups of patients, characterized by disrup-
tions in one of three identiﬁed protein-protein complexes. Details of this
method are described in Chapter 7.5 and in the Supporting Material online.
The second hypothesis addressed in this study concerned the recurrent
111
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aberrations accompanying the ETV6/RUNX1. The t(12;21) chromoso-
mal translocation is believed to be an initiating event in development of
leukaemia, however it has been hypothesized that additional genetic changes
are necessary to develop leukaemia. In this study, after identifying the recur-
rent aberrations, we tried to investigate their sequential gain and to identify
the important early leukaemogenic events, secondary to ETV6/RUNX1.
This task was performed using a branching oncogenic tree model, resulting
in a observations similar to presented in other studies of t(12;21) childhood
ALL (Figure 2, Paper V).
Finally, the long segments of ampliﬁcations and deletions of genetic material
aﬀect the number of copies of the genes included within those segments.
Therefore, we additionally examined the known microRNAs residing within
those segments. microRNAs can regulate protein-coding gene targets, thus
they may play an oncogenic or tumour suppressive role, depending on their
transcription levels, DNA methylation and CpG content of the surrounding
regions, mutations and the genes they regulate. In this study we have iden-
tiﬁed the potentially important microRNA clusters aﬀected by CNAs and
described their putative role in oncogenesis (Supporting Material online).
Supporting Material for this paper is available online from: http://
onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09083.x/suppinfo.
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Summary
The chromosomal translocation t(12;21) resulting in the ETV6/RUNX1
fusion gene is the most frequent structural cytogenetic abnormality among
patients with childhood acute lymphoblastic leukaemia (ALL). We investi-
gated 62 ETV6/RUNX1-positive childhood ALL patients by single nucleo-
tide polymorphism array to explore acquired copy number alterations
(CNAs) at diagnosis. The mean number of CNAs was 2·82 (range 0–14).
Concordance with available G-band karyotyping and comparative genomic
hybridization was 93%. Based on three major protein-protein complexes
disrupted by these CNAs, patients could be categorized into four distinct
subgroups, defined by different underlying biological mechanisms relevant
to the aetiology of childhood ALL. When recurrent CNAs were evaluated
by an oncogenetic tree analysis classifying their sequential order, the most
common genetic aberrations (deletions of 6q, 9p, 13q and X, and gains of
10 and 21) seemed independent of each other. Finally, we identified the
most common regions with recurrent gains and losses, which comprise
microRNA clusters with known oncogenic or tumour-suppressive roles.
The present study sheds further light on the genetic diversity of ETV6/
RUNX1-positive childhood ALL, which may be important for understand-
ing poor responses among this otherwise highly curable subset of ALL and
lead to novel targeted treatment strategies.
Keywords: childhood acute lymphoblastic leukaemia, ETV6/RUNX1 trans-
location, genome-wide screening.
Acute lymphoblastic leukaemia (ALL) is the most common
cancer in children (Hjalgrim et al, 2003). In B-lineage child-
hood ALL the most frequent structural cytogenetic abnor-
mality, present in 25% of the cases, is the chromosomal
translocation t(12;21)(p13;q22) resulting in the ETV6/
RUNX1 fusion gene (Shurtleff et al, 1995; Forestier et al,
2008). The event-free survival (EFS) of childhood ALL
patients after first line therapy is approximately 80% (Schmi-
egelow et al, 2010), however presence of the ETV6/RUNX1
fusion gene is generally associated with a more favourable
prognosis, with an EFS of approximately 90% (Forestier
et al, 2008). The ETV6/RUNX1 fusion gene is believed to
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represent an initiating event in the development of this
childhood ALL subset. This initiating event, seen as early as
in utero (Wiemels et al, 1999; Hjalgrim et al, 2002), most
likely requires additional genetic changes in order to lead to
leukaemia e.g. ETV6/RUNX1 transcripts have been demon-
strated in normal cord blood samples at low levels (Mori
et al, 2002; Lausten-Thomsen et al, 2011) and neither ETV6/
RUNX1-positive knock-in mouse models nor carriers of
ETV6/RUNX1-positive pre-leukaemic cells will all develop
leukaemia (Fischer et al, 2005; Hong et al, 2008). Thus, the
development of ETV6/RUNX1-positive leukaemia requires
one or more secondary genetic changes and previous studies
have indeed shown additional genetic changes in the majority
of ETV6/RUNX1-positive childhood ALL patients (Forestier
et al, 2007; Mullighan et al, 2007; Kawamata et al, 2008; Lil-
ljebjorn et al, 2007, 2010; Parker et al, 2008; Mullighan et al,
2008; van Delft et al, 2011).
In the present study, we applied high-resolution Affyme-
trix GeneChip® 500K profiling to 62 ETV6/RUNX1-positive
childhood ALL patients to explore in detail copy number
alterations (CNAs) throughout the genome. Furthermore, we
investigated the inter-dependencies of the recurrent CNAs
and involvement in protein-protein complexes among them,
and correlated the CNAs with biologically relevant microR-
NAs (miRNAs) affected by the aberrations.
Methods and materials
Patients
The ETV6/RUNX1-positive childhood ALL patients (aged
between 1 and 15 years at the time of diagnosis) from Den-
mark, Norway, Sweden and Iceland were diagnosed and
enrolled in the Nordic Society for Paediatric Haematology
and Oncology (NOPHO) treatment protocols (NOHPO
ALL-92 or NOPHO ALL-2000) (Schmiegelow et al, 2010). A
total of 133 patients were found to be positive for ETV6/
RUNX1 by fluorescent in situ hybridization (FISH) and/or
reverse transcription polymerase chain reaction (RT-PCR) by
routine investigation from 1996–2007, and diagnostic
tumour DNA samples were available for 99 of these patients.
Ten samples were of poor quality and/or had insufficient
amount of DNA to be analysed and of the remaining sam-
ples, 62 fulfilled the quality criteria (QC) for inclusion in the
bioinformatics analyses (Table 1). The study was approved
by The Capital Region of Denmark Committee on Biomedi-
cal Research Ethics and The Danish Data Protection Agency.
G-band karyotyping and comparative genomic
hybridization
G-band karyotyping was performed as part of the routine
investigation on short-term cultured leukaemic cells by stan-
dard techniques. As part of a separate study, high-resolution
comparative genomic hybridization (CGH) was performed
for a subset of the patients (Kristensen et al, 2003). G-band
karyotyping and/or CGH data was available in 54 (87·1%) of
the included cases (Table S1).
Single nucleotide polymorphism (SNP) array analysis
DNA from bone marrow or blood samples acquired at diag-
nosis was extracted and purified by sodium chloride and eth-
anol precipitation. For SNP array analysis the DNA was
processed and hybridized to Affymetrix GeneChip® Mapping
500K array set according to the manufacturer’s instructions
(Affymetrix, Santa Clara, CA, USA). The Affymetrix Gene-
Chip® Mapping 500K array set comprises two arrays and is
processed by two assay kits differing only in the restriction
enzyme used (Affymetrix GeneChip® Mapping 250K Nsp
Assay Kit and Affymetrix GeneChip® Mapping 250K Sty
Assay Kit). Briefly, 250 ng DNA was digested by either Nsp I
or Sty I, followed by ligation of adaptors, allowing PCR
amplification of fragments in sizes from 200 to 1100 bp.
PCR products were fragmented and end-labelled with biotin.
Samples were subsequently hybridized to the arrays. The
Table 1. Patient characteristics and copy number alterations.
Characteristics Patients
Gender
Male 37 (59·7%)
Female 25 (40·3%)
Age, years, median (range) 4·17 (1·30–15)
WBC, 9109/l, median (range) 11·5 (0·80–110)
Risk group
SR 28 (45·2%)
IR 23 (37·1%)
HR 11 (17·7%)
Treatment protocol
NOPHO ALL-92 33 (53·2%)
NOPHO ALL-2000 29 (46·8%)
Events
Induction failure 0 (0%)
Resistant disease 0 (0%)
Relapse 4 (6·5%)
Death in remission 0 (0%)
Secondary malignancy 0 (0%)
Total events 4 (6·5%)
EFS 93·5%
CNA (mean)
Gains > 1 Mb 0·73 (0–8)
Gains < 1 Mb 0·02 (0–1)
Losses > 1 Mb 1·24 (0–8)
Losses < 1 Mb 0·85 (0–6)
Total > 1 Mb 1·97 (0–9)
Total < 1 Mb 0·85 (0–6)
Total 2·82 (0–14)
WBC, white blood cell count; SR, standard risk; IR, intermediate
risk; HR, high risk; NOPHO, Nordic Society for Paediatric Haema-
tology and Oncology; EFS, event-free survival; CNA, copy number
alteration; Mb, megabase.
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arrays were washed and stained with phycoerythrin-conju-
gated streptavidin (SAPE) using the Affymetrix Fluidics Sta-
tion® 450 and were scanned in the Affymetrix GeneChip®
2500 scanner to generate fluorescent images, as described in
the Affymetrix GeneChip® protocol. Cell intensity files (CEL
files) were generated in the GeneChip® operating software
(GCOS) version 5.0.
Data processing
The signal intensity data based on the raw CEL files was gen-
erated using the Affymetrix Power Tools (APT) Software
Package. First, for each array a QC call rate was generated
using the Dynamic Model algorithm (Di et al, 2005).
According to the manufacturer’s recommendations, only
samples achieving call rates ! 93% were used for further
analysis. For the 62 samples and 200 controls fulfilling QC,
genotype calls were generated using the BRLMM algorithm
(http://array.mc.vanderbilt.edu/microarray/dna/brlmm.pdf).
Allele-specific signals were extracted from median polish
summarized and quantile normalized Perfect Match (PM)
probe-intensity values. The R-GADA package (Pique-Regi
et al, 2010) was employed to detect the recurrent CNAs. The
package implements a segmentation algorithm to call CNAs
based on genome alternation detection analysis (GADA).
During the segmentation procedure the parameters control-
ling the trade-off between the sensitivity and false discovery
rate (FDR) were set to achieve high specificity at the cost of
sensitivity. The minimum segment length required for classi-
fication as a CNA was 8 probes, in order to exclude detec-
tion of false alterations due to extreme outliers. The 200
controls were used to exclude alterations representing the
normal CNAs. Final estimation of copy number states was
verified by visual examination.
Data visualization and biological correlations
The display of all the CNAs in circos format was done accord-
ing to Krzywinski et al (2009). Recurrent CNAs were defined
as gains or deletions of material occurring in the same region
in at least two patients and plotted as a heatmap (Fig S1). The
recurrent CNAs were then analysed further with a CRAN R
package Oncotree 0·31 to determine a tree model for oncogen-
esis (Desper et al, 1999; Szabo & Boucher, 2002).
To explore functional modules that are potentially affected
by the CNAs, enrichment analysis on protein-protein interac-
tion complexes was performed using custom written Perl
scripts. Only patients with losses of genetic material were
included in this analysis, as these are likely to result in a
direct loss of function and hence are most disruptive to the
complexes. Using a curated collection of protein-protein
complexes (Lage et al, 2007), we defined a set of complexes
that categorized the patients into distinct subgroups defined
by different underlying biological mechanisms. All combina-
tions of 2–5 protein-protein complexes were tested to find a
set of complexes representing the largest possible group of
patients with the smallest possible overlap between different
complexes. From the final collection of complex sets that
best fulfilled the criteria, only those that comprised of genes
highly expressed in B lymphoblasts were selected and priori-
tized according to leukaemia-related annotations among Bio-
Alma terms assigned to the complexes. The miRNA
annotations were based on miRBase version 16 (Griffiths-
Jones, 2010) while their experimentally validated target infor-
mation was collected from miRecords and miRWalk databas-
es (Xiao et al, 2009; Dweep et al, 2011).
Results
Genomic profiling of ETV6/RUNX1-positive childhood
ALL patients
The SNP array analysis revealed a total of 174 CNAs (30
were recurrent) among the 62 successfully analysed cases
(whole chromosome deletions and amplifications each
counted as one cytogenetic change). Of these, 129 were dele-
tions, 77 above 1 Mb (including two whole X chromosome
deletions), and 52 focal deletions below 1 Mb. A total of 45
gains were detected, of which 44 were above 1 Mb (including
18 whole chromosome gains), and only one focal amplifica-
tion below 1 Mb (Fig 1 and Table S1). Since the 500K arrays
do not have any probes covering the p arms of chromosomes
13, 14, 15, 21 and 22, some large amplifications of these
chromosomes may actually be trisomies. The mean number
of CNAs per patient was 2·82 (range 0 –14) and 13 cases
(21%) did not display any CNAs (Table 1 and Table S1).
Concordance between G-band karyotyping and/or CGH
and the SNP array analysis data was 93%. Thus, in 51 of the
54 cases with available data, the SNP array results either con-
firmed and/or added to G-band karyotyping and/or CGH
(Table S1). As summarized in Fig 1, all but chromosome 17
demonstrated CNAs above 1 Mb. If focal lesions are
included, all chromosomes demonstrated alterations. The
most common CNAs above 1 Mb involved deletions of 12p
(39%), 6q (13%), 9p (10%), 11q (10%), 13q (10%), 8p (8%)
and amplifications of Xq (11%) (one female and six males),
21 (10%), 10 (5%) and Xp (5%) (two females and one
male). Of the focal changes, the most common included
deletions in 14q32·33 (21%), 7p14·1 (18%), 22q11·22 (13%),
14q11·2 (8%) and 7q34 (6%).
Biological correlations
Overall, neither individual aberrations nor heatmap clustering
of the recurrent aberrations (Fig S1) correlated significantly
with age or white blood cell count (WBC). In an attempt to
classify the patients more distinctively, a systems biology
approach was applied investigating the likely effects of losses
of genetic material at the protein complex level. Grouping of
patients in this way reflects more closely the clinical parame-
Genome-Wide Analysis of ETV6/RUNX1-Positive Childhood ALL
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ters and suggests different potential biological mechanisms
underlying the leukaemogenesis (Data S1, Fig S2).
Next, the inter-dependency of the recurrent CNAs was
investigated by an oncogenetic tree analysis to explore the
sequential order of CNAs as previously done by Lilljebjorn
et al (2010). By this approach, deletions of 12p, 14q32 and
gain of 21q were classified as early events, i.e. being close to
the root and acting as new roots of their own subtree
(Fig 2). Importantly, even though gain of 12p (the most
common additional aberration) was close to the root, it did
not seem to be a required precursor for other changes.
Furthermore, the most common aberrations in ETV6/
RUNX1-positive patients (deletions of 6q, 9p, 12p, 13q, and
X, and chromosome 10 and 21 amplifications) (Forestier
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Fig 1. The recurrent cytogenetic alterations in ETV6/RUNX1 patients plotted in Circos format (Krzywinski et al, 2009). The chromosomes are
presented clockwise with the p arm starting from 0, followed by the centromere marked in red and by the q arm. The gains are shown in
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et al, 2007), seemed independent of each other, i.e. the
occurrence of one did not change the likelihood of occur-
rence of the others. Still, 9p deletions seemed to precede 8p
deletions and chromosome X deletions were rooted in 8p
deletion according to the oncogenetic branching model
(Fig 2). The reported estimated false-positive error rate was
0·0007 and the false-negative error rate was 0·30.
Finally, regions undergoing recurrent aberrations in the
patients were also investigated for transcribed miRNAs. miR-
NAs can regulate protein-coding gene targets, thus they may
play an oncogenic or tumour suppressive role, depending on
their transcription levels, DNAmethylation and CpG content of
the surrounding regions, mutations and the genes they regulate
(Data S2). The most frequently deleted regions, containing
important miRNA clusters, were on 11q and 13q, while the most
frequently amplified regions were on chromosomes 21 and X,
comprising other miRNA clusters (Data S2 and Table S2).
Discussion
The present study sheds further light on the genetic diversity
of ETV6/RUNX1-positive childhood ALL. Overall, the mean
number of alterations per patient (2·82, range 0–14) is in
agreement with previous studies of ETV6/RUNX1-positive
childhood ALL patients (Forestier et al, 2007; Mullighan
et al, 2007; Parker et al, 2008; Lilljebjorn et al, 2010; van
Delft et al, 2011). Higher specificity was prioritized in
attempt to reduce the rate of false positive findings, at the
cost of reduced sensitivity, especially with regard to detection
of focal aberrations. Furthermore, due to the size of the
study, some recurrent changes may have been missed if they
did not occur in at least two patients. On the other hand,
the strict criteria increased the reliability of the oncogenetic
tree and systems biology analyses, and is furthermore sup-
ported by the high concordance with previous results of G-
band karyotyping and CGH analyses. The larger alterations:
12p, 6q, 9p, 11q, 13q and gains of chromosome 21 and Xq
occurred in at least 10% of the patients, supporting previous
reports (Forestier et al, 2007; Mullighan et al, 2007; Kawa-
mata et al, 2008; Lilljebjorn et al, 2007, 2010; Parker et al,
2008; Mullighan et al, 2008; van Delft et al, 2011). Moreover,
gain of Xq is far more common in males than in females,
which supports the previous findings of Lilljebjorn et al
(2007); (Lilljebjorn et al, 2010) and could imply loss of X
chromosome silencing of that specific region in females lead-
ing to similar gene dosage effects in both sexes. The affected
gene(s) remains to be determined.
Importantly, these non-random aberrations should be
interpreted by their putative biological consequence. Here we
proposed an alternative grouping of patients based on inte-
grative analysis of recurrent CNAs and involved protein-pro-
tein interaction complexes, which may suggest different
underlying biological mechanisms. This classification reflects
that deletions of different genes, often from different chro-
mosomes, may lead to disruption of the same complex
resulting in a similar phenotype. In most cases the loss of a
gene, evidenced through CNAs, leads to perturbation of
interaction with another gene with high connectivity in the
complex, and therefore is likely to have a functional effect.
To speculate on the relationship and order by which these
CNAs occur, we used a branching oncogenetic tree model.
The model identified deletions on 12p, 14q32 and gain of
Fig 2. Oncogenetic tree. A probabilistic model of the sequential order of acquiring of the copy number alterations. The root of the tree represents
the initial event - the t(12;21) chromosomal translocation. The numbers at each edge indicate the probabilities of transition along the given edge
by the time of observation.
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21q as important early leukaemogenic events secondary to the
ETV6/RUNX1 translocation. Later, independent events
include the most common changes in ETV6/RUNX1-positive
childhood ALL patients, such as deletions of 6q, 9p, 13q and X
and amplification of chromosome 10, suggesting these changes
occur later in the development of the leukaemic clone. These
implications need to be confirmed, if possible, in studies
directly observing the sequential order of occurrence of CNAs.
A recent study also demonstrated a similar model with data
from 164 ETV6/RUNX1-positive childhood ALL patients (Lil-
ljebjorn et al, 2010). The authors demonstrated independence
between deletions on 6q, 9p and 12p, however with 6q and 9p
closer to the root. Also amplification of chromosome 21 was
far down a subtree rooting from 6q deletion. However, the
two models cannot be compared directly because the resolu-
tion of analysed aberrations differed between the two studies.
Furthermore, Anderson et al (2011) has also recently per-
formed an oncogenetic tree mapping, however the study only
explored pre-selected CNAs at single cell level in individual
patients. Thus, the results and those from the present study
are not directly comparable, but the nonlinear branching nat-
ure of the sequence of the acquired CNAs is alike.
Finally, we associated recurrent CNAs with miRNAs tran-
scribed in those regions in order to elucidate the conse-
quences on gene regulation of the investigated miRNAs
targets. Here we observed deletions and amplifications in sev-
eral chromosomal regions containing miRNAs known to be
associated with tumourigenecity, leukaemia and regulation of
apoptosis among others (Data S2). Thus, miRNAs may play
a crucial role in childhood ALL by targeting a number of
proteins and affecting various functional pathways.
Even though many clinical trials classify ETV6/RUNX1-
positive childhood ALL as one group, their cytogenetic diver-
sity calls for refinement in the classification of these patients,
which ultimately may lead to a better understanding of their
natural history (including determination of pre- and postna-
tal hits) (Greaves, 2006), the clinical presentation and their
specific treatment requirements. Based on CNAs in protein-
protein complexes, we described four groups of patients. This
analysis could be further refined in the future with a larger
number of samples and higher density arrays.
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Chapter 11
Summary and perspectives
This thesis presents the current state-of-art in the ﬁeld of functional genomic
variations and introduces childhood acute lymphoblastic leukaemia as an
excellent model for studying pharmacogenomics. The main thrust of this
thesis concentrates on investigating genomic variations in context of inter-
individual diﬀerences in patients’ treatment response (Paper III), suscepti-
bility to adverse side eﬀects (Paper IV) and identifying subgroups of patients
with potentially diﬀerent disease aetiology (Paper V). These investigations
are accompanied by discussion of available genotyping technologies (Chap-
ter 5 and Chapter 6.2) and introduction of a novel, cost-eﬀective method
of genotyping by multiplexed targeted sequencing (Paper II). Chapter 4
provides a brief overview of predicting eﬀects of SNPs on their transcript,
subsequent prediction of deleteriousness of a given variant, accompanied by
comparison of mutability and deleteriousness of amino acid changes (Paper
I) and ﬁnally identifying more speciﬁc molecular mechanisms aﬀected by
the variant by applying an ensemble of prediction tools for proteins. The
presented strategies to discover associations to phenotypes of interest include
associations of single SNPs as well as sets of SNPs grouped by functional
modules in which they are likely to operate (Chapter 7). One of the methods
applied in Paper III (described in Chapter 7.2) facilitates including the rare
variant genotypes in the analysis to investigate accumulation of variants
in certain genomic regions or protein-protein complexes, and a pathway
analysis (described in Chapter 7.3) applied in Papers III and IV allows
more robust analysis identifying non-linear interactions between genotypes
and pinpointing well-deﬁned biological mechanisms contributing to the phe-
notype. Furthermore, a discussion on personal genomes (Chapter 1.4) is
followed by a suggestion of a simple way of assessing individual disease risk
based on overrepresentation of genomic variants in disease-associated gene
sets (Chapter 7.4). Finally, integrative analysis of acquired copy number
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alterations presented in Chapter 7.5 and Paper V introduces a way of elu-
cidating diﬀerent biological mechanisms underlying the leukaemogenesis by
identifying disruptions of functional protein-protein complexes.
Overall, the work presented in this thesis provides a proof-of-concept
that large-scale hypothesis-driven studies are an emerging alternative to
data-driven GWA studies. Such a study design facilitates interpretation of
results and integration of data for analyses of eﬀects mediated via various
genes acting in the same pathway or protein-protein complex. Several other
studies on clinical aspects of treatment in childhood ALL have been planned
and approved by the NOPHO society, including studies on life-threatening
toxicities and metabolism of speciﬁc drugs.
In the remaining part of this thesis I will conclude with some ﬁnal re-
marks on the perspectives of the ﬁeld of pharmacogenomics and personalized
medicine.
11.1 Functional variations
The work presented in this thesis concerns mostly germline genomic variation
(except for Paper V), however when studying cancer one should not forget
that the observed clinical phenotypes are a result of a complex interplay
between the host and tumour genetic factors. Since leukaemia is generally a
chemosensitive cancer [24], the hypothesis presented in Chapter 7 stated that
majority of leukaemia relapses are caused by insuﬃcient systemic exposure
to certain drugs, rather than cancer chemoresistance. The results of the
study (Paper III) are quite promising, however they still fail to explain all
the incidences of relapse. In order to fully understand this process ideally one
would examine matched host and tumour samples. It is also possible that
other factors beyond point mutations and polymorphisms may contribute to
the phenotype, including copy number variation, methylation patterns, as
well as expression patterns of genes, proteins and non-coding RNAs. Clearly,
relapse can be caused by diﬀerent molecular mechanisms and is therefore
impossible to be explained by a single variant in the genome. On the other
hand, MRD levels after remission induction therapy are likely to be sensitive
to changes in treatment protocols and measurement methods. Therefore
integrative variant analysis provides a way of capturing those diﬀerences
and identifying common aﬀected mechanisms of action, deﬁned for instance
by biological pathways. The study on infection susceptibility, even though
conducted on much smaller group of patients, yields seemingly more accurate
classiﬁcations, possibly due to clear deﬁnition of the phenotype and consid-
erate contribution of genetics. This reﬂects the fact that one of the keys to
a successful association study is a clear deﬁnition of a phenotype and leads
us to believe that future studies planned by the NOPHO society concerning
clearance of speciﬁc drugs or susceptibilities to particular toxicities may yield
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even more interesting results.
One of the major diﬃculties in studies investigating impact of genomic vari-
ation on observed phenotypes is the gap in our understanding of non-coding
and synonymous variations. Our lack of understanding of the potential func-
tionality of those variants does not imply unimportance and eventually those
types of variations have to be addressed in the analyses. Furthermore, there
is increasing evidence that rare variations can have a considerate contribution
to a variety of phenotypes and so far the only eﬀorts to include this type of
variants in analysis is to investigate whether particular genomic regions are
enriched in rare variations, without trying to interpret and understand their
actual functionality. Finally, one of the limiting factors in genomic variation
analyses might be the incompleteness of the reference human genome, which
for most parts of the genome likely reﬂects the DNA of any individual, but
might diﬀer signiﬁcantly in highly variable or repetitive regions. A recent
study by MacArtur et al. [77] reports that any individual carries approx-
imately 100 loss-of-function variants, resulting in approximately 20 genes
being completely inactivated which leads to great inter-individual variability
of gene content. Clearly, it is easy to imagine an opposite situation in which
all individuals probably have a unique copy of a number of genes. This is
an obvious obstacle in the current methods for NGS data analysis where the
sequencing reads are mapped back to the reference genome, since certain
regions of the genome are not yet characterized. When doing SNP calling
analyses, the normal procedure it to compare the observed sequence with the
reference genome, which introduces the assumption of the contents of the
reference sequence being ”normal” while any diﬀerences being ”alternative
alleles”, even if the ”alternative” allele is in fact the prevalent one in general
population. In future, application of single molecule sequencing could help
overcome some of those problems, however this technology is still burdened
with very high error rates and until this methodology improves one can at-
tempt to create alternative reference genomes by population speciﬁc genome
assemblies.
11.2 Personalized medicine
The ﬁeld of personalized medicine is rather far from the vision of applying
drugs speciﬁcally tailored to patients genetic proﬁles, however it is getting
much closer to optimizing the drug dosing based on an individual’s DNA.
With the exponential decline in sequencing costs and constant improve-
ments in the technology, NGS is making its way into the clinic to assist
in the clinical interpretation of patient’s genetic proﬁles. The ﬁndings of
pharmacogenetics studies are starting to be introduced into clinical settings,
and up to date 118 drugs contain labels approved by the Food and Drug
Administration (FDA) agency recommending genotype-speciﬁc dosing or
at least recognizing the inﬂuence of genetic variation on drug response or
safety (source: www.fda.gov). Furthermore, genomic data has been shown
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to improve the disease classiﬁcations and to help redeﬁning the disease
phenotypes as well as the therapeutic strategies. For instance, whole-genome
expression proﬁles have been utilized to identify a new subclass of Burkitt￿’s
lymphoma from diﬀuse B-cell lymphoma without prior knowledge of the
classes [32], while estrogen receptor status can be used to determine the
best treatment options in breast cancer [126]. Integration of the genomic
information together with its derivatives, such as the transcriptome, pro-
teome and metabolome seems crucial to investigate the whole landscape of
a disease. Recent story of Michael Snyder’s personal omics [23] shows that
indeed this approach can be successful in predicting the disease risks and
monitoring of the biological changes between healthy and diseased states.
His integrative personal omics proﬁle indicated a high risk of developing
type 2 diabetes, despite lack of family history of the disease. This ﬁnding
motivated him to monitor the glucose levels and indeed during the time of
the study he discovered that he had developed the disease, however due to
detection in early stage few changes in life-style were suﬃcient to prevent
the further development of the disease. Since the content of our DNA is
stable during lifetime, we are in principle able to predict the disease risk and
susceptibility at any time in our life and therefore we may hope to observe a
shift in medical care expenses from disease treatment to disease prevention
in the future. Before that happens, several ethical issues have to be resolved
including the issue whether to inform patients about the risks of untreatable
diseases or whether patients should be able to decide about this themselves.
As an example, when James Watson had his genome sequenced, the only
region he refused to reveal was the APOE gene containing a known variant
signiﬁcantly increasing the susceptibility to Alzheimer’s disease. Finally, the
issue of privacy of the genomic data has to be addressed, since sharing of
the data could have potential economical or social aspects including poten-
tial increase in health insurance cost or diﬃculties in ﬁnding a job due to
predicted high disease risk.
Regardless of the technological and ethical issues, genomic data is the driving
force behind personalized medicine. Personalized medicine is not likely to
change the traditional medicine but instead it can optimize it to individual
patient’s needs increasing the eﬃcacy and at the same time reducing the
side eﬀects of the treatment.
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